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“Far better it is to dare mighty things - even though checkered by failure - than to dwell 
in that perpetual twilight that knows not victory, nor defeat.”
—Theodore Roosevelt
1“In the    Netherlands,    one in eight    women will be        diagnosed     with    breast cancer”
       9
BACKGROUND
With an estimated 1.15 million new cases worldwide each 
year and a relatively good prognosis, breast cancer is the most 
prevalent cancer in the world today (Parkin et al., 2005). In 
the Netherlands, one out of eight women will be diagnosed 
with breast cancer at some moment in her life (Kiemeney 
et al., 2008). Most women with breast cancer will undergo 
some type of surgery in combination with radiation therapy, 
chemotherapy, or both. 
While considerable research and attention has focused on the 
time of diagnosis, treatment and survivorship, little attention 
has been paid to the period immediately following the 
completion of treatment. In this fi rst year after treatment, but 
also thereafter, women may experience physical, emotional and 
social problems (Ganz et al., 1996). Common concerns include 
fear of recurrence, uncertainty about the future, and coming 
to terms with changes in body image and life roles (Renton et 
al., 2002; Wyatt et al., 1993). Physical symptoms are another 
concern for breast cancer survivors. Fatigue, recurrent pain 
and sensory discomfort in the surgical area, lymph edema, and 
hormonal changes that can cause menopausal symptoms, are 
among the most troubling symptoms following treatment.
General introduction
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In most countries, women are asked to come for frequent follow-up visits to the 
hospital following their completion of treatment, especially in the fi rst year (Pestalozzi & 
Castiglione, 2008). The main objectives of these follow-up visits are the early detection 
of a loco regional recurrence or a second primary breast cancer, the detection and 
registration of side effects of treatment and provision of information and psychological 
support (Pestalozzi & Castiglione, 2008; Struikmans et al., 2008). However, there has 
been much debate whether these objectives of breast cancer follow-up are adequately 
met in current clinical practice (Kimman et al., 2007a; Montgomery et al., 2007; Pennery 
& Mallet, 2000). First, neither the frequency (Jacobs et al., 2001; Schapira, 1993) nor 
the intensity (GIVIO, 1994; Rosselli Del Turco et al., 1994) of follow-up seems to infl uence 
the chances of cure. Second, there is a general feeling among clinicians of limited patient 
time during clinic visit to adequately address often complex psychosocial issues. Indeed, 
patients often feel uncomfortable expressing emotional concerns and asking questions 
(Pennery & Mallet, 2000). Also, it has been demonstrated that outpatient clinic visits may 
induce anxiety because of the risk of detecting a recurrence (Allen, 2002).
Hence, not only do the current frequent follow-up strategies seem to miss their most 
important goals, they also depend heavily on expensive and scarce specialized knowledge 
for routine history taking and physical examinations. As a result, alternative follow-up 
strategies have been proposed, such as follow-up by a general practitioner (Grunfeld et 
al., 2006) and nurse-led (Koinberg et al., 2004) or telephone follow-up (Beaver et al., 
2009b; Montgomery et al., 2008a). Although these studies show that different follow-up 
models can be equally effective as traditional hospital follow-up, measured by a variety 
of outcomes, these models are not yet widely applied in clinical practice. Several authors 
urge new research to evaluate the costs in relation to the benefi ts of current and alternative 
follow-up strategies (Grunfeld, 2009; Meropol et al., 2009; Montgomery et al., 2007). 
Furthermore, the new NICE guidelines for treatment and follow-up of breast cancer (2009) 
promote the incorporation of patient preferences into decision making (Harnett et al., 
2009).
ECONOMIC EVALUATION IN HEALTH CARE
Economic evaluation assesses the relative ‘value for money’ of health interventions 
(Weinstein & Stason, 1977). Health interventions are to be interpreted in a broad 
sense. They include preventive health programs, curative health care, rehabilitation 
services and palliative care, and within these health interventions, use of drugs, medical 
devices, behavioral therapy et cetera (Drummond et al., 2005; Gold et al., 1996). 
Economic evaluations provide information on the costs and consequences of health care 
interventions. This information may help policy makers in deciding how to allocate health 
care resources, provide evidence for clinical guidelines and promote the transparency of 
health care.
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There are several types of economic evaluations that differ in the way in which the 
consequences of health care interventions are taken into account (Drummond et al., 
2005). In a cost-minimization analysis (CMA) only the costs of the alternative interventions 
are compared. A CMA is performed if the alternatives are equally effective, but its use 
has been criticized as it is rarely an appropriate method of analysis (Briggs & O’Brien, 
2001). In a cost-benefi t analysis (CBA) consequences are expressed in monetary terms. 
CBA is not frequently used though, as assigning monetary values to health outcomes is 
diffi cult and controversial (Anell & Norinder, 2000). In a cost-effectiveness analysis (CEA) 
consequences are measured in natural or physical units, e.g. detected cases of breast 
cancer, prevented strokes, or life years gained. Cost-utility analysis (CUA) is a specifi c form 
of CEA, in which the effects of health care interventions on life expectancy and health-
related quality of life (HRQoL) are combined (Drummond et al., 2005; Gold et al., 1996). A 
widely used approach which combines outcomes is the Quality-Adjusted Life Year (QALY); 
it assigns to each period of time a value corresponding to the HRQoL during that period. 
The value (i.e. utility) typically lies on a scale between 0 (to represent death) and 1 (to 
represent full health). The number of QALYs related to a health outcome is then expressed 
as the value given to a particular health state multiplied by the length of time spent in that 
health state (Gold et al., 1996). 
In CEA the economic value of two alternative interventions is compared by dividing the 
difference in costs between the alternatives by the difference in health outcomes. If QALYs 
are the measure of outcome, health care interventions are compared in terms of their 
incremental cost per QALY. Thus, the aim of CEA is not just to minimize costs, but also to 
provide information on the value-for-money or so-called incremental cost-effectiveness, 
that is the additional costs needed to obtain additional health gains (Drummond et al., 
2005; Gold et al., 1996). The decision about which intervention to provide requires 
information about the maximum amount of Euros that funders (e.g. society, insurance 
companies) are willing to pay for these additional health gains. 
THE PATIENT PERSPECTIVE
Policy makers and clinicians increasingly aim to take the patient’s perspective into account 
in medical decision making (Coulter, 1997; Harnett et al., 2009). Patients may respond 
better to treatment and comply better to guidelines when they are involved in decision 
making and satisfi ed with their care and treatment setting (Jackson et al., 2001; Kizer, 
2002; Worthington, 2004). Patient satisfaction is believed to refl ect personal preferences 
of the patient, the patient’s expectations, and the realities of the care received (Ware 
et al., 1983). Hence, satisfaction and preferences are not only related to health gains, 
but also to benefi ts beyond health gains, such as the provision of information, location 
of treatment and staff attitudes. Patient satisfaction can be measured using validated 
questionnaires (Hagedoorn et al., 2003). 
Another method which is increasingly used in health care to measure satisfaction and 
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preferences is the discrete choice experiment (DCE) (Ryan, 1999b; Ryan & Gerard, 2003).
A DCE is an attribute based stated preference valuation technique which is grounded 
in economic theory (Lancaster, 1966; McFadden, 1974) and enables consideration of 
the contribution to overall value of each of the defi ned characteristics or attributes of an 
intervention (Louviere et al., 2000). Preferences are quantifi ed by analyzing the responses 
that respondents provide in surveys about how they would behave in hypothetical choice 
situations. Respondents are asked to choose their preferred alternative from a set of 
two or more hypothetical alternatives. The alternatives are health care interventions 
(e.g. follow-up strategy) described by their key characteristics (attributes), such as the 
health care provider and frequency of visits. The respondents’ evaluation of an alternative 
depends on the levels of the attributes (for example, a nurse, medical specialist or 
general practitioner). The relative importance of attributes and levels to respondents and 
the trade-offs made between them, can be assessed by asking respondents to make 
choices between multiple alternatives with different levels of attributes. DCEs are found 
to be a valid and reliable approach to elicit preferences in a health care context (Bryan 
et al., 2000) and are recognized as a useful tool for medical decision making (Lancsar & 
Louviere, 2008; Ryan & Gerard, 2003). 
OBJECTIVE OF THE THESIS
The objective of this thesis is threefold. First, the effectiveness of nurse-led telephone 
follow-up instead of hospital follow-up and of a short educational group program (EGP) 
in addition to follow-up are investigated in a randomized controlled setting. The primary 
measure of effectiveness is patient-reported health-related quality of life (HRQoL). 
Furthermore, feelings of anxiety and control and other psychological measures are 
investigated. Second, an economic evaluation from the societal perspective is performed 
to determine the most cost-effective out of four follow-up strategies (i.e. hospital 
follow-up, nurse-led telephone follow-up and both strategies combined with the EGP). 
Third, the patient’s perspective on breast cancer follow-up is further explored. Patient 
satisfaction with nurse-led telephone follow-up is compared to satisfaction with hospital 
follow-up. Moreover, the strength and heterogeneity of patient preferences for specifi c 
characteristics of follow-up are explored using discrete choice experimentation. Research 
results are thought to improve resource-allocation decisions and enhance dissemination 
of cost-effective follow-up strategies.
OUTLINE OF THESIS
CHAPTER 2 outlines a literature review on current follow-up strategies and their 
effectiveness in terms of detecting recurrences and providing information and support. 
Implications for future research are discussed, taking into account existing knowledge 
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on patients’ needs and expectations. CHAPTER 3 provides a detailed description of the 
interventions, design and execution of the study protocol of the randomized controlled 
trial (RCT). The RCT with a 2x2 factorial design investigates the effectiveness of nurse-led 
telephone follow-up and EGP in the fi rst year after breast cancer treatment. In CHAPTER 4 
the RCT results are presented. The effectiveness of nurse-led telephone follow-up and EGP 
are measured by HRQoL, feelings of anxiety and control, and role functioning and emotional 
functioning. In CHAPTER 5 results are reported of a study investigating the responsiveness 
of the EQ-5D in breast cancer patients after treatment. In economic evaluations, the EQ-
5D is often used to measure utilities for the purpose of QALY calculations. It is investigated 
whether changes in EQ-5D utility scores, which are determined using societal values 
for health states, are representative for patient reported health changes. CHAPTER 6 
describes results of the economic evaluation performed alongside the RCT. Four follow-
up strategies for the fi rst year after treatment are compared. Following guidelines for 
economic evaluations a societal perspective is taken, including all relevant costs and 
effectiveness expressed in QALYs. CHAPTER 7 deals with patient satisfaction with nurse-
led telephone follow-up regarding technical competences of the health care provider, 
interpersonal aspects, access of care and general satisfaction. CHAPTER 8 describes 
results of the discrete choice experiment used to explore patient preferences for several 
characteristics of breast cancer follow-up. CHAPTER 9 summarizes the main research 
fi ndings of this thesis and offers a general discussion, addressing some considerations 
related to the research and several recommendations for clinical practice and policy and 
future research. 
Chapter 2
 
“The value of frequent 
outpatient follow-up is still 
a controversial issue”2
Follow-up after treatment 
for breast cancer: 
why do we still adhere to frequent 
outpatient clinic visits?
KIMMAN ML, VOOGD AC, DIRKSEN CD, FALGER P, HUPPERETS P, KEYMEULEN K, HEBLY M, 
DEHING C, LAMBIN Ph, BOERSMA LJ. 
EUR J CANCER 2007;43(4):647-53
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ABSTRACT
Follow-up after curative treatment for breast cancer consists 
of frequent outpatient clinic visits, scheduled at regular 
intervals. Its aim is primarily to detect local disease recurrence, 
or a second primary breast cancer, but also to provide 
information and psychosocial support. The cost-effectiveness 
of these frequent visits is being questioned however, leading 
to a search for less intensive follow-up strategies, such as 
follow-up by the general practitioner, patient-initiated or 
nurse-led follow-up or contact by telephone. These strategies 
are generally considered to be safe, but they are not yet 
widely accepted in clinical practice. Since brief interventions 
based on self-education and information have been shown to 
be able to improve quality of life, we hypothesize that these 
interventions may lead to a better acceptance of reduced 
follow-up by both patients and professionals.
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INTRODUCTION
After curative treatment for breast cancer women frequently attend scheduled follow-up 
examinations. The main objective of these examinations is to detect local disease recurrence 
or a second primary breast cancer in an early stage, hoping that this may increase the 
chances of cure. Yet, follow-up should also provide information and psychological support. 
Another aim is to collect data on late effects of surgery, radiotherapy and chemotherapy 
for audit or research and to provide feedback to physicians (Rojas et al., 2005; Rutgers 
et al., 1989). However, there has been much debate whether these objectives of breast 
cancer follow-up are adequately met in current clinical practice (Brada, 1995; Dewar, 
1995). First, neither the frequency (Jacobs et al., 2001; Schapira, 1993) nor the intensity 
(GIVIO, 1994; Rosselli Del Turco et al., 1994) of follow-up have been shown to infl uence 
the chances of cure. Second, there is a general feeling amongst clinicians that there 
is limited time during the outpatient clinic visit to adequately address often complex 
psychosocial issues. Indeed, patients often feel uncomfortable with expressing emotional 
concerns and asking questions (Pennery & Mallet, 2000). Also, it has been demonstrated 
that the outpatient clinic visits may induce anxiety because of the risk of detecting tumor 
relapse (Allen, 2002). Finally, to provide feedback to professionals on the effectiveness 
and side-effects of their treatments, less frequent follow-up may be suffi cient as well. 
Not only do the current frequent follow-up strategies seem to miss their most important 
goals, they also depend heavily on expensive and scarce specialized knowledge for 
routine history taking and physical examinations. Financial constraints force oncologists 
and policy makers to search for alternative, more cost-effective, follow-up strategies. 
The aim of this paper is to explore the literature for scientifi c evidence why physicians 
and patients should still adhere to frequent outpatient clinic visits after breast cancer 
treatment, as recommended in the current European and American guidelines for breast 
cancer follow-up. In addition, we summarize studies on alternative strategies, focusing on 
the two main goals of breast cancer follow-up: 1) detecting recurrences or new primaries 
and 2) providing psychosocial support to improve quality of life (QoL). Finally, implications 
for future research are discussed, taking into account existing knowledge on patients’ 
needs and expectations.
CURRENT FOLLOW-UP STRATEGIES AND THEIR EFFECTIVENESS
In Europe, the European Society for Medical Oncology (ESMO) recommends that follow-up 
of primary breast cancer consists of history taking and physical examinations every three 
to six months in the fi rst three years after treatment, every six to 12 months for the next 
three years, and annually thereafter. A mammography is taken every one to two years. 
More intensive surveillance (i.e. with additional radiological examinations of liver, lungs 
and bones and laboratory tests) is not routinely recommended for asymptomatic patients 
(ESMO, 2001). In a recent update of the follow-up guidelines by the American Society 
of Clinical Oncology (ASCO) a similar frequency of history taking, physical examination 
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and mammography was proposed. However, there is no high-level evidence supporting 
these frequent follow-up visits and the current practice of mammography surveillance 
(Khatcheressian et al., 2006).
Effectiveness of follow-up on detecting recurrent disease
Intensive surveillance used to be common practice in the seventies and eighties. Large 
randomized trials by Roselli del Turco et al. (1994) and the GIVIO investigators (1994) 
have shown that follow-up based on routine outpatient clinic visits combined with 
annual mammography is as effective with regard to overall survival, as follow-up with 
intensive surveillance. Since then, several papers with varying levels of evidence have 
been published questioning even the effectiveness of routine outpatient clinic visits (de 
Bock et al., 2004a; Jacobs et al., 2001; te Boekhorst et al., 2001; Wheeler et al., 1999). 
Wheeler et al. (1999) performed a longitudinal study of 416 consecutive patients after 
the diagnosis of primary breast cancer and found that frequent early follow-up provided 
no clear clinical gain for the great majority of patients, since early relapse was rare in the 
fi rst year. Te Boekhorst et al. (2001) conducted a retrospective review in 270 patients 
with recurrent breast cancer and also found the clinical impact of follow-up to be low, as 
most patients had symptomatic recurrences (63%). If specifi cally looking at loco regional 
recurrences, routine follow-up was more effective, detecting 66% of these recurrences. 
However, early detection did not translate into improved survival. 
Stronger evidence is available from a meta-analysis of twelve studies by de Bock et al. 
(2004a). This analysis included 5045 breast cancer patients and 378 isolated loco 
regional recurrences and showed that approximately 40% of recurrences were diagnosed 
in asymptomatic patients during routine visits or routine tests (95% confi dence interval 
35% to 45%). Forty-one percent of recurrences were diagnosed outside these routine 
visits and tests and 18% of recurrences were diagnosed in symptomatic patients at 
their routine visits. Although the rate of women diagnosed during routine follow-up with 
an asymptomatic recurrence seems signifi cant, the overall incidence of loco regional 
recurrence is low. Thus by using frequent routine follow-up in this fi rst two years, much 
effort is needed to detect only a very small proportion of curable locoregional recurrences 
early (de Bock et al., 2004a). 
A simulation study by Jacobs et al. (2001) confi rmed these fi ndings. They tested various 
follow-up strategies with regard to the frequency of outpatient clinic visits. It was found that 
the gain in life expectancy with standard follow-up compared to no follow-up examination 
at all is only about 2 months in breast cancer patients aged 50 years and treated with 
curative intent. In older women, the gain was even less. 
Effectiveness of follow-up in providing psychosocial support
Providing psychosocial support to improve QoL is another important aim of the follow-
up. Breast cancer has an enormous psychological impact on patients and their partners, 
triggering fears of prolonged suffering, disability and a foreshortened life perspective. 
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High levels of anxiety, depression, and distress are estimated to occur in about 35% of 
patients after treatment (Clark et al., 2003). These patients should be identifi ed and 
referred for specialized psychosocial support. Others depend on the follow-up visits to the 
medical specialist for information and some form of psychosocial support. The question 
remains whether short routine outpatient clinic visits are suffi cient and appropriate 
enough for this type of support. Several studies have indicated that they are not (Allen, 
2002; Pennery & Mallet, 2000). Pennery and Mallet (2000) conducted a cross-sectional 
survey among 24 breast cancer patients of different age and found that most patients 
felt hurried and uncomfortable with expressing emotional concerns or asking questions 
during the outpatient clinic visit. Eighteen women stated that they would prefer to receive 
all or part of their follow-up from a breast care nurse. Allen interviewed six breast cancer 
patients and found that the scheduled clinic visits produced anxiety about breast cancer 
recurrence in women who were otherwise free from this particular form of anxiety. Thus, 
anxiety created the need to attend the clinic in order to gain reassurance about well-being 
(Allen, 2002). Since the numbers of patients in these studies were rather small, more 
research investigating the quality of psychosocial support during follow-up is urgently 
needed. 
WHAT DO PATIENTS NEED AND EXPECT? 
Several studies investigated breast cancer patients’ needs after treatment and their 
expectations about follow-up examinations, by using interviews or questionnaires. 
Important needs that patients expressed were reassurance and social support (Pennery 
& Mallet, 2000), confi rmation, continuity, accessibility and information (Koinberg et al., 
2001), cancer expertise of clinical staff and a good relationship with the doctor (Adewuyi-
Dalton et al., 1998). Renton et al. (2002) surveyed the opinion of 134 women attending a 
breast cancer follow-up clinic to establish what they considered the most important topics 
for discussion at follow-up. Information on risk of recurrence (70%), benefi ts and side 
effects of treatment (61%) and the risk of breast cancer affecting their daughters (41%) 
were highlighted the most. A cross-sectional survey by de Bock et al. (2004b) showed that 
patients’ expectations of routine follow-up were high and sometimes unrealistic. Seventy-
four out of 84 patients (88%) believed that early detection of distant metastases would 
contribute to a cure. Therefore, most of these patients preferred additional investigations 
to be part of the follow-up and more than half preferred lifetime follow-up, performed by 
a medical specialist. 
These studies show that women differ greatly in their needs and preferences regarding 
follow-up. Moreover, the needs and preferences deviate from available evidence on the 
effectiveness of routine follow-up, stressing the need for more information and education 
about the particular aims and effects of follow-up. 
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ALTERNATIVE FOLLOW-UP STRATEGIES FOR BREAST CANCER TO REDUCE CLINICAL 
WORKLOAD AND COSTS
To make more effi cient use of scarce specialized expertise, reduced follow-up strategies 
have been proposed. These include follow-up by the general practitioner or nurse, and 
patient-initiated follow-up (see table 1a). Also, replacing clinic visits by telephone interviews 
is increasingly being used as a presumably safe and cost-effective way of follow-up.
Follow-up by the general practitioner
In a randomized study by Grunfeld et al. (1996), 296 women with stage ≤ III breast cancer 
received routine follow-up either in the hospital or in general practice. Results indicated 
that general practice follow-up was not associated with increase in time to diagnosis 
of recurrence, increase in anxiety, or deterioration in health related QoL, and patients’ 
Table 1a - Trials investigating strategies for breast cancer follow-up aimed at reducing clinical workload 
and costs.
Author (year) Aim of the study Design/ 
Participants
Results
Grunfeld et al 
(1996)
(1999)
To assess the effect 
of transferring follow-
up from hospital to 
general practice (GP)
RCT: 296 
women with 
stage I, II or III 
breast cancer
GP follow-up was not associated with in-
crease in time to diagnosis of recurrence 
or decreased quality of life (QoL). No 
signifi cant difference between groups in 
anxiety or depression scores was found. 
The GP group indicated greater satisfac-
tion than the hospital group.
Grunfeld et al 
(2006)
To assess whether 
GP follow-up is a safe 
and acceptable alter-
native to specialist 
follow-up
RCT: 968 
women with 
stage I, II or III 
breast cancer
No differences in recurrences, recur-
rence-related serious clinical events or 
health related QoL were found between 
the GP group and the specialist group.
Gulliford et al 
(1997)
To compare regular 
follow-up with follow-
up restricted to the 
time of mammog-
raphy
RCT: 211 
women with 
stage I, II or III 
breast cancer
Patients undergoing less frequent 
follow-up did not increase their use of 
GP or telephone services. Patients were 
highly supportive to pursue less frequent 
follow-up.
Brown 
et al
(2002)
To assess the benefi ts 
of clinic follow-up 
compared to patient 
initiated follow-up
RCT: 61 
women with 
stage I breast 
cancer
No differences in QoL, psychological mor-
bidity or satisfaction with care were found 
between the groups.
Koinberg et al 
(2004)
To compare follow-up 
by the physician with 
nurse-led follow-up on 
demand
RCT: 264 
women with 
stage I and II 
breast cancer
No statistically signifi cant differences in 
levels of anxiety, depression and satisfac-
tion were found between the groups. 
Also, no differences concerning time to 
recurrence or death were detected.
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satisfaction with follow-up was higher, compared to hospital follow-up (Grunfeld et al., 
1999a). The economic evaluation showed that the mean costs per patient for 18 months 
of follow-up in general practice were only one third of those per patient in the hospital 
follow-up (Grunfeld et al., 1999b). A later similarly randomized trial by Grunfeld et al. 
(2006) with long-term follow-up in 986 patients showed that follow-up can be offered by 
the general practitioner without concern that important recurrence-related serious events 
will occur more frequently or that health-related QoL will be affected negatively compared 
to routine follow-up.
Patient-initiated follow-up
In a study by Gulliford et al. (1997), the experiences of breast cancer patients who attended 
an outpatient clinic for follow-up were compared with those in whom routine follow-up was 
restricted to a single visit only after mammography. All patients were advised to examine 
their breasts each month and to request an appointment if they felt a lump or developed 
any other symptom. Of 211 eligible patients, 196 (93%) opted for randomization in the 
study. No increased use of local practitioner services or telephone calls to the hospital 
was apparent in the group randomized to less frequent follow-up. Although QoL was 
not analyzed in this study, this cohort of patients was highly supportive of the option to 
pursue less frequent follow-up. Brown et al. (2002) compared routine outpatient clinic 
follow-up and patient-initiated follow-up in women treated for stage I breast cancer in a 
small randomized trial (n=62), and found that patient-initiated follow-up was a safe and 
possibly cost-effective alternative to routine follow-up for women at low risk of recurrence. 
However, this study was not suffi ciently powered to draw fi rm conclusions. 
Nurse-led telephone follow-up
A literature review by Cox and Wilson on nurse-led services and telephone interventions 
in follow-up for patients with all forms of cancer showed that nurse-led follow-up services 
were acceptable, appropriate and effective (Cox & Wilson, 2003). Specifi cally looking at 
breast cancer, Koinberg et al. (2004) conducted a randomized trial comparing usual follow-
up by the medical specialist (n=131) with nurse-led follow-up on demand (n=133). In the 
nurse-led group, patients met with an experienced nurse three months after surgery. They 
received information about how to recognize recurrence and were requested to contact 
the nurse for any concerns related to breast cancer. The nurse arranged a mammography 
at one-year intervals and reported the results by telephone or letter. No statistically 
signifi cant differences were found in levels of anxiety, depression or satisfaction with follow-
up between the two groups. In addition, there were no differences in time to recurrence 
or death. These data suggest equal validity of both approaches, but the limited number 
of patients prohibits drawing fi rm conclusions on this subject. Furthermore, the nurse-led 
group reported 450 less visits to the medical specialist but 177 more phone calls and 88 
more visits to the nurse, than the specialist-led group (Koinberg et al., 2004). No costs 
were calculated, but it may be thought that the substantial reduction in medical specialist 
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visits would have led to cost reduction. Similar results were found in trials investigating 
nurse-led telephone follow-up as an alternative to conventional outpatient clinic follow-up 
in other cancers (Helgesen et al., 2000; Sardell et al., 2000). 
INTERVENTIONS AFTER CANCER TREATMENT TO PROVIDE PSYCHOSOCIAL SUPPORT
A number of studies have been performed using various group intervention formats to 
provide psychosocial support for cancer patients. Results varied and refusal rates for 
extensive programs were often high (Clark et al., 2003). Only few studies focused on 
women treated for breast cancer (see table 1b). 
Author (year) Aim of the study Design/ Partici-
pants
Results
Helgeson et al 
(1999)
(2000)
To compare the 
effectiveness of an 
education-based and 
a peer-discussion 
based group inter-
vention
RCT: 312 women 
with stage I, II or 
III breast cancer
The educational intervention improved 
self-esteem and body image and re-
duced disturbing thoughts. Peer-assisted 
discussion groups were only helpful for 
women who lacked support from their 
partners, but harmful for women with 
high support levels.
Antoni 
et al (2001)
To test the effects 
of a group cognitive-  
behavioral stress    
management inter-
vention
RCT: 100 women 
with stage 0, I, 
II or III breast 
cancer
The intervention reduced prevalence of 
moderate depression, but did not affect 
other measures of emotional distress.
Koinberg et al 
(2006)
To compare a 
multidisciplinary 
educational program 
(MP) with traditional 
follow-up visits to a 
physician
Prospective 
non-randomized 
study: 96 women 
with stage I or II 
breast cancer
Women in the MP increased their physi-
cal and functional well-being. Women 
with traditional follow-up increased 
functional well-being, while social/family 
well-being decreased over time. Women 
with traditional follow-up also scored 
lower in their overall coping capacity.
Helgeson et al. (1999) found in a randomized trial (n=312) that an education-based 
intervention increased psychological and physical functioning by enhancing self-esteem 
and reducing disturbing intrusive thoughts about the illness, both immediately following 
and six months after the intervention. In addition, peer-assisted discussion groups were 
helpful for a subgroup of women who lacked emotional support from their partners, but 
could be harmful for women with high support levels (Helgeson et al., 2000). The positive 
effects of the education intervention dissipated with time, but the differences with the 
control group remained signifi cant over a 3-year period (n=252) (Helgeson et al., 2001). A 
randomized trial by Antoni et al. (2001) (n=100) tested effects of a 10-week group cognitive-
Table 1b - Trials investigating group interventions for women treated for primary breast cancer.
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behavioral stress management intervention that focused on coping with daily stressors 
related to breast cancer and on optimizing one’s use of social resources. The intervention 
reduced prevalence of moderate depression and enhanced optimism about the future, 
but did not affect other measures of emotional distress, such as mood disturbance and 
thought intrusion and avoidance. A recently published non-randomized study by Koinberg 
et al. (2006) compared a short multidisciplinary educational program (n=50) with 
traditional follow-up visits to a physician (n=46) after breast cancer surgery. The program 
was led by a specialized nurse in oncology and comprised four sessions of lectures and 
discussions on topics related to breast cancer. The program aimed to strengthen the self-
care ability of participants, in addition to promoting health and to facilitating sense of 
coherence. Results of this study indicated that the educational program was comparable 
to a traditional physician follow-up program in terms of well-being, aspects of self-care and 
coping ability, and could thus be an alternative to traditional physician follow-up.
IMPLICATIONS FOR FUTURE RESEARCH
In summary, the randomized clinical trials investigating the effects of less frequent follow-
up (Brown et al., 2002; Gulliford et al., 1997) and nurse-led follow-up (Koinberg et al., 
2004) were too small to allow fi rm conclusions on the safety of these reduced follow-
up strategies. Nevertheless, several retrospective studies (de Bock et al., 2004a; te 
Boekhorst et al., 2001) and the simulation study of Jacobs et al. (2001) strongly suggest 
that only few patients would benefi t from frequent routine follow-up visits in terms of early 
detection of curable loco regional recurrence. Since this early detection of loco regional 
recurrences does also not seem to translate into improved survival (Wheeler et al., 
1999), the cost-effectiveness of frequent follow-up in terms of survival benefi t is highly 
questionable. In addition to primarily clinical considerations, routine follow-up also has a 
psychosocial component, but there is only limited time during outpatient clinic visits to 
address this. Moreover, it has been suggested that these visits may induce a high level of 
anxiety (Allen, 2002). 
In the last decade, alternative strategies for follow-up have been proposed. Trials 
investigating less frequent follow-up, nurse-led follow-up, and shared care with the 
patient’s family doctor, show promising results with respect to QoL and patient satisfaction 
(Grunfeld et al., 2006; Gulliford et al., 1997; Koinberg et al., 2004). Additionally, a short 
educational group program may be able to reduce outpatient clinic visits to the specialist 
(Koinberg et al., 2006). Yet, alternative follow-up strategies are not widely applied in clinical 
practice and frequent conventional oncologist follow-up is still common practice. Several 
reasons could explain this situation. First, fi nancial incentives for medical specialists 
might play a role. A more likely explanation could be the, probably false, perception of 
many medical specialists that patients need frequent reassurance. In addition, many 
patients have false expectations that frequent follow-up visits will result in better overall 
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survival (de Bock et al., 2004b). Finally, another reason may be that trial-based economic 
evaluations, supporting the conclusions that reduced strategies are indeed cost-effective 
to society, are scarce. 
We hypothesize that improvements in psychosocial support and education of patients may 
lead to better acceptance rates in both patients and medical specialists with respect to a 
reduced follow-up strategy. Furthermore, we recognize that the cost-effectiveness of both 
reduced follow-up policies as well as educational group programs should be determined 
to justify implementation of new strategies. 
In the Netherlands, we have started a randomized trial investigating the cost-effectiveness 
of four different follow-up strategies for primary breast cancer patients. These strategies 
include the routine frequent outpatient clinic visits as described in current guidelines; 
follow-up in the fi rst two years reduced to annual mammography, with telephone interviews 
by a nurse practitioner at the other time points of the routine strategy (3, 6, 12 and 18 
months) and; each of these strategies combined with a short educational group program, 
focusing on enhancing QoL. In this study, nurse practitioners have a major role in the 
follow-up. The increased use of nurse practitioners is an important trend in cancer care; 
they are uniquely educated to provide quality specialty care, are easily accessible and they 
can provide continuity of care to the patients. Thus, their role may lead to high patients’ 
satisfaction. Also, they are likely to reduce costs associated with follow-up.
CONCLUSION
The value of frequent outpatient follow-up in the fi rst few years after curative treatment 
for breast cancer is still a controversial issue. There is no strong evidence that routine 
outpatient clinic visits are effective with regard to the detection of recurrences, as most 
recurrences are detected between scheduled appointments. Moreover, routine follow-
up has a major impact on costs and staff resources. Therefore, alternative follow-up 
strategies have been tested and well-received by patients, not adversely affecting patient 
satisfaction or QoL. However, there still seem to be barriers preventing the full fl edged 
implementation of these new strategies in clinical practice. More psychosocial support 
and better education and information to the patient, may lead to a better acceptance of 
reduced follow-up policies. A trial investigating the cost-effectiveness of a reduced follow-
up strategy, combined with additional psychosocial support and education, is currently 
underway.
3“The MaCare trial is a multicenter trial,    in which breast cancer patients are randomized    into four follow-up strategies”
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ABSTRACT
[Background] This paper describes the design of the MaCare trial. The 
MaCare trial compares the cost-effectiveness of four follow-up strategies 
for curatively treated breast cancer patients. We investigate the costs and 
effects of nurse-led telephone follow-up and a short educational group 
program. [Methods/design] The MaCare trial is a multicenter randomized 
clinical trial in which 320 breast cancer patients are randomized into four 
follow-up strategies, focused on the fi rst 18 months after treatment: 1) 
standard follow-up; 2) nurse-led telephone follow-up; 3) arm 1 with the 
educational group program; 4) arm 2 with the educational group program. 
Data is collected at baseline, and 3, 6, 12 and 18 months after treatment. 
The primary endpoint of the trial is cancer-specifi c quality of life (QoL) 
as measured by the global health/QoL scale of the EORTC QLQ-C30. 
Secondary outcomes are perceived feelings of control, anxiety, patients’ 
satisfaction with follow-up and costs. A cost-effectiveness analysis will be 
performed from a societal perspective. [Discussion] Reduced follow-up 
strategies for breast cancer have not yet been widely applied in clinical 
practice. Improvement of psychosocial support and information to patients 
could lead to a better acceptance of reduced follow-up. The MaCare 
trial combines a reduced follow-up strategy with additional psychosocial 
support. Less frequent follow-up can reduce the burden on medical 
specialists and costs. The educational group program can improve QoL of 
patients, but also less frequent follow-up can improve QoL by reducing the 
anxiety experienced for each follow-up visit. Results of the trial will provide 
knowledge on both costs and psychosocial aspects regarding follow-up 
and are expected in 2009.
Improving the quality and efficiency of 
follow-up after curative treatment 
for breast cancer - rationale 
and study design of the MaCare trial
KIMMAN ML, VOOGD AC, DIRKSEN CD, FALGER P, HUPPERETS P, KEYMEULEN K, HEBLY M, 
DEHING C, LAMBIN Ph, BOERSMA LJ. 
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BACKGROUND
With an estimated 1.15 million new cases worldwide each year, breast cancer is by far 
the most frequent cancer in women. Because of its high incidence and relatively good 
prognosis, breast cancer is also the most prevalent cancer in the world today (Parkin et 
al., 2005). After curative treatment for breast cancer women frequently attend scheduled 
follow-up examinations. Usually the follow-up is most frequent in the fi rst 2-3 years (2-4 
times a year); thereafter the frequency is reduced to once a year in most countries. The 
main objective of these examinations is to detect local disease recurrence or a second 
primary breast cancer in an early stage, hoping that this may increase the chances of 
cure. Follow-up should also provide information and psychological support. Another aim 
is to collect data on late effects of surgery, radiotherapy and chemotherapy for audit or 
research and to provide feedback to physicians (Rojas et al., 2005; Rutgers et al., 1989). 
However, there is much debate whether the objectives of breast cancer follow-up are 
adequately met in current practice (Brada, 1995; Dewar & Kerr, 1985). Schapira (1993) 
reported that the early frequent outpatient clinic visits with only physical examination and 
an annual mammography do not improve early detection of recurrence or overall survival. 
Since then, several studies have investigated the effect of the frequency (Jacobs et al., 
2001) and intensity (GIVIO, 1994; Rosselli Del Turco et al., 1994) of follow-up on overall 
survival, without fi nding evidence supporting the necessity of frequent or intensive follow-
up. Furthermore, instead of providing psychosocial support, it has been demonstrated 
that the outpatient clinic visit may induce anxiety because of the risk of detecting tumor 
relapse (Allen, 2002; Pennery & Mallet, 2000).
Although the current frequent follow-up strategies thus seem to miss their most important 
goals, they do depend heavily on expensive and scarce specialized knowledge for routine 
history taking and physical examination. Financial constraints have forced oncologists 
and policy makers to search for alternative and cost-effective follow-up strategies. 
Studies on follow-up by the general practitioner, patient-initiated or nurse-led follow-
up or contact by telephone showed no difference in time to detection of recurrence or 
patients’ perceived quality of life (QoL) (Brown et al., 2002; Grunfeld et al., 2006; Grunfeld 
et al., 1996; Gulliford et al., 1997; Koinberg et al., 2004). Nevertheless, these reduced 
strategies have not yet been widely accepted and applied in clinical practice. This may 
on the one hand be ascribed to the perception of many medical specialists that most 
patients need reassurance and psychosocial support, and on the other hand to the false 
expectations of many patients that frequent follow-up will result in a better overall survival 
(de Bock et al., 2004b). Improvement of the psychosocial support and education of the 
patients may lead to a better acceptance of both patients and medical specialists of a 
reduced follow-up policy. A number of studies have been performed using various group 
intervention formats for breast cancer patients to provide psychosocial support. However, 
most interventions mainly focused on intensive psychological support (10 sessions 
or more), showing varying results and often high refusal rates (Clark et al., 2003). 
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No trials have been performed that combine a reduced follow-up policy in the fi rst two 
years with an acceptable strategy to provide information and education. For this reason, 
two interventions for early breast cancer follow-up were developed for the study that is 
discussed in this paper; nurse-led telephone follow-up and a short educational group 
program (EGP). The primary aim of the so-called MaCare trial (Mamma carcinoma and 
afterCare) is to investigate the impact of these interventions on cancer-specifi c QoL and 
costs and thus to determine which of these follow-up strategies is the most cost-effective. 
This paper reports on the methodological design of the trial as well as the contents of the 
interventions and the economic evaluation.
METHODS
Study design
The MaCare trial is a multicenter randomized trial, in which breast cancer patients who 
are treated with curative intent are randomized between four follow-up strategies (see 
fi gure 1, page 28): 
1) Follow-up as usual; fi ve outpatient clinic visits in the fi rst 18 months (at 3, 6, 9, 12 and 
18 months), with a mammography at one year.
2) Nurse-led telephone follow-up; a mammography at one year combined with an 
outpatient clinic visit, and telephone interviews by a breast care nurse (BCN) or nurse 
practitioner (NP) at the same time points as during the usual follow-up (i.e. 3, 6, 9 and 18 
months).
3) Similar to arm 1, combined with the EGP.
4) Similar to arm 2, combined with the EGP.
After 18 months patients return to the current follow-up strategy, i.e. follow-up once a year.
Setting 
The trial is carried out in seven hospitals and two radiotherapy clinics located in the south 
of The Netherlands. Medical specialists working in the participating centers have been 
recruiting patients since July 2005 and will continue recruitment until approximately 
September 2007. Follow-up as usual takes place in the hospital where surgery and 
chemotherapy were performed, alternating between the surgeon, medical oncologist 
and radiation oncologist. The telephone follow-up is performed by the nurse practitioner 
(NP) or breast care nurse (BCN) working at this hospital. An NP is a registered nurse 
who has acquired (at masters level) the expert knowledge base, complex decision-
making skills and clinical competencies for expanded practice. The BCN is a qualifi ed 
nurse who has had specialist training in breast care and who guides the patient 
throughout treatment. In this paper the term BCN is used and refers to both types of 
nurses. The EGP is held at cancer information centers. These centers are specialized 
in providing support to (ex-) cancer patients and their relatives through education and 
organizing activities. Selecting participants from multiple centers and locations in the 
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Netherlands allows us to include a representative selection of breast cancer patients. 
Participation is voluntary and after written informed consent is obtained. Prior to the start 
of the study the protocol was approved by the Medical Ethical Committee of MAASTRO 
Clinic. Furthermore, all participating centers signed a declaration on local feasibility 
before inclusion of their fi rst patient, according to the Dutch law and regulations.
Study population
Selection of participants
Patients are recruited and included within six weeks after completion of treatment with 
curative intent by the medical specialist of the last treatment modality. Eligibility criteria 
are summed up in table 1. If eligible, the medical specialist introduces the MaCare trial 
to the patient and gives her a detailed information sheet. Within two weeks, the research 
assistant contacts the patient to explain the aim and implications of the trial again. 
Eligibility criteria are checked once more and the research assistant asks whether the 
patient wants to participate.
Breast cancer patients without distant metastases, within 6 weeks after treatment 
(n=320)
r t r ti t  it t i t t t t , it i    ft r tr t t 
( )
Surgery +/- radiotherapy +/- chemotherapy; included by last treating medical 
specialist
r r  /- r i t r  /- t r ; i l   l t tr ti  i l 
i li t
Surgeonr Medical oncologisti l l i t Radiation oncologisti ti  l i t
1. Follow-up as usual 
(n=80)
. ll -   l 
( )
3. Follow-up as usual + EGP
(n=80)
. ll -   l  
( )
2. Nurse-led telephone follow-
up 
(n=80)
. r -l  t l  f ll -
 
( )
4. Nurse-led telephone follow-
up + EGP 
(n=80)
. r -l  t l  f ll -
   
( )
R
Figure 1. Design of MaCare trial
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Non-participants
Patients who are eligible for inclusion but not interested in participation are asked to 
fi ll out the same baseline questionnaires (see outcome parameters) as participants. By 
assessing whether there are differences between participants and non-participants the 
external validity of the study results can be determined.
Sample size calculations 
The primary outcome measure is cancer specifi c QoL at 12 months after randomization, 
measured by the global health/QoL scale of the EORTC QLQ-C30. A baseline score of 
64 with a standard deviation of 17 (Gijsen & Koppejan-Rensenbrink, 2003; Nagel et 
al., 2001) is considered as a starting point. In an analysis of the clinical signifi cance of 
changes in QoL, Osoba et al. (1998) showed that patients judge a change between 5-10 
to be small, between 10-20 to be moderate, and more than 20 to be large. Consequently, 
we considered a change smaller than 5 points to be no change. To show that QoL of 
patients in arms 2 and 4 (telephone follow-up) is at least similar to patients in arm 1 and 
3 (usual follow-up) with a power of 80% and a signifi cance level of 0.05, the required 
number of patients per group is 80. With these 320 patients an improvement in QoL, by 
adding the EGP compared to no EGP, of 10 points with a power of 0.95 and a signifi cance 
level smaller than 0.01 can be detected. A dropout rate of 10% is accounted for in these 
calculations. 
Randomization
After written informed consent and completion of the baseline questionnaire, randomization 
by minimization is performed by the Comprehensive Cancer Center Limburg. Patients are 
pre-stratifi ed by treatment modalities and hospital. After randomization, the research 
assistant contacts the patient and informs her about the assigned study arm, thus 
whether she will receive standard or telephone follow-up and whether she will be invited 
to join the EGP.
Table 1: Study inclusion and exclusion criteria
Inclusion criteria
Female patients with breast cancer without distant metastases
WHO performance scale 0-2
Treated with curative intent (i.e. lumpectomy or mastectomy, with or without radiotherapy and/or 
chemotherapy)
Treatment completed < 6 weeks prior to randomization
Able to speak and read fl uently in Dutch
Exclusion criteria
Participation in another trial, requiring more frequent follow-up
Medical diseases (treatment-related side-effects, concomitant tumors) requiring frequent follow-up
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Interventions
Usual care
The fi rst study arm, the standard arm, consists of follow-up as described in the Dutch 
guidelines. After treatment, the patient has an outpatient clinic visit with the medical 
specialist or BCN every three months during the fi rst year, every six months during the 
second year, and thereafter once a year until at least fi ve years. Mammography is taken 
once a year.
Nurse-led telephone follow-up
In study arms 2 and 4 a mammography is taken once a year, which is combined with 
a visit to the medical oncologist, the surgeon, BCN or the radiation oncologist. At the 
other regular follow-up times (i.e. at 3, 6, 9 and 18 months), the BCN has a telephone 
interview with the patient. The telephone interview is done by open discussion and a semi 
structured questionnaire, including screening for physical - especially loco regional - and 
psychosocial symptoms, and compliance to hormonal therapy. Data on the side effects 
of treatment are also collected during the interview. Furthermore, the BCN informs about 
general well being of the patient, her family-life, relationships and work reintegration. If 
the patient does not feel reassured an additional appointment is made for her to come to 
the hospital. The telephone follow-up is mainly meant to reduce the workload of medical 
specialists, with possible reduction of costs, but could also infl uence QoL as a result of a 
reduction of stressful visits to the outpatient clinic (Allen, 2002). To adequately perform 
the telephone interview, all participating BCNs attained training, specifi cally developed 
for this study. In this training nurses are informed on the most recent developments 
in breast cancer treatment and follow-up, develop a semi-structured questionnaire for 
support during the interview, and practice their telephone communication skills with a 
breast cancer patient.
 
Educational group program
In arms 3 and 4 of the study, the patient and her partner (or close friend or family 
member) are invited to participate in the Educational Group Program (EGP) within three 
months after treatment. The basic theory underlying the EGP is the transaction process 
theory of stress (Lazarus & Folkman, 1984). The group-format program focuses on the 
fi rst two stages of the transaction process theory of stress, the primary and secondary 
appraisal. The EGP therefore consists of two interactive group sessions of 2,5 hours of 
patient education. In the fi rst session, which addresses the primary appraisal, a BCN 
provides information on possible side effects of the different treatments and issues such 
as prostheses, exhaustion, hereditary issues and fi nancial consequences. Also, signs 
and symptoms of recurrences are discussed. A health care psychologist concentrates on 
psychological consequences, like anxiety, depression and changed family role patterns. 
The second session focuses on the second appraisal, i.e. information is provided on 
possible coping strategies and actions that could be undertaken when symptoms occur.
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Furthermore, information on the various health care workers and additional interventions 
is given. Discussions are stimulated by the speakers, addressing issues such as how to 
deal with anxiety, mood changes and changes in relationships. In this way, patients and 
their partners are stimulated to be alert to symptoms, and to enhance self-effi cacy in 
adopting one of the proposed actions or coping strategies. It is expected that this will 
lead to a better QoL. During the second session a volunteer from the Dutch Breast Cancer 
Association presents regional activities available for participants. The EGP is completed 
with a relaxation exercise. After the two sessions, participants receive a small booklet 
encompassing the topics discussed in the program. The BCN and health care psychologist 
use standardized presentations, so that the EGPs given during the time of this study 
are as similar as possible. Furthermore, by using standard presentations, different 
teams can lead the EGP and the program will be easily transferable to other settings. 
Primary and secondary outcome measures
Primary outcome measure
The primary domain for improvement for both interventions in the trial is cancer-specifi c 
QoL. Cancer-specifi c QoL is measured by the QoL scale of the European Organisation 
for Research and Treatment of Cancer (EORTC) QLQ-C30. The EORTC QLQ-C30 has a 
validated Dutch-language version available (Aaronson et al., 1993). 
Secondary outcome measures
Secondary outcome measures are perceived behavioral control, anxiety, patients’ 
satisfaction with follow-up, generic health-related quality of life and societal costs. 
Perceived behavioral control is measured by the Dutch version of the Mastery Scale (Pearlin 
& Schooler, 1978). A question whether the patient is experiencing emotional support from 
partner (if applicable) is added. Anxiety is measured by the validated Dutch version of the 
State-Trait Anxiety Inventory (STAI) (van der Ploeg, 1980). Patients’ satisfaction with follow-
up will be assessed using the validated Patient Satisfaction Questionnaire - NL (PSQ-NL) 
(Hagedoorn et al., 2003). Generic health-related quality of life is measured by the EuroQol-
5D (EQ-5D) (EuroQoL-Group, 1990).
Societal costs are determined by the hospital information systems and prospective cost-
diaries. More details on the costs are provided in the economic evaluation section.
Time schedule 
Patients complete questionnaires at baseline, and at 3, 6, 12 and 18 months intervals. 
Costs-diaries are fi lled out by the patients over a four week period, at the same time 
points. The questionnaires and cost-diaries are sent by mail. If not returned within 14 days, 
patients are contacted by the research assistant and are asked to continue participation.
Statistical analysis
To evaluate differences in QoL outcome between the study arms, the data will be analyzed 
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using a multivariate linear regression model. In this model both the EGP factor and the 
telephone factor will be taken into account. In addition, variables such as age, hospital 
treatment, and experienced support of a partner, will be brought into the model. The 
procedure will be performed four times as QoL is assessed at 3, 6, 12 and 18 months. 
Differences in satisfaction with care, perceived behavioral control and anxiety will 
be analyzed in the same way. Participation at group meetings will be analyzed using 
logistic regression models. Differences in medical consumption will be evaluated using 
a multivariate linear regression model. Subgroup analyses will be performed to identify 
specifi c patient characteristics that could predict the optimal follow-up strategy for the 
individual patient. Data will be analyzed according to the intention-to-treat principle.
The number of recurrences is expected to be very low with a follow-up of 18 months 
(Bartelink et al., 2001). Statistical analysis of the difference in time-to-detection per group 
will therefore be limited to descriptive statistics.
Economic evaluation
Parallel to the trial an economic evaluation will be performed, comparing the costs and 
effects of each separate follow-up strategy, in order to determine the most cost-effective 
follow-up. The cost-effectiveness comparison thus includes four different strategies 
corresponding to the four study-arms. The cost-effectiveness ratio(s) will be expressed as 
the incremental cost per quality-adjusted life year (QALY). In order to be able to construct 
a QALY, the scores on the fi ve dimensions of the EuroQol (Dolan, 1997) are used. The cost-
effectiveness analysis is performed from a societal perspective. Sensitivity analyses will 
subsequently be performed on several variables. For future costs and effectiveness data, 
a discount rate of 4% will be handled. In order to quantify the uncertainty surrounding the 
costs and effectiveness results, bootstrap analyses will be performed.
The cost-analysis from a societal perspective includes all health care costs and costs 
outside the health care sector. The cost-analysis will be performed by means of the micro-
costing method, whereby a detailed inventory of the resource use per patient will take 
place (Gold et al., 1996). Costs are calculated by multiplying resource utilization with 
the cost-price per unit. Health care costs refer to hospital costs and costs of other health 
care facilities. Hospital costs consist of personnel, material, capacity costs and overhead 
associated with the four programs and costs of (scheduled and unscheduled) outpatient 
hospital visits, telephone interviews and medical services (e.g. laboratory tests, bone 
scans, et cetera). Most of these costs are estimated by using existing resource registration 
systems and available cost prices through the fi nancial departments of the participating 
centers. In case true cost prices are not readily available in all participating centers the 
existing cost-prices of the University Hospital Maastricht or offi cial directive prices are 
used (Oostenbrink et al., 2004). Costs of telephone follow-up consist of personnel costs 
of the BCN and telephone costs. Costs associated with the EGP primarily consist of the 
personnel costs. Other health care costs include costs of visits to the general practitioner, 
medication, psychological and/or psychiatric (emergency) care. 
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Costs outside the health care sector refer to out-of-pocket expenditures and productivity 
costs due to reductions in paid work and/or domestic activities. These costs are 
determined by a prospective cost diary, which is fi lled in by the patient at baseline, and 
thereafter at four time points (3, 6, 12 and 18 months after treatment) for a period of 
four weeks. Productivity losses due to absence from work are estimated by means of the 
friction cost method (Koopmanschap et al., 1995; Oostenbrink et al., 2004). In case of 
domestic or other unpaid activities, shadow prices will be used.
DISCUSSION
Current frequent follow-up is not meeting its intended aims, but does raise the burden on 
medical specialists, leading to high medical costs. Although studies investigating reduced 
follow-up have shown that there is no difference in time to detection of recurrence and 
patients perceived QoL, reduced follow-up has not yet been widely accepted and applied. 
Medical specialist may feel that patients need constant reassurance and patients have 
the false expectation that frequent follow-up will improve survival (de Bock et al., 2004b). 
Improvement of psychosocial support and information to patients could lead to a better 
acceptance of reduced follow-up. The trial reported in this paper combines these two 
aspects. By performing an economic evaluation parallel to the trial, the ultimate aim is to 
fi nd an alternative and more cost-effective follow-up strategy. We expect the educational 
group program to help breast cancer patients and their partners in dealing effectively and 
effi ciently with the consequences of a recent diagnosis and treatment of a potentially fatal 
disease. This increase in perceived behavioral control is expected to improve QoL. The 
nurse-led telephone calls are expected to render visits to the outpatient clinic superfl uous, 
which may subsequently reduce the anxiety experienced by patients for each follow-up 
visit. Looking at costs, the telephone follow-up is expected to be cost-saving, due to fewer 
visits to the medical specialist. The EGP is expected to result in a slight cost-increase per 
patient in the fi rst follow-up year, as compared to standard follow-up. However, due to the 
expected increase in QoL it may yield 1) reduced health care costs and 2) possibly lower 
costs due to a reduction in productivity losses. 
The close cooperation with many centers enables us to reach a representative study 
population of women treated for primary breast cancer and enhances the generalizability 
of the trial results. In addition, BCNs are systematically trained to perform telephone 
follow-up and the EGP is based on standardized presentations. If one or both interventions 
appear to be successful, they are easily transferable to other settings. Finally, results may 
be extended to other cancer patients, but a further study would be required.
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ABSTRACT 
[Objective] To investigate whether frequent hospital follow-up in the fi rst year 
after breast cancer treatment might partly be replaced by nurse-led telephone 
follow-up without deteriorating health-related quality of life (HRQoL), and whether 
a short educational group program (EGP) would enhance HRQoL. [Design] 
Pragmatic, 2x2 factorial, randomized controlled trial. [Setting] Multicenter 
study in the Netherlands. [Participants] Between July 2005 and March 2008, 
seven hospitals and two radiation therapy clinics included 320 breast cancer 
patients who were treated with curative intent. [Interventions] Participants were 
randomized to follow-up care as usual (3-monthly outpatient clinic visits), nurse-
led telephone follow-up, or the former strategies combined with an educational 
group program. [Main outcome measures] The primary outcome for both 
interventions was HRQoL, measured by the EORTC QLQ-C30 questionnaire. 
Secondary outcomes were role and emotional functioning, and feelings of control 
and anxiety. [Results] Data of 299 patients were available for evaluation. In the 
primary analysis, 150 patients allocated to nurse-led telephone were compared 
to 149 patients in hospital follow-up, and 149 patients allocated to EGP were 
compared to 150 patients not allocated to the EGP. There was no signifi cant 
difference in HRQoL between nurse-led telephone and hospital follow-up at 12 
months after treatment (p=0.42; 95% CI for difference: -1.93 to 4.64) and neither 
between follow-up with or without EGP (p=0.86; 95% CI for difference: -3.59 to 
3.00). Furthermore, no differences were found in role and emotional functioning, 
and feelings of control and anxiety (all p-values > 0.05). [Conclusions] Replacing 
most hospital follow-up visits in the fi rst year after breast cancer treatment by 
nurse-led telephone follow-up does not impede patient outcomes. Hence, nurse-
led telephone follow-up seems an appropriate way to reduce clinic visits.
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INTRODUCTION
After curative treatment for breast cancer women commonly attend regular follow-up ex-
aminations. In most countries, follow-up is rather frequent (2-4 times annually) in the fi rst 
2-3 years; thereafter frequency is reduced to once a year (Khatcheressian et al., 2006; 
Pestalozzi & Castiglione, 2008). The aim of these follow-up examinations is to detect local 
disease recurrence or a second primary breast cancer, but also to provide information 
and psychosocial support (Khatcheressian et al., 2006; Pestalozzi et al., 2005). However, 
there has been much debate regarding the value of this routine follow-up of women with 
breast cancer. Current follow-up patterns depend heavily on expensive and scarce special-
ized knowledge for routine history taking and for physical examinations, but do not always 
provide optimal care for patients (Grunfeld, 2009; Kimman et al., 2007a; Montgomery et 
al., 2009; Montgomery et al., 2007; Pennery & Mallet, 2000). 
Alternative follow-up strategies have been proposed, such as follow-up by general prac-
titioners (Grunfeld et al., 2006), nurse-led follow-up (Koinberg et al., 2004) or telephone 
follow-up (Beaver et al., 2009b; Montgomery, 2009). Although studies have shown that 
these alternative follow-up models can be equally effective as traditional hospital follow-
up, as measured by a variety of outcomes, these models are not yet widely applied in 
clinical practice. Results may not have been suffi ciently convincing, or perhaps medical 
specialists believe that patients need frequent reassurance. Moreover, patients may have 
false expectations that frequent follow-up will result in better overall survival (de Bock et 
al., 2004b). Improvement of psychosocial support and education of patients may lead to 
better acceptance by both patients and specialists of a reduced follow-up policy (Koinberg 
et al., 2006). A number of studies have been performed using various group interven-
tion formats in order to provide psychosocial support for breast cancer patients. However, 
most interventions focused on intensive psychological support (10 sessions or more) and 
showed varying results and often high refusal rates (Clark et al., 2003; Helgeson et al., 
1999). 
Since the educational aspects of these group interventions were most successful (Helge-
son et al., 2000), a short educational group program (EGP) was developed for the study 
presented in this paper, specifi cally focusing on psychosocial and physical sequelae of 
breast cancer treatment. We hypothesized that the EGP would increase health-related 
quality of life (HRQoL) in the fi rst year after treatment. In addition, nurses were trained 
to perform telephone follow-up to replace most of the hospital visits in the fi rst year after 
treatment. We hypothesized that HRQoL of patients receiving nurse-led telephone follow-
up would be at least similar to HRQoL of patients after hospital follow-up. To test these 
hypotheses we performed a randomized controlled trial with a 2x2 factorial design was 
performed. The aim of the current paper is to report on the effects of nurse-led telephone 
follow-up and the EGP on HRQoL and several other psychological aspects. Data on cost-
effectiveness obtained in this trial will be reported in a separate paper.
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METHODS
Recruitment, design and sample
Details of the randomized controlled trial (RCT) design and protocol execution have been 
reported previously (ISRCTN 74071417) (Kimman et al., 2007b). In sum, the study was 
a multicentre RCT with a 2x2 factorial design. Between 2005 and 2008, 320 females 
were recruited through seven hospitals and two radiotherapy clinics in the South of the 
Netherlands. Participants were eligible for inclusion if they had completed breast cancer 
treatment with curative intent less than six weeks prior to randomization with a WHO 
performance score between 0-2, and were fl uent in speaking and reading Dutch. Exclusion 
criteria were distant metastases and/or participation in another clinical trial or medical 
illness requiring more frequent follow-up. All eligible patients received detailed study 
information from their medical specialist. This study information included information on 
the purpose and effectiveness of breast cancer follow-up, and signs and symptoms of 
possible recurrences.
After approximately one week a research assistant contacted the patient by telephone 
to answer any questions and, when a patient was willing to participate, ask to provide 
written informed consent. Participants were then randomly assigned to one of four follow-
up strategies (study arms) during the fi rst 18 months after treatment; i.e. 1) hospital 
follow-up as usual: fi ve outpatient clinic visits in the fi rst 18 months (at 3, 6, 9, 12 and 
18 months), including a mammography at 12 months; 2) nurse-led telephone follow-up: 
a mammography at 12 months combined with an outpatient clinic visit, and telephone 
interviews by a breast care nurse (BCN) at the same time points as for usual follow-up (i.e. 
3, 6, 9 and 18 months); 3) arm 1 plus educational group program (EGP); 4) arm 2 plus 
EGP. Study arms were combined for analysis as follows: hospital follow-up (arms 1 and 
3) compared to nurse-led telephone follow-up (arms 2 and 4); and EGP (arms 3 and 4) 
compared to no EGP (arms 1 and 2). 
Randomization by minimization (Taves, 1974) was performed by the independent 
Comprehensive Cancer Centre Limburg using a computerized randomization programme 
(ALEA). Patients were pre-stratifi ed by hospital and treatment modality (surgery, surgery 
+ radiotherapy, surgery + chemotherapy, and surgery + radiotherapy + chemotherapy). 
The study protocol was approved by the Medical Ethical Review Board of MAASTRO Clinic 
(NL). All participating centres signed local feasibility declarations, according to Dutch law 
and regulations, prior to inclusion of the fi rst patient.
Procedures and interventions
For patients randomized to hospital follow-up, care was provided by the surgeon, medical 
oncologist, radiation oncologist and/or breast care nurse (BCN). Follow-up visits consist-
ed of medical history taking and physical examination; scheduled duration was 10 min-
utes. For patients randomized to telephone follow-up, follow-up was performed by a BCN 
specifi cally trained for this study. The telephone interview consisted of a semi-structured 
questionnaire including screening for physical -especially loco-regional- and psychological 
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symptoms, treatment side effects, compliance with hormonal therapy plus open discus-
sion of these issues. Furthermore, the BCN informed about patients’ general well-being, 
family life and work reintegration. Time scheduled for the telephone interview was 20 
minutes.
In study arms 3 and 4, patients and their partners were invited to participate in the EGP 
which consisted of two interactive group sessions of 2.5 hours each (with two weeks in 
between). The EGP took place regularly so that each patient could participate within three 
months after completion of treatment. A BCN provided information on possible treatment 
side effects and topics such as signs and symptoms of possible recurrences, prostheses 
and fatigue. A health care psychologist addressed psychological and social consequences 
of breast cancer, particularly anxiety and changes in family and social role patterns, and 
discussed psychological coping strategies. The EGP was concluded with a relaxation exer-
cise; also, participants received a booklet encompassing all topics discussed in the EGP. 
Outcome measures
Primary outcome measure
The primary outcome for both interventions was HRQoL at 12 months after randomization, 
measured by EORTC QLQ-C30. This self-administered disease-specifi c HRQoL 
questionnaire is validated for oncological clinical research (Bottomley & Aaronson, 2007; 
Fayers & Bottomley, 2002) and has a validated Dutch version available (Aaronson et 
al., 1993). The EORTC QLQ-C30 consists of 30 items and provides scores on multi-item 
functional subscales (e.g. role, emotional functioning), multi-item symptom scales (e.g. 
fatigue, pain), a HRQoL (global health) subscale and a number of single items (e.g. sleep 
disturbance). The HRQoL subscale consists of two items: (1) How would you rate your 
overall health during the past week? and; (2) How would you rate your overall quality of life 
during the past week? Items are rated on a 7-point Likert-scale, ranging from “very bad” to 
“excellent”. Scores on HRQoL and functional subscales range from 0 to 100, with higher 
scores representing higher levels of functioning and HRQoL.
Secondary outcome measures
Secondary outcomes were emotional and role functioning, anxiety and perceived feelings 
of control. Emotional and role functioning were measured by EORTC QLQ-C30. The 
emotional functioning subscale consists of four items concerning presence of feelings 
of depression, tension, loss of concentration and fear. The role functioning subscale 
concerns the (dis)ability to perform daily activities. Both subscales are rated on a 4-point 
Likert scale and transformed to a score between 0 and 100.
Anxiety was measured by the state anxiety scale of the validated Dutch version of the 
State-Trait Anxiety Inventory (STAI) (van der Ploeg, 1980). This 20-items questionnaire 
measures the contemporary condition of “state anxiety” initiated by current life events. 
Scores range from 20-80, a higher score indicating greater anxiety.
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Perceived feelings of control were measured by the Dutch version of the Mastery Scale 
(Pearlin & Schooler, 1978). This questionnaire consists of seven statements about 
feelings of control (e.g. “I have little control over the things that happen to me”). A 
separate statement about experienced emotional support from partner was added. Rating 
alternatives ranged from “strongly disagree” to “strongly agree” and average scores were 
calculated (range from 0 to 5), with higher scores representing higher perceived feelings 
of control. 
Statistical analysis
Sample size calculations were based on HRQoL measured by EORTC QLQ-C30 (Aaronson 
et al., 1993). A baseline score of 64 with a standard deviation of 17 was considered as 
a starting point (Gijsen & Koppejan-Rensenbrink, 2003; Nagel et al., 2001). An analysis 
of the clinical signifi cance of HRQoL changes showed that patients indicate a change be-
tween 5–10 to be small, between 10–20 to be moderate, and of more than 20 to be large 
(Osoba et al., 1998). Consequently, we considered a change smaller than 5 to mean no 
change. A power analysis on our study design required 320 breast cancer patients in or-
der to demonstrate that HRQoL of patients with nurse-led telephone follow-up would be at 
least similar (i.e. < 5 points difference) to patients in the hospital follow-up (non-inferiority 
analysis; power 80%, α 0.05). Also, with 320 patients, a moderate improvement in HRQoL 
(i.e. > 10 points difference) in patients attending the EGP could be detected (superiority 
analysis; power 95%, α < 0.01). A dropout rate of 10% was accounted for in these cal-
culations. Sample size was calculated for main effects only and assumed no interaction 
between the two interventions.
Patients completed questionnaires before randomization at baseline, and at 3, 6, 12 and 
18 months after respective treatments. Data were entered and analyzed with SPSS 17.0. 
Missing data were imputed by means of Rubin’s multiple imputation procedure using the 
defaults in SPSS 17.0, generating fi ve datasets (Schafer, 1999; Sterne et al., 2009). All 
analyses were performed with each of the fi ve data sets, and results were pooled
Differences in patient characteristics between participants and non-participants were 
compared using the X2 test and independent sample t-test. The primary analysis assessed 
the above pre-defi ned effects of both interventions. Patients remained in the study arm 
to which they were assigned, whether or not they completed the intervention given to the 
arm. Additionally, we included an interaction effect to test for interaction/mutual effect 
modifi cation between interventions. Regression analyses were used to predict primary 
and secondary outcome differences at 12 months after randomization by including or 
excluding interventions. Linear mixed models were fi tted with EGP (yes/no) and telephone 
follow-up (yes/no) as fi xed factors and patient as random factor. In addition, recruitment 
hospital, age, education, time since end of treatment and treatment modality were 
included as covariates. Primary and secondary outcomes were adjusted for baseline 
differences. 
Figure 1. Flow of participants through trial
Study introduced to patients who met inclusion criteria (n = 881)Study introduced to patients who met inclusion criteria (n = 881)
Randomized (n = 320)Randomized (n = 320)
Not willing to participate (n = 561)
• Preference face-to-face contact: 26.9%
• Not interested in EGP: 16.5%
• Other reasons (tired, busy, questionnaires): 24.6%
• Reason unknown: 32%
Not willing to participate (n = 561)
• Preference face-to-face contact: 26.9%
• Not interested in EGP: 16.5%
• Other reasons (tired, busy, questionnaires): 24.6%
• Reason unknown: 32%
Arm 3
Hospital f-up + EGP
(n=79)
Arm 3
Hospital f-up + EGP
(n=79)
Arm 1 
Hospital follow-up
(n=79)
Arm 1 
Hospital follow-up
(n=79)
Arm 2
Telephone follow-up
(n=85)
Arm 2
Telephone follow-up
(n=85)
Arm 4 
Telephone f-up + EGP
(n=77)
Arm 4 
Telephone f-up + EGP
(n=77)
Lost to follow-up (n=4):
• Recurrence (n=1)
• Other cancer (n=2)
• Metastases (n=1)
Lost to follow-up (n=4):
• Recurrence (n=1)
• Other cancer (n=2)
• Metastases (n=1)
Lost to follow-up (n=3):
• > 2 questionnaires 
missing (n=1)
• Other cancer (n=1)
• Metastases (n=1)
Lost to follow-up (n=3):
• > 2 questionnaires 
missing (n=1)
• Other cancer (n=1)
• Metastases (n=1)
Lost to follow-up (n=5):
• Patient request (n=1)
• >2 questionnaires 
missing (n=1)
• Other cancer (n=1)
• Metastases (n=2)
Lost to follow-up (n=5):
• Patient request (n=1)
• >2 questionnaires 
missing (n=1)
• Other cancer (n=1)
• Metastases (n=2)
Lost to follow-up (n=9):
• Patient request (n=3)
• > 2 questionnaires 
missing (n=2)
• Recurrence (n=1)
• Metastases (n=2)
• Herceptin (n=1)
Lost to follow-up (n=9):
• Patient request (n=3)
• > 2 questionnaires 
missing (n=2)
• Recurrence (n=1)
• Metastases (n=2)
• Herceptin (n=1)
74 patients analyzed
91.5% of all
questionnaires returned
74 patients analyzed
91.5% of all
questionnaires returned
76 patients analyzed
95.1% of all
questionnaires returned
76 patients analyzed
95.1% of all
questionnaires returned
75 patients analyzed
93.7% of all
questionnaires returned
75 patients analyzed
93.7% of all
questionnaires returned
74 patients analyzed
91.5% of all
questionnaires returned
74 patients analyzed
91.5% of all
questionnaires returned
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Since protocol violation may bias the trial (in either direction), per protocol analyses 
including only patients who properly followed the study protocol were also performed and 
reported, as recommended by Piaggio et al. (2006) and Jones et al. (1996). Furthermore, 
explorative subgroup analyses were performed according to level of anxiety, age, level 
of education, use of chemotherapy and level of support from partner. Analyses were 
performed by creating an interaction term between the intervention and subgroup and 
testing the signifi cance of the interaction in the regression model.
RESULTS
Patients 
Between June 2005 and March 2008, 320 of 881 eligible patients (36.4%) agreed to 
participate in the study (fi gure 1). Nearly half of the patients who refused to participate 
(n=240) agreed to fi ll out the baseline questionnaire for comparison with participants. 
At baseline, participants did not differ from non-participants with respect to education, 
marital status, HRQoL, emotional functioning and feelings of anxiety (all p-values > 0.05). 
However, participants were signifi cantly younger than non-participants (mean age 60 
years (SD=10.2), p < 0.001). 
Throughout the trial, 21 patients (6.5%) were lost to follow up for various reasons (e.g. 
development of metastases, recurrence, or three or more missing questionnaires) (fi gure 1). 
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Data from 299 patients were available for the analysis; 149 patients randomized to 
hospital follow-up and 150 patients randomized to telephone follow-up; and 149 patients 
randomized to follow-up with EGP and 150 patients randomized to follow-up without EGP, 
at three months. Baseline demographic and treatment characteristics were similar for 
patients randomized to telephone and hospital follow-up and for those with or without 
EGP (table 1). Mean sample age was 56 years (SD=9.9).
Table 1. Baseline and sociodemographic characteristics of participants in intervention (telephone follow-
up or educational group program (EGP) and control arms. Values are numbers (percentages) unless stated 
otherwise. RT=radiotherapy and CH=chemotherapy.
Hospital 
f-up
(n=149)
Telephone 
f-up (n=150)
EGP
(n=149)
No EGP
(n=150)
All partici-
pants
(n=299)
Age at recruitment
Mean in years (SD) 56.2 (10.7) 55.5 (9.0) 55.3 (10.4) 56.3 (9.4) 55.8 (9.9)
Range in years 23 - 78 34 - 75 23 - 76 34 - 78 23-78
Level of education
Low 45 (30.2) 57 (38.0) 51 (34.2) 51 (34.0) 102 (34.1)
Middle 62 (41.6) 56 (37.3) 60 (40.3) 58 (38.7) 118 (39.5)
High 42 (28.2) 37 (24.7) 38 (25.5) 41 (27.3) 79 (26.4)
Marital status
Married 109 (73.2) 103 (68.7) 104 (69.8) 108 (72.0) 212 (70.9)
Unmarried 16 (10.7) 17 (11.3) 17 (11.4) 16 (10.7) 33 (11.0)
Cohabiting 9 (6.0) 20 (13.3) 13 (8.7) 16 (10.7) 29 (9.7)
Widowed 15 (10.1) 10 (6.7) 15 (10.1) 10 (6.7) 25 (8.4)
Tumor stage
Stage I 91 (61.1) 90 (60.0) 85 (57.0) 96 (64.0) 181 (60.5)
Stage IIa 35 (23.5) 34 (22.7) 36 (24.2) 33 (0.22) 69 (23.1)
Stage IIb 8 (5.4) 13 (8.7) 13 (8.7) 8 (5.3) 21 (7.0)
Stage III 13 (8.7) 11 (7.3) 12 (8.1) 13 (8.7) 24 (8.0)
Unknown 2 (1.3) 2 (1.3) 3 (2.0) - 4 (1.3)
Treatment modality
Surgery 15 (10.1) 14 (9.3) 13 (8.7) 16 (10.7) 29 (9.7)
Surgery + RT 89 (59.7) 89 (59.3) 91 (61.1) 87 (58.0) 178 (59.5)
Surgery + CH 7 (4.7) 8 (5.3) 8 (5.4) 7 (4.7) 15 (5.0)
Surgery + RT + CH 38 (25.5) 39 (26.0) 37(24.8) 40 (26.7) 77 (25.8)
Hormonal therapy 50 (33.6) 44 (29.3) 48 (32.2) 46 (30.7) 94 (31.4)
Health scores (mean (SD))
Health-related quality of life 70.5 (17.8) 67.2 (19.0) 70.5 (18.9) 67.3 (17.9) 68.9 (20.1)
Emotional functioning 77.7 (20.4) 69.9 (25.7) 75.8 (23.6) 71.8 (23.3) 73.8 (23.5)
Role functioning 68.6 (29.3) 62.6 (27.8) 67.2 (29.9) 64.0 (27.4) 65.6 (28.7)
Feelings of anxiety 39.3 (11.3) 40.9 (11.8) 39.0 (11.5) 41.2 (11.6) 40.1 (11.6)
Feelings of control 2.6 (0.8) 2.6 (0.8) 2.5 (0.7) 2.6 (0.8) 2.6 (0.8)
Compliance to the protocol
Ten patients randomized to telephone follow-up preferred to receive hospital follow-up 
instead, and 20 patients with telephone follow-up received only one telephone follow-up 
contact, which was considered as protocol violation. Hence, 120 out of 150 patients in 
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the telephone follow-up arms, received telephone follow-up according to protocol. The 30 
patients who violated the protocol did not differ from other patients in the telephone follow-
up group regarding age, education, treatment modality, role functioning and feelings of 
control at baseline (all p-values > 0.05). However, their HRQoL and emotional functioning 
were signifi cantly lower and feelings of anxiety higher than protocol compliers (p-values of 
respectively 0.02, 0.01 and 0.01).
Ten out of 149 patients randomized to EGP did not attend the meetings. These patients 
did not differ from those attending the EGP regarding age, education, treatment modality 
and all outcome measures (all p-values > 0.05). Seventy-eight patients (52%) were 
accompanied by their partner at one or both meetings.
Primary outcome: health-related quality of life (HRQoL)
Intention to treat and per protocol analyses showed almost identical results (table 2). 
Results from the intention to treat analyses are discussed below. There was no signifi cant 
difference in HRQoL between nurse-led telephone and hospital follow-up at 12 months 
after treatment (p=0.42). The 95% confi dence interval for difference between mean 
HRQoL scores at 12 months after treatment was -1.93 to 4.64. A positive mean difference 
indicates higher levels of functioning for nurse-led telephone follow-up, while a negative 
difference indicates higher levels of functioning in the hospital follow-up. Yet, HRQoL 
signifi cantly improved over time (p=0.01), but without signifi cant differences in slope of 
improvement between both follow-up groups (p=0.41) (fi gure 2).
Similarly, there was no signifi cant difference in HRQoL between follow-up with or 
without EGP at 12 months after treatment (p=0.86). The 95% confi dence interval for 
difference between mean HRQoL scores at 12 months was -3.59 to 3.00. Again, there 
was no signifi cant difference in slope of improvement between follow-up groups (p=0.10) 
(fi gure 2). Finally, there was no signifi cant interaction effect between EGP and nurse-led 
telephone follow-up with respect to HRQoL (p=0.50).
Figure 2. Average health-related quality of life (HRQoL) scores on the EORTC QLQ-C30 questionnaire 
at baseline, and 3, 6 and 12 months after treatment: telephone versus hospital follow-up (left) and 
an educational group program (EGP) versus no EGP (right). Error bars represent the 95% confi dence 
interval.
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Secondary outcomes 
Role and emotional functioning, and feelings of control and anxiety improved over time, 
but there were no signifi cant differences between patients randomized to telephone and 
hospital follow-up (table 2). Similarly, differences between having participated in EGP or 
not with respect to role and emotional functioning and feelings of control and anxiety, 
were not signifi cant at 12 months after treatment. 
Table 2. Outcome fi ndings by study group adjusted for treatment, hospital, outcome variable at baseline, 
age, educational level and time since treatment. Intention to treat analysis: n=150 for telephone f-up, 
n=149 for hospital f-up; n=149 for EGP, n=150 for no EGP. Per protocol analysis: n=120 for telephone f-up, 
n=159 for hospital f-up; n=139 for EGP, n=160 for no EGP.
Estimated 
difference
95% Confi dence 
Interval for differenceª
p-value
Intention to treat analysis
Health-related quality of life
Telephone f-up vs hospital f-up 1.35 -1.93 to 4.64 0.42
EGP vs no EGP -0.29 -3.59 to 3.00 0.86
Emotional functioning
Telephone f-up vs hospital f-up 2.23 -1.50 to 5.96 0.24
EGP vs no EGP -1.66 -5.32 to 2.00 0.37
Role functioning
Telephone f-up vs hospital f-up 2.56 -2.12 to 7.24 0.28
EGP vs no EGP 1.23 -3.45 to 5.92 0.61
Feelings of anxiety
Telephone f-up vs hospital f-up -0.84 -2.78 to 1.11 b 0.40
EGP vs no EGP -0.10 -2.07 to 2.15 b 0.92
Perceived feelings of control
Telephone f-up vs hospital f-up -0.07 -0.22 to 0.07 0.32
EGP vs no EGP 0.00 -0.15 to 0.15 0.99
Per protocol analysis
Health-related quality of life
Telephone f-up vs hospital f-up 0.27 -3.20 to 3.75 0.88
EGP vs no EGP -0.75 -4.20 to 2.69 0.67
Emotional functioning
Telephone f-up vs hospital f-up 1.56 -2.28 to 5.30 0.43
EGP vs no EGP -1.47 -5.26 to 2.32 0.45
Role functioning
Telephone f-up vs hospital f-up 2.28 -2.61 to 7.16 0.36
EGP vs no EGP 1.37 -3.49 to 6.23 0.58
Feelings of anxiety
Telephone f-up vs hospital f-up -0.13 -2.15 to 1.89 b 0.90
EGP vs no EGP -0.40 -2.43 to 1.63 b 0.70
Perceived feelings of control
Telephone f-up vs hospital f-up -0.09 -0.24 to 0.07 0.28
EGP vs no EGP -0.02 -0.20 to 0.15 0.80
ª Positive differences imply a higher level of functioning in the telephone and EGP group.
b Negative differences imply less anxiety in the telephone and EGP group.
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Subgroup analyses
Explorative subgroup analyses according to level of anxiety, age, education, use of 
chemotherapy, and level of support from partner did not identify specifi c subgroups of 
patients for whom the interventions would have been more effective than for others (data 
not shown).
DISCUSSION
Follow-up of breast cancer patients continues to be controversial despite almost two 
decades of research. Current frequent follow-up is not meeting its intended aims, but 
does raise the burden on specialized staff and hospital resources. This multicentre 
randomized controlled trial (RCT) showed that some hospital clinic visits in the fi rst year 
after treatment could well be replaced by nurse-led telephone follow-up without a loss 
of HRQoL, a decrease in role and emotional functioning and feelings of control, nor an 
increase in feelings of anxiety. It was also found that an educational group program (EGP) 
did not lead to a signifi cant improvement in HRQoL, or any other outcome measures.
In a recently published paper on this RCT we reported high patient satisfaction scores 
for both nurse-led telephone as well as hospital follow-up. Moreover, the numbers of 
hospital visits were substantially less in the telephone group compared to hospital follow-
up (Kimman et al., 2010a). The present positive fi ndings regarding nurse-led telephone 
follow-up are similar to those reported in earlier studies (Beaver et al., 2009b; Gulliford et 
al., 1997; Montgomery et al., 2008a). Hence, results from this RCT lend further support 
to acceptability, feasibility, and patient satisfaction associated with telephone follow-up 
instead of hospital follow-up. The RCT by Beaver and colleagues, comparing nurse-led 
telephone follow-up with hospital follow-up, showed that telephone follow-up signifi cantly 
improved satisfaction and did not produce excess anxiety compared with hospital follow-
up. Women were on average 20 months after end of treatment when entering the trial 
(Beaver et al., 2009b). Since in the present study women entered immediately after 
treatment both trials may be seen as complementary and both provide evidence that 
telephone follow-up appears appropriate for patients in different phases after treatment 
(Beaver et al., 2009b). 
With respect to HRQoL and feelings of control and anxiety, the EGP did not meet our initial 
expectations. Based on these effectiveness results we would be hesitant to recommend 
unconditional implementation of the present EGP. However, an interesting fi nding in 
Beaver’s study was that, although information needs of patients reduced over time, 20-
30% still reported need for more information by the end of the study. This suggests that 
other methods to improve patients’ information may be added to nurse-led telephone and 
hospital follow-up. Although not specifi cally investigated, the short-term EGP developed for 
our study could be an effective way to meet information needs of patients. Furthermore, 
a non-randomized study (n=96) by Koinberg and colleagues (2006), in which traditional 
hospital follow-up was compared to a short multidisciplinary educational program 
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(replacing hospital visits) similar to our EGP, reported that both follow-up programs were 
equivalent in terms of well-being, aspects of self-care and coping abilities (Koinberg et 
al., 2006). Hence, our EGP might be a substitute for (some) traditional hospital follow-up 
visits. In our study, the EGP was complementary to hospital and telephone follow-up, and 
not yet used as a full substitute. 
Our study achieved a relatively low participation rate of 36%. However, considering that 
patients fi nd hospital visits reassuring (Beaver & Luker, 2005) and were asked to forego 
these visits and physical examinations for this study, as well as the fact that patients 
were made aware of the status quo and generally prefer this (Salkeld et al., 2000), this 
low participation rate was anticipated. Importantly, the cooperation with many centres 
enabled us to reach a representative study population of women treated for primary breast 
cancer, thus enhancing generalization of the results to a national level. Nevertheless, 
the low participation rate and considerable protocol violation in the telephone follow-up 
may suggest that instead of a one-size-fi ts-all approach, more individualized follow-up 
may have to be applied, taking into account specifi c patient preferences. Patients who 
violated the protocol had lower HRQoL and higher levels of anxiety at the end of treatment; 
therefore for these patients hospital follow-up may be more appropriate. Moreover, our 
recent study on preferences for follow-up in the fi rst year after breast cancer treatment 
showed that preferences for the health care provider for follow-up and for participation 
in an EGP were very heterogeneous (Kimman et al., 2010b). Nevertheless, it must be 
realized that implementation of reduced or individualized follow-up strategies asks for a 
paradigm shift, requiring attitude change among both medical specialists and patients 
and efforts to prevent false expectations of follow-up effi cacy. In addition, it is important 
to fi rst explore whether a more individualized follow-up indeed shows improved outcomes 
in terms of satisfaction and HRQoL and is feasible in clinical practice.
In conclusion, replacement of most hospital follow-up visits in the fi rst year after treatment 
by nurse-led telephone follow-up does not impede patient outcomes. Hence, nurse-led 
telephone follow-up seems an appropriate way to reduce clinic visits and represents an 
accepted alternative strategy. An EGP may be appropriate to address information needs, 
but it may not unequivocally affect positive HRQoL outcomes. 
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Responsiveness of the EQ-5D 
in breast cancer patients 
in their first year after treatment
KIMMAN ML, DIRKSEN CD, LAMBIN Ph, BOERSMA LJ. 
HEALTH AND QUALITY OF LIFE OUTCOMES 2009;7(1):11
ABSTRACT 
[Background] The EQ-5D is a generic health-related quality of life (HRQoL) 
measure that is used for the purpose of economic evaluations of health 
interventions. Therefore, it has to be responsive to meaningful changes 
in health in the patient population under investigation. The aim of this 
study was to investigate the responsiveness of the EQ-5D in breast cancer 
patients in their fi rst year after treatment. [Methods] The subscale global 
health of the disease-specifi c HRQoL measure EORTC QLQ-C30 was 
used as a reference instrument to determine meaningful changes in 
health and identify subgroups of patients: patients reporting a moderate-
large deterioration, small deterioration, a small improvement, moderate-
large improvement, or no change in health status. Responsiveness was 
evaluated by calculating standardized response means (SRMs) in the fi ve 
subgroups of patients and performing analysis of variance procedures. 
The two HRQoL measures were fi lled out two weeks and one year after 
fi nalizing curative treatment for breast cancer (n=192). [Results] The EQ-
5D was able to capture both improvements and deteriorations in HRQoL. 
SRMs of the EQ VAS and EQ-5D Index were close to zero in the subgroup 
reporting no change and increased and decreased adequately in the 
subgroups reporting small and moderate changes. Additional analysis 
of variance procedures showed that the EQ-5D was able to differentiate 
between subgroups of patients with no change and moderate-large 
deterioration or improvement in health. [Conclusions] The EQ-5D seems 
an appropriate measure for the purpose of economic evaluations of health 
intervention in breast cancer patients after treatment.
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INTRODUCTION
With an estimated 1.15 million new cases worldwide each year and a relatively good 
prognosis, breast cancer is the most prevalent cancer in the world today (Parkin et al., 
2005). After curative treatment for breast cancer, women attend frequent follow-up visits 
to be examined for possible local or regional recurrence or a second primary breast 
tumor, and to receive psychosocial support (ESMO, 2001; Khatcheressian et al., 2006a). 
However, no strong evidence exists that regular follow-up is effective with regard to disease 
free survival or overall survival (de Bock et al., 2004a; Jacobs et al., 2001; te Boekhorst 
et al., 2001), or in providing psychosocial support (Allen, 2002; Pennery & Mallet, 2000). 
Hence, the assessment of outcomes like patient satisfaction and health-related quality of 
life (HRQoL) is common practice in clinical oncology trials investigating alternative follow-
up strategies and psychosocial interventions for breast cancer survivors (Antoni et al., 
2001; Grunfeld et al., 1999a; Helgeson et al., 2001; Kimman et al., 2007a; Kimman et 
al., 2007b; Koinberg et al., 2004; Marcus et al., 1998; Meneses et al., 2007; Sandgren 
& McCaul, 2003). Given the high prevalence of breast cancer and budget constraints 
in health care, it is also important to understand the impact of alternative strategies 
on economic outcomes. Therefore, clinical trials are increasingly incorporating generic 
HRQoL measures, such as the EQ-5D, for the purpose of economic evaluations (Pickard 
et al., 2007). The EQ-5D is a standardized multi-dimensional health state classifi cation 
system. It generates a single index score for each health state (EuroQoL-Group, 1990). 
Index scores, in turn, can be used to calculate quality adjusted life years (QALYs), which 
is the most preferred summary outcome measure in economic evaluations (Drummond 
et al., 2005). 
A substantial and growing body of literature regarding the usefulness of the EQ-5D in 
cancer has emerged, supporting its validity and reliability (Pickard et al., 2007). However, 
the responsiveness of the EQ-5D, defi ned as its ability to capture true underlying changes 
in the patients’ health status over time (Terwee et al., 2003), is highly dependent on 
patient population and setting. In comparison with disease-specifi c instruments, the 
responsiveness of the EQ-5D was found to be comparable in one study (Krabbe et al., 
2004), but more often it is found to be less responsive than disease-specifi c instruments 
(Eurich et al., 2006; Krahn et al., 2007; van de Willige et al., 2005; Wiebe et al., 2003). 
Hence, the usefulness of the EQ-5D may be limited if it is not able to detect changes in 
health status in the patient population under investigation. 
To our knowledge, the responsiveness of the EQ-5D has not yet been examined in breast 
cancer patients after treatment. Therefore, we use data from a randomized clinical trial 
investigating several follow-up strategies for curatively treated breast cancer patients 
(Kimman et al., 2007b) to address whether the EQ-5D is responsive to changes in HRQoL 
in a population of breast cancer patients in their fi rst year after treatment.
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METHODOLOGY
Study population
Participants were enrolled in a randomized clinical trial investigating the cost-effectiveness 
of nurse-led telephone follow-up and a short educational group program after curative 
treatment for breast cancer (MaCare trial, ISRCTN 74071417) (Kimman et al., 2007b). 
Patients in the trial were all female, treated for breast cancer with curative intent, and 
had no concomitant tumors or comorbidity requiring hospital visits. There were no 
age restrictions. Patients were included in the trial after fi nalizing treatment and after 
giving written informed consent. Treatment included surgery and/or radiotherapy and/
or chemotherapy. Follow-up appointments took place at 3,6,9 and 12 months after 
treatment. For the purpose of studying the responsiveness of the EQ-5D, patients who 
had had their 12 months follow-up were eligible. The EQ-5D and the disease-specifi c 
EORTC QLQ-C30 were sent to patients at home two weeks after the end of treatment 
(T0) and twelve months after treatment (T1). Of 220 eligible patients, 29 patients failed 
to complete both instruments at both measurements due to either random missings 
within the instruments (n=19) or because they were a study drop-out (n=10). A total of 
192 patients were therefore included in the analysis. Their demographic and clinical 
characteristics can be found in table 1. Patients were analyzed regardless of follow-up 
strategy in the trial.
The MaCare trial was approved by the Independent Ethics Committee of MAASTRO Clinic. 
Table 1. Characteristics of participants (n=192)
Characteristic Descriptive statistic
Age
Mean (SD) 55.8 (10.1) yrs
Range 23-79 yrs
Level of education
Low 69   (35.9%)
Middle 96   (50.0%)
High 27   (14.1%)
Tumor stage
Stage I 99   (51.6%)
Stage II 61   (31.8%)
Stage III 17   (8.6%)
Unknown 15   (7.8%)
Treatment modality
Surgery 17   (8.9%)
Surgery and radiotherapy 107 (55.7%)
Surgery and chemotherapy 13   (6.8%)
Surgery and radiotherapy and chemotherapy 55   (28.6%)
Hormonal therapy 65   (34%)
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HRQoL Instruments
EQ-5D
The EQ-5D is a short generic health-related quality of life instrument that consists of two 
parts: a self-classifi er and a Visual Analogue Scale (EQ VAS). The self-classifi er comprises 
fi ve items relating to problems in the following domains: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression (EuroQoL-Group, 1990). Each domain has three 
levels, namely, “no problems”, “some problems” and “severe problems”. Combinations 
of these categories defi ne a total of 243 health states. Dolan et al (Dolan, 1997) have 
presented 42 of these health states to approximately 3000 members of a representative 
sample of the UK general population, which were valued using the time-trade-off (TTO) 
technique. Based on these valuations, for each health state a utility score can be deducted, 
called the EQ-5D Index score. These EQ-5D Index scores may vary between -0.59 (worst 
health) and 1.00 (perfect health). On the EQ VAS respondents can indicate their overall 
self-perceived health state on a scale ranging from 0 to 100, where 0 is equivalent to the 
worst imaginable health state and 100 is equivalent to the best imaginable health state.
EORTC QLQ-C30
The EORTC QLQ-C30 from the European Organization for Research and Treatment of 
Cancer is a self-administered disease-specifi c HRQoL questionnaire and is validated for 
oncology clinical research (Aaronson et al., 1993; Bottomley & Aaronson, 2007; Fayers 
& Bottomley, 2002). It has also been validated (McLachlan et al., 1998) and found to be 
responsive (Osoba et al., 1994) specifi cally in breast cancer patients and is widely used 
in breast cancer research investigating HRQoL after treatment (Arndt et al., 2005; Arndt 
et al., 2004; Goodwin et al., 2004; Helgesson et al., 2007; Schou et al., 2005; Waldmann 
et al., 2007). The HRQoL questionnaire consists of 30 items. After transformation, the 
EORTC QLQ-C30 has several multi-item functional subscales (e.g. physical, emotional 
functioning), multi-item symptom scales (e.g. fatigue, pain), a global health subscale, and 
single items to assess symptoms (e.g. sleep disturbance). Scores on the functional and 
global health scales range from 0 to 100, where a higher scale score represents a higher 
level of functioning and therefore HRQoL. 
Analyses of responsiveness
To assess the responsiveness of the EQ-5D three steps were taken, following 
recommendations recently published by Revicki et al. (2008). First, a criterion, or anchor, 
that is related to the measure under investigation, was selected to identify whether 
patients had changed (either improved or worsened) over time. Second, when the 
relationship between the anchor and EQ-5D was confi rmed, patients were classifi ed into 
subgroups according to changes in their health status. Third, to examine responsiveness, 
statistical indicators for change were calculated and analysis of variance procedures were 
performed.
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Step 1: Selecting an anchor; global health of the EORTC QLQ-C30
Selecting anchors should be based on criteria of relevance for the disease indication, 
clinical acceptance and validity, and evidence that the anchors have some relationship 
with the measure under investigation (Revicki et al., 2008). For this study, the subscale 
global health of the EORTC QLQ-C30 was proposed as a criterion for clinical change. The 
global health subscale consists of two items: (1) How would you rate your overall health 
during the past week? and; (2) How would you rate your overall quality of life during the 
past week?
Correlations between global health scores and the EQ-5D Index and EQ VAS were calculated 
to examine whether the anchor was acceptable. It is recommended that 0.30-0.35 is 
used as a correlation threshold to defi ne acceptable association between an anchor and 
a change score on the HRQoL outcome measure (Revicki et al., 2008).
Step 2: Classifying patients into subgroups
Change scores on global health of the EORTC QLQ-C30 were used to identify subgroups 
of patients. In an analysis of the clinical signifi cance of changes in HRQoL, Osoba et al. 
(1998) showed that patients judge a change between 5-10 on the global health scale of 
the EORTC QLQ-C30 to be small, between 10-20 to be moderate, and more than 20 to 
be large. Consequently, a change smaller than 5 points was considered to be no change. 
Taking into account both deteriorations and improvements, this results in a maximum of 
7 subgroups.
Step 3: Examining responsiveness
Responsiveness to change was evaluated using a statistical indicator, the standardized 
response mean (SRM). The SRM is the change in score divided by the standard deviation 
of the change in score. It is independent of sample size and widely used today (Husted 
et al., 2000). SRMs were calculated for the EQ-5D Index and EQ VAS, for all subgroups of 
patients. Scores were interpreted using benchmarks for effect sizes: 0.20 through 0.49 
was interpreted as small, 0.50 through 0.79 as moderate and   0.80 as large (Cohen, 
1988). Additionally, analysis of variance, with Games Howell post hoc procedures, was 
performed to compare the mean change scores on the EQ-5D Index and EQ VAS between 
the ‘no change’ subgroup and the other subgroups identifi ed in step 2. 
RESULTS
Step 1. Selecting an anchor
The global health scale of the EORTC QLQ-C30 correlated to the change scores of the EQ-
5D Index and EQ VAS (r=0.423 and r=0.634 respectively). Hence, global health was found 
to be an appropriate anchor and was used to classify subgroups. 
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Step 2. Classifying patients into subgroups
After twelve months, 6 patients (3%) reported a large deterioration on global health, 
17 (9%) reported a moderate deterioration, 14 (7%) reported a small deterioration, 55 
(28%) reported no change, 28 (16%) reported a small improvement, 32 (17%) a moderate 
improvement and 40 (21%) reported a large improvement on global health.
Due to a relatively small number of patients reporting a moderate or large deterioration, 
it was decided to create one subgroup for patients with both moderate and large 
deteriorations (‘moderate-large deterioration’) and, for easy comparison, also one 
subgroup for both moderate and large improvements (‘moderate-large improvement’). 
Hence, fi ve subgroups were identifi ed, classifying patients reporting a (1) moderate-large 
deterioration (n=23), (2) small deterioration (n=14), (3) no change (n=55), (4) a small 
improvement (n=28) and (5) moderate-large improvement in health status (n=72).
Step 3. Examining responsiveness 
Mean baseline scores, scores at the twelve month measurement and change scores are 
presented for all HRQoL measures in table 2. The EQ VAS and EQ-5D Index both moved 
in the expected direction, indicating negative changes (deterioration) in the subgroups 
reporting deterioration on global health of the EORTC QLQ-C30 and positive changes 
(improvements) in the subgroups reporting improvements on global health. Accordingly, 
only a minor change on the EQ VAS and no change on the EQ-5D Index were reported in 
the no change subgroup of the EORTC QLQ-C30. 
Table 2. Baseline scores (T0), twelve months scores (T1) and mean change scores with standard  deviations. 
SRMs of the EQ VAS and EQ-5D Index for all subgroups of patients.
EORTC QLQ-C30 EQ-5D Index EQ VAS
Subgroup T0 T1 ∆ (sd) T0 T1 ∆ (sd) SRM T0 T1 ∆ (sd) SRM
Moderate-large 
deterioration 
(n=23)
79.3 56.9 -22.5
(10.8)
73.0 59.8 -13.2
(11.2)
-1.17 0.72 0.57 -0.15
(0.29)
-0.52
Small deteriora-
tion (n=14)
75.6 67.3 -8.3
(0.0)
74.4 69.4 -5.1
(12.0)
-0.42 0.73 0.72 -0.01
(0.18)
-0.05
No change (n=55) 80.9 80.9 0.0
(0.0)
79.0 79.9 0.7
(8.8)
0.08 0.82 0.82 0.00
(0.21)
0.01
Small improve-
ment (n=28)
71.2 80.1 8.3
(0.0)
70.9 77.7 6.1
(7.7)
0.79 0.78 0.80 0.02
(0.14)
0.16
Moderate-large 
improvement 
(n=72)
58.2 85.6 27.4
(11.9)
65.0 77.4 12.1
(12.7)
0.95 0.71 0.83 0.13
(0.20)
0.62
To examine responsiveness, SRMs were calculated for the EQ-5D Index and EQ VAS (table 
2). In the subgroup of patients whose global health had not changed, accordingly, neither 
the SRM of the EQ-5D Index, nor of the EQ VAS indicated an effect. SRMs of the EQ-5D 
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Index for the subgroups indicating a small deterioration or small improvement were too 
small (i.e. SRM < 0.20) to be considered as an effect. In contrast, SRMs of the EQ VAS 
indicated a small effect in these subgroups. SRMs of the subgroups with moderate and 
large improvements or deteriorations in global health indicated a moderate effect on the 
EQ-5D Index (i.e. SRM > 0.50) and a large effect on the EQ VAS (i.e. SRM > 0.80). 
Analysis of variance procedures were performed to evaluate whether the EQ-5D could 
discriminate between the fi ve subgroups (table 3). Results indicated that when the EQ-
5D Index score was used as the outcome measure, the subgroup reporting no change 
on global health differed signifi cantly from the subgroup reporting moderate and large 
improvements. The subgroups reporting small improvements or a small or moderate and 
large deterioration could not be differentiated from the ‘no change’ subgroup. The EQ 
VAS on the other hand was able to discriminate between the ‘no change’ subgroup and 
the subgroups reporting a moderate and large improvement and moderate and large 
deterioration.
Table 3. Analysis of variance
Global health EORTC QLQ-C30 EQ-5D Index EQ VAS
Subgroup Mean difference 
(SE)
p-value Mean difference 
(SE)
p-value
No change 
(n=55)
Moderate-large 
deterioration (n=23)
-0.14 (0.07) 0.228 -13.88 (2.65) < 0.001
Small deterioration 
(n=14)
0.01 (0.05) 1.000 -5.78 (3.44) 0.470
Small improvement 
(n=28)
0.02 (0.04) 0.984 5.37 (1.93) 0.054
Moderate-large 
improvement (n=72)
0.13 (0.04) 0.006 11.38 (1.97) < 0.001
DISCUSSION
An incre asing number of clinical trials is investigating the effectiveness of follow-up 
strategies and psychosocial interventions for breast cancer patients after treatment, 
using HRQoL as an important outcome measure (Goodwin et al., 2003; Montazeri et al., 
2008). Hence, a good responsiveness of the HRQoL measure used seems essential. Our 
study showed that the EQ-5D was able to detect both improvements and deteriorations in 
health. However, according to Cohen’s benchmarks for effect sizes (Cohen, 1988), the EQ-
5D Index was not responsive to small changes in health. The inability of the EQ-5D Index 
to detect small changes might be explained by its structure. It is generally acknowledged 
that more response options lead to a higher responsiveness (Wiebe et al., 2003). The 
domains of the EQ-5D have only three response levels, making it diffi cult to pick up small 
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changes in health. In addition, in the subgroup of patients reporting no change and the 
subgroup reporting a small improvement on global health, baseline scores on the EQ-
5D Index were relatively high. These high scores were a result of large proportions of 
respondents already in the top category of domains of the EQ-5D. This ceiling effect is a 
well known feature of the EQ-5D and left little room for improvement (Brazier et al., 2004). 
A straightforward solution would be to attempt to produce a better, more responsive, 
generic index measure. Recent studies on an EQ-5D with fi ve response levels for each 
domain showed increased descriptive power and suggest better discriminatory power 
(Janssen et al., 2008a; Janssen et al., 2008b). Hence a less severe ceiling effect and 
increased benefi t in the detection of small health changes are expected (Janssen et al., 
2008b). Unfortunately, an offi cial fi ve-level descriptive system is not yet available. 
Additional analysis of variance procedures to investigate responsiveness showed that the 
EQ-5D Index and the EQ VAS both could not differentiate between subgroups reporting no 
change and small changes in global health. For the EQ-5D Index this was in accordance 
with the small SRMs in these subgroups. For the EQ VAS however, the non-signifi cant 
differences were unexpected, as the SRMs indicated moderate effects. This inability of 
the EQ VAS to discriminate might be explained by the small number of patients in these 
subgroups (n=14 and n=28 respectively). Analysis of variance procedures and especially 
post hoc procedures are sensitive to population variances and differences in sample 
size in subgroups. Hence, with a larger sample size, the EQ VAS might have been able 
to differentiate between subgroups with no change and small changes in health. This 
argument also holds true for the EQ-5D Index, which could not discriminate between 
the ’no change’ subgroup and the subgroup reporting a moderate-large deterioration in 
health (n=23).
A limitation of this study was that the responsiveness was investigated using a single 
anchor, while ideally multiple anchors should be used to investigate the responsiveness of 
an instrument (Guyatt et al., 2002). A clinical variable, such as whether or not a recurrence 
was detected, would be a suitable second anchor to classify subgroups of patients. 
However, in the clinical trial from which participants were used for these analyses, only 
few (< 10) recurrences were reported, and unfortunately, these participants were study 
drop-outs. Hence, an appropriate second anchor was not available. Further research into 
the responsiveness of the EQ-5D in breast cancer patients should aim to include multiple 
anchors.
In summary, results of this study showed that the EQ-5D was able to capture both 
improvements and deteriorations in HRQoL of breast cancer patients after treatment, but 
small changes in health were not recognized as being meaningful. However, in economic 
evaluations the EQ-5D is primarily used to measure outcome for QALY analysis rather than 
measuring HRQoL for clinical purposes. Within the framework of economic evaluations, 
an incremental cost-effectiveness ratio (i.e. additional cost per QALY gained) is more 
informative than the difference in HRQoL alone. Therefore, a small difference in the EQ-
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5D Index might still be meaningful if additional costs for such a change in HRQoL are very 
low. Hence, the EQ-5D should indeed be able to pick up relevant changes in health and 
should be able to differentiate between subgroups of patients to some extent, but cut-off 
points for effect sizes or discriminative ability are less relevant in the context of economic 
evaluations. 
CONCLUSION
In this study the responsiveness of the EQ-5D was investigated for its use in economic 
evaluations of health interventions in breast cancer patients after primary treatment. 
The EQ-5D was able to detect improvements and deteriorations in health and could 
discriminate between patients with no change in health and patients with moderate-
large changes in health. Therefore, the EQ-5D seems an appropriate HRQoL measure for 
economic evaluations in breast cancer patients after treatment.
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ABSTRACT
[Objective] An economic evaluation of four follow-up strategies for the fi rst year after 
breast cancer treatment, including traditional hospital follow-up, nurse-led telephone 
follow-up, and the former strategies combined with an educational group program (EGP). 
[Design] Cost-effectiveness analysis at 12 months follow-up alongside a randomized 
controlled trial (RCT). [Setting] Multicenter study in the Netherlands.  [Participants] 
299 breast cancer patients from seven hospitals and two radiotherapy clinics in the 
Netherlands who were treated with curative intent. [Interventions] Participants were 
randomized to follow-up care as usual (3-monthly outpatient clinic visits), nurse-led 
telephone follow-up, or the former strategies combined with the EGP. [Main outcome 
measures] Costs were measured using individual level cost data from cost diaries and 
hospital registrations. Quality-adjusted life years (QALYs) were measured using the EQ-
5D. Outcomes were expressed in incremental cost-effectiveness ratios (ICERs) and cost-
effectiveness acceptability curves. [Results] Hospital follow-up plus EGP yielded most 
QALYs (0.776; 95% CI 0.753 to 0.799), but also incurred the highest mean annual costs 
(€4914; 95% CI 3793 to 6192). The ICER of hospital follow-up plus EGP versus the next 
best alternative, nurse-led telephone follow-up plus EGP (0.772 QALYs; 95% CI 0.745 
to 0.797 and €3971; 95% CI 2975 to 5186), amounted to €235.750/QALY. As hospital 
and telephone follow-up without EGP both incurred higher costs and less QALYs than 
telephone follow-up plus EGP, the former strategies were judged inferior. Assuming a 
threshold value of €40.000 per QALY, hospital follow-up plus EGP was not considered 
cost-effective and therefore telephone follow-up plus EGP was the preferred strategy. 
The probability of telephone follow-up plus EGP being cost-effective ranged from 49% 
to 62% for different QALY threshold values. Secondary and sensitivity analyses showed 
that these results were robust. [Conclusions] Nurse-led telephone follow-up plus EGP is 
likely to be a cost-effective follow-up strategy after treatment for breast cancer. It may lead 
to substantial cost reductions, without loss of health-related quality of life compared to 
traditional hospital follow-up. It seems warranted to critically assess current guidelines for 
breast cancer follow-up.
Economic evaluation of four follow-up 
strategies after curative treatment 
for breast cancer: results of an RCT
KIMMAN ML, DIRKSEN CD, VOOGD AC, FALGER P, GIJSEN BCM, THURING M, LENSSEN 
A, VAN DER ENT F, VERKEYN J, HAEKENS C, HUPPERETS P, NUYTINCK JKS, VAN RIET Y, 
BRENNINKMEIJER SJ, SCHEIJMANS L, KESSELS A, LAMBIN Ph, BOERSMA LJ.
UNDER REVIEW
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INTRODUCTION
In the Netherlands, one out of eight women will be diagnosed with breast cancer at some 
moment in her life (Kiemeney et al., 2008). After treatment, these women will bring frequent 
follow-up visits to the hospital in order to be examined for local disease recurrence or 
second primary breast cancer, and for information and psychosocial support (Pestalozzi 
& Castiglione, 2008; Struikmans et al., 2008). However, the need for frequent follow-up 
of breast cancer patients remains controversial despite almost two decades of research. 
There has been much debate regarding the effectiveness of routine follow-up of these 
patients (Kimman et al., 2007a; Montgomery et al., 2007; Pennery & Mallet, 2000), while 
at the same time it is associated with a signifi cant cost burden (Meropol et al., 2009). 
Less specialized follow-up strategies have been proposed demonstrating equal patient 
satisfaction and health-related quality of life (HRQoL) compared to traditional hospital 
visits (Grunfeld et al., 2006, Koinberg et al., 2004, Beaver et al., 2009b, Montgomery 
et al., 2008a). To date, these alternative strategies, however, have not been structurally 
implemented in clinical practice. Several authors have urged to evaluate the costs in 
relation to the benefi ts of current and alternative follow-up strategies (Grunfeld, 2009; 
Meropol et al., 2009; Montgomery et al., 2007). Therefore, we performed a randomized 
controlled trial investigating the effectiveness of both a nurse-led telephone follow-up 
instead of hospital visits and a short educational group program (EGP) during the fi rst year 
after breast cancer treatment, which included an economic evaluation (Kimman et al., 
2007b). Results of this economic evaluation may improve resource-allocation decisions 
and enhance dissemination of cost-effective follow-up strategies.
METHODS
Design, sample and interventions
Details of the trial design and protocol execution have been reported previously (ISRCTN 
74071417) (Kimman et al., 2007b). In sum, between 2005 and 2008, 320 females 
were recruited through seven hospitals and two radiotherapy clinics in the South of the 
Netherlands. Participants were eligible when they had completed treatment for breast 
cancer (tumor stage I-III) within six weeks prior to randomization. They were randomly 
assigned to one of four follow-up strategies (study arms) for the fi rst 18 months following 
treatment; i.e. 1) hospital follow-up as usual: fi ve outpatient clinic visits in the fi rst 18 
months (at 3, 6, 9, 12 and 18 months), including a mammography at 12 months; 2) nurse-
led telephone follow-up: a mammography at 12 months combined with an outpatient 
clinic visit, and telephone interviews at the same time points as for usual follow-up; 3) 
arm 1 plus educational group program (EGP); 4) arm 2 plus EGP. Telephone follow-up 
was performed by a trained breast care nurse (BCN) and consisted of a semi-structured 
questionnaire including screening for physical and psychological symptoms, treatment 
side effects, compliance with hormonal therapy, and an open discussion of these issues. 
The EGP consisted of two interactive group sessions of 2.5 hours each: a BCN provided 
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information on possible treatment side effects and topics such as prostheses, fatigue, 
and signs and symptoms of possible recurrences. A health care psychologist addressed 
psychological and social consequences of breast cancer, and discussed possible 
psychological coping strategies. 
The economic evaluation compared costs and effects of these four follow-up strategies 
from a societal perspective, with a time horizon of one year. During the trial 21 patients 
(6.5%) dropped out for various reasons, as reported in a previous paper (Kimman et al., 
2010a). Hence, data for the economic evaluation was available of 299 patients. The mean 
age of the sample was 55.8 years (range 27 to 78). Details on tumor stage and received 
treatment of participants are provided in table 1. 
Table 1. Baseline characteristics of participants of the economic evaluation (n=299). Values are numbers 
(percentages) unless stated otherwise.
 All participants (n=299)
Age at recruitment in years
Mean (SD) 55.8 (9.9)
Range 23-78
Level of education
Low 102 (34.1)
Middle 118 (39.5)
High 79 (26.4)
Employment status
Paid employment 91 (30.4)
Hours of paid employment per week (mean and SD) 8.9 (13.6)
Tumor stage
Stage I 181 (60.5)
Stage IIa 69 (23.1)
Stage IIb 21 (7.0)
Stage III 24 (8.0)
Unknown 4 (1.3)
Treatment modality
Surgery 29 (9.7)
Surgery + radiotherapy (RT) 178 (59.5)
Surgery + chemotherapy (CH) 15 (5.0)
Surgery + RT + CH 77 (25.8)
Hormonal therapy (yes) 94 (31.4)
Measure of effect
The quality-adjusted life year (QALY) was chosen to represent health gain (Earnshaw 
& Lewis, 2008). The QALY is a measure of life expectancy weighted by health-related 
quality of life (HRQoL), the latter which is represented by utility scores. In the present 
study, HRQoL was measured with the EQ-5D, a questionnaire responsive to changes in 
health in breast cancer patients after conclusion of treatment (Kimman et al., 2009). The 
EQ-5D comprises fi ve dimensions: mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression. Each dimension is rated at three levels: no problems (1), some 
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problems (2) and major problems (3). Based on preferences elicited from a general UK 
population, EQ-5D health states (e.g. 1-1-2-1-3) may be converted into utility scores (Index 
scores) (Dolan, 1997). In the present study, utility scores were measured at baseline, 
and 3, 6 and 12 months after treatment and were subsequently used to calculate 
QALYs according to the following formula: {[(utility score at baseline + utility score at 3 
months)/2]*3/12 + [(utility score at 3 months + utility score at 6 months)/2]*3/12 + 
[(utility score at 6 months + utility score at 12 months)/2]*6/12}. 
Measure of costs
Cost analysis was performed from the societal perspective which includes health care and 
non health care related costs (e.g. productivity loss, informal care) as a result of breast 
cancer (Earnshaw & Lewis, 2008; Oostenbrink et al., 2004). Hormonal therapy costs 
were not included since these were considered part of standard treatment if feasible. 
Complete hospital resource use data on an individual level (e.g. diagnostic procedures, 
outpatient clinic visits, telephone interviews) were retrieved from hospital information 
systems. Resource use outside the hospital (e.g. general practitioner visits, physical 
rehabilitation) was determined by means of cost diaries as kept by participants (Goossens 
et al., 2000). These were completed prospectively at 3, 6 and 12 months, for four week 
periods each. Resource use was interpolated to the study period under the assumption 
that data obtained from these cost diaries would be representative of the in between 
periods (Goossens et al., 2000). 
Cost prices for resource use were primarily obtained from the Dutch governmental manual 
for health care cost analysis (Oostenbrink et al., 2004). All cost prices were converted to 
2008 Euros by means of price index numbers (Bureau of Statistics, 2008). Cost prices 
per unit of resource use for the main cost drivers are presented in table 2 (page 62). 
Costs for hospital visits were based on cost prices for academic hospitals. Productivity 
costs were calculated using the human capital approach (HCA) (Hodgson, 1994). Costs 
for the EGP included the hourly wages of the health care psychologist and BCN, the use 
of facilities and the information booklet, as well as travel costs of patients. The cost price 
for telephone follow-up consisted of the average duration of the follow-up (18 minutes) 
multiplied by the hourly wage of a specialized nurse, adding 45% for hospital overhead 
costs and the average costs of a telephone call.
Statistical analysis
The base case analysis was performed based on intention to treat. Multiple imputation 
was used to replace missing values with plausible estimates, and generated fi ve data 
sets (Schafer, 1999). Results were provided as pooled estimates of these sets. Bootstrap 
simulations with 1000 replications were used to calculate 95% confi dence intervals 
around mean costs and effects of the four study arms (Briggs et al., 1997). Differences 
between the four groups in resource use, costs and QALYs were reported descriptively and 
were not compared statistically to avoid problems with multiple testing, and because the 
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focus of the economic evaluation was on the combined costs and effects in order to assess 
cost-effectiveness. To investigate cost-effectiveness of the four strategies, incremental 
cost-effectiveness ratios (ICERs) were calculated. When more than two strategies are 
compared, as is the case in this study, ICERs are calculated using rules of dominance and 
extended dominance (Fenwick & Byford, 2005). In this approach, strategies are ranked 
by QALYs, from the most effective to the least effective, and if a strategy is less effective 
and more costly than the previous strategy, it is said to be dominated and is excluded from 
the calculation of ICERs. Hence, this process compares strategies in terms of observed 
differences in costs and effects, regardless of the statistical signifi cance of the difference. 
Bootstrapped sample means (1000) from costs and effectiveness data were used to 
quantify the uncertainty associated with the ICERs. Subsequently, cost-effectiveness 
acceptability curves (CEACs) were derived in order to show the probability of each strategy 
being the optimal choice, for a range of possible maximum values a decision maker is 
willing to pay for a QALY (Fenwick et al., 2004). Bootstrapping was performed using Excel 
2000. Other analyses were performed using the SPSS package, version 17.0® for Windows 
(SPSS INC 2009)
Secondary analyses 
Secondary analyses were performed to assess the robustness of the base case results. 
First, an analysis was performed according to the actually applied follow-up strategy (per 
protocol analysis). Second, an analysis was performed excluding productivity costs. A third 
analysis took a limited health care perspective, including only health care related costs. 
Several one-way sensitivity analyses were performed in order to assess the impact of the 
unit prices of telephone contacts and hospital visits. We used the highest reported value 
for telephone contact (55 minutes) and the generic cost price for a hospital visit (€54.15).
A series of subgroup analyses compared cost-effectiveness data according to age, use 
of chemotherapy, and levels of anxiety and support from partner. Finally, a subsample of 
patients for whom 18 months data were available (n=244) was used in order to investigate 
whether cost-effectiveness results could be extrapolated to the 2nd year after treatment. 
In this analysis, costs and effects incurred between 12 and 18 months were discounted 
using a 4% discount rate (Oostenbrink et al., 2004).
RESULTS
Effects and costs
Table 3 summarizes the percentage of patients reporting any problems (level (2) and 
(3) combined) on the fi ve dimensions of the EQ-5D as well as utility (index) scores, 
at all measurement time points. Due to substantial baseline utility differences, 
subsequent utility scores are (also) presented using a regression-based adjustment 
as recommended by Manca et al. (2005), and taking into account regression to the 
mean effects (van Asselt et al., 2009). Utility gains were most notable in the telephone
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Table 2. Unit prices. All unit prices are expressed in Euros at 2008 values. EGP = educational group 
program, MS = medical specialist, BCN = breast care nurse.
Cost category Unit price in Euro (2008) a,b
Direct health care costs
General practitioner 21.88 / visit b1
Physiotherapist 24.64 / visit b1
Rehabilitation program c 1500 b2
Educational group program (EGP) d 135 b3
Other health care professionals e 24.64 / visit b1
Home care domestic 23.50 / hour b1
Home care nursing 43.75 / hour b1
Medication f Various b4
Hospital follow-up (MS / BCN) 108.30 / visit b1
Telephone MS 12.83 / 5 min call b5
Telephone BCN 21.50 / follow-up contact b5
Postoperative surgery g Various / procedure b1
Mammography/ultrasound 79.75 / 82.10 / test b1
Breast biopsy 127.19 / procedure b1
Laboratory tests Various / test b1
Cardiology or lung tests Various / test b1
Other diagnostics h Various / procedure b1
Costs for in-hospital days i 598.89 / day b1
Direct non health care costs
Paid help 10 / hour b1
Informal care 8.99 / hour b1
Costs of lost production
Paid work 19.22 / hour b6
Domestic tasks 8.99 / hour b1
Out of pocket costs
Reported by patients j Various b7
Drugs j Various b7
a When necessary, cost prices were converted to 2008 by means of price index numbers. 
b Source of unit price: 1 Dutch manual for cost prices (Oostenbrink et al 2004); 2 Tariff for health 
insurer; 3 Calculation included cost location, wage of health care providers, material, travel costs; 4 www.
farmacotherapeutischkompas.nl (including tax + recepy fee of €6.11); 5 Calculations based on time per 
call multiplied by wage and overhead costs; 6 Gross wage, female 55-65, CBS; 7 as reported by patient.
c Rehabilitation program: a 12-week group program for cancer patients combining physical exercise and 
psycho-education. 
d Educational group program (study intervention): two group sessions outside hospital by a health care 
psychologist and breast care nurse (including booklet).
e Other health care professionals such as lymph edema therapist, alternative healers.
f Medication was sub grouped to tranquilizers, antibiotics, antidepressants, pain killers, drugs for side-
effects of treatment, and other drugs.
g Included breast reconstruction, treatment of wounds/abscess, lymph edema.
h Included CTs, MRIs, PET whole body scans, et cetera
i Average of total costs for in-hospital days, including intake assessment and nursing.
j Out-of-pocket costs included costs for over the counter medication, massage, parking costs, et cetera
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Table 3. Percentage of patients reporting ANY problems on the EQ-5D, the EQ-5D index scores at baseline, 
3, 6 and 12 months after treatment and adjusted QALYs for the four study arms.
Measurement Dimensions of EQ-5D Hospital 
f-up
Telephone 
f-up
Hospital 
f-up + EGP
Telephone 
f-up + EGP
              % of patients reporting ANY problems
Baseline Mobility 22.2 30.3 16.0 22.2
Self-care 5.4 5.3 2.7 3.0
Usual activities 52.7 54.7 48.0 55.4
Pain/discomfort 64.9 68.4 50.7 66.2
Anxiety/depression 42.7 50.0 33.3 36.5
Index score 0.736 0.728 0.804 0.722
3 months Mobility 21.1 30.8 16.8 24.9
Self-care 5.4 3.7 1.3 5.7
Usual activities 47.0 46.8 42.7 46.8
Pain/discomfort 63.8 60.0 42.1 51.4
Anxiety/depression 51.1 47.4 37.9 41.9
Index score 0.721 0.757 0.810 0.775
Index score (adjusted)1 0.727 0.767 0.780 0.789
6 months Mobility 21.6 26.3 18.1 26.4
Self-care 4.3 0.0 0.5 8.6
Usual activities 36.5 40.0 33.3 47.0
Pain/discomfort 54.6 53.4 45.9 54.6
Anxiety/depression 38.6 45.8 40.0 43.5
Index score 0.760 0.771 0.803 0.758
Index score (adjusted)1 0.766 0.780 0.776 0.770
12 months Mobility 24.9 18.2 26.7 28.4
Self-care 10.0 5.3 2.4 10.5
Usual activities 34.6 37.4 36.0 33.0
Pain/discomfort 60.8 57.6 48.0 50.0
Anxiety/depression 34.1 40.3 36.3 33.2
Index score 0.733 0.768 0.786 0.771
Index score (adjusted)1 0.739 0.777 0.759 0.783
QALY 0.740 0.762 0.801 0.761
QALY (adjusted)1 0.747 0.769 0.776 0.772
95% CI (0.707-0.778) (0.746-0.794) (0.753-0.799) (0.745-0.797)
1 QALYs were adjusted using a regression-based approach
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follow-up and telephone follow-up plus EGP groups, but overall QALYs were highest for 
hospital follow-up plus EGP. This is partly explained by the high baseline utility scores. 
Adjustment for baseline differences resulted in smaller QALY differences, but hospital 
follow-up plus EGP remained the most effective strategy. We used the adjusted QALY for 
the construction of cost-effectiveness acceptability curves, which refl ects the fi nding that 
baseline scores were higher for this strategy. Table 4 and 5 show resource utilization and 
costs during the study period. 
Table 4. Mean resource use per patient over 12 months (in number of contacts or tests unless stated 
otherwise). EGP = Educational group program, MS = medical specialist, BCN = breast care nurse
Resource category Hospital f-up 
mean (SD)
Telephone f-up 
mean (SD)
Hosp + EGP 
mean (SD)
Tel + EGP 
mean (SD)
Direct health care resources
General practitioner 1.7 (2.7) 1.6 (3.1) 1.5 (2.8) 0.8 (1.7)
Physiotherapist 7.0 (14.5) 8.6 (16.2) 10.1 (19.8) 8.5 (16.0)
Revalidation 0.1 (0.3) 0.2 (0.4) 0.1 (0.3) 0.2 (0.4)
Other health care professionals 1.5 (3.4) 3.0 (7.2) 2.1 (3.6) 2.1 (3.7)
Home care domestic (in hours) 8.9 (32.3) 7.3 (27.8) 6.2 (27.1) 3.7 (11.7)
Home care nursing (in hours) 0.4 (1.4) 1.1 (5.2) 0.4 (1.5) 0.6 (2.0)
Visits MS 5.5 (2.4) 2.6 (1.8) 5.3 (2.0) 2.9 (2.4)
Visits BCN 0.5 (1.3) 0.7 (1.4) 0.5 (1.4) 0.6 (1.2)
Telephone MS 0.2 (0.5) 0.1 (0.6) 0.2 (0.8) 0.1 (0.3)
Telephone BCN 0.1 (0.5) 2.4 (1.2) 0.1 (0.3) 2.3 (1.0)
Mammography/ultrasound 1.6 (1.1) 1.7 (1.0) 1.5 (0.8) 1.7 (1.0)
Biopsy 0.1 (0.3) 0.1 (0.4) 0.1 (0.3) 0.1 (0.4)
Laboratory tests 11.8 (23.9) 5.7 (16.0) 4.6 (8.8) 4.4 (13.7)
Cardiology and lung tests 0.3 (1.1) 0.0 (0.1) 0.1 (0.4) 0.1 (0.2)
Other diagnostic tests 1.2 (2.1) 0.6 (1.2) 0.9 (1.6) 0.5 (0.9)
In-hospital days 0.6 (2.5) 0.1 (0.4) 0.1 (0.9) 0.1 (0.3)
Direct non health care resources
Paid help (in hours) 18.4 (50.7) 6.9 (26.4) 16.5 (37.8) 7.7 (23.9)
Informal care (in hours) 21.7 (65.9) 45.8 (136.6) 19.7 (38.5) 37.1 (125.9)
Productivity loss
Paid work (in hours) 60.3 (151.3) 85.2 (228.4) 98.0 (238.9) 68.9 (188.5)
Domestic tasks (in hours) 32.7 (105.1) 45.9 (123.4) 25.5 (77.8) 14.7 (27.9)
Economic evaluation of four follow-up strategies after breast cancer
       65
Table 5. Mean costs per patient (in Euros) over 12 months. 
EGP = educational group program, MS = medical specialist, BCN = breast care nurse
Mean costs in 12 months (Euros)
Cost category Hospital f-up Telephone 
f-up
Hospital f-up 
+ EGP
Telephone 
f-up + EGP
Direct health care costs
General practitioner 81 77 63 50
Physiotherapist 172 212 249 209
Revalidation 114 237 108 219
Educational group program 0 0 135 135
Other health care professionals 218 305 303 318
Home care (domestic/nursing) 226 219 166 111
Medication 23 20 18 23
Visits MS 712 357 666 350
Visits BCN 59 83 57 67
Telephone MS 3 3 2 1
Telephone BCN 2 52 2 49
Postoperative surgery 83 55 42 0
Mammography/ultrasound 131 137 123 139
Breast biopsy 9 12 14 10
Laboratory tests 92 47 69 41
Cardiology or lung tests 12 0 2 1
Other diagnostic tests 148 69 135 65
Costs for in-hospital days 362 53 82 43
Subtotal health care costs 2447 1938 2236 1831
(Bootstrapped 95% CI) (1974 - 3014) (1604 - 2303) (1864 - 2713) (1468 - 2196)
Direct non health care costs
Paid help 184 69 165 77
Informal care 195 412 177 333
Subtotal 379 481 342 410
(Bootstrapped 95% CI) (196 - 609) (256 - 807) (232 - 473) (201 - 682)
Costs of lost production
Paid work 1159 1637 1884 1325
Domestic tasks 294 412 230 133
Subtotal 1453 2049 2114 1458
(Bootstrapped 95% CI) (848 - 2163) (1159 - 3111) (1202 - 3321) (692 - 2344)
Out of pocket costs
Reported by patients 130 177 202 257
Drugs 10 27 20 15
Subtotal 140 204 222 272
(Bootstrapped 95% CI) (89 - 209) (141 - 277) (133 - 340) (144 - 417)
Subtotal non health care costs 1972 2734 2678 2140
(Bootstrapped 95% CI) (1308 - 2713) (1706 - 3873) (1642 - 3941) (1171 - 3317)
TOTAL COSTS 4419 4672 4914 3971
(Bootstrapped 95% CI) (3410 - 5501) (3489 - 6033) (3793 - 6192) (2975 - 5186)
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Economic analysis
In the base case analysis, hospital follow-up plus EGP yielded most QALYs (0.776), but 
also incurred highest mean annual costs (€4914). The ICER of hospital follow-up plus 
EGP versus the next best alternative, telephone follow-up plus EGP (0.772 QALYs and 
€3971), amounted to €235.750/QALY. Assuming a threshold of €40.000, as is argued 
for by the Dutch Council for Public Health and Health Care (RVZ, 2006), hospital follow-up 
plus EGP is not considered cost-effective and therefore telephone follow-up plus EGP was 
the preferred strategy (table 6). As hospital and telephone follow-up without EGP both 
incurred higher costs and less QALYs than telephone follow-up plus EGP, the former were 
judged to be dominated (i.e. inferior).
Figure 1 shows the cost-effectiveness acceptability curves and indicates that for a range 
of QALY threshold values (€0 - €80.000), the probability that telephone follow-up plus EGP 
was cost-effective ranged between 49 and 62%. 
Figure 1. Cost-effectiveness acceptability curves base case analysis
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Secondary analyses
Per protocol analysis, analysis excluding productivity costs and analysis from a health 
care perspective all showed that telephone follow-up plus EGP was the preferred follow-
up strategy, assuming a QALY threshold of €40.000. Furthermore, one-way sensitivity 
analyses showed that changing unit prices for telephone follow-up and hospital visits did 
not alter conclusions (table 6). 
Subgroup analyses (table 7, page 72/73) showed that for patients with high levels of 
anxiety, hospital follow-up plus EGP is most cost-effective if society would be willing to 
pay at least €33.269 for one QALY gain compared to hospital follow-up. Given a threshold 
of €40.000, the probability of being cost-effective was 49%. Age, level of education, and 
chemotherapy treatment did not infl uence cost-effectiveness results. Finally, telephone 
follow-up plus EGP was also the most cost-effective strategy in the analysis with a time 
horizon of 18 months. 
DISCUSSION
Key fi ndings
This comprehensive economic evaluation provided a detailed insight into the cost-
effectiveness of four follow-up strategies for breast cancer patients during their fi rst year 
after treatment. Hospital follow-up plus EGP yielded most QALYs, but it was also the most 
costly follow-up strategy of the study. The ICER of hospital follow-up plus EGP versus the 
next best alternative, telephone follow-up plus EGP, amounted to €235.750/QALY. Hospital 
follow-up plus EGP was not considered to be cost-effective and telephone follow-up plus 
EGP was the preferred follow-up strategy. The probability of telephone follow-up plus EGP 
being most cost-effective ranged from 60% when applying a more conservative threshold 
value of €20.000 to 58% with a threshold of €40.000. Secondary and sensitivity analyses 
showed that these results were robust. However, for patients with high levels of anxiety 
after treatment, hospital follow-up plus EGP was the preferred strategy in terms of cost-
effectiveness. 
The detailed cost analysis showed that health care costs were lower if some fi rst year 
hospital follow-up visits were replaced by nurse-led telephone follow-up. This was mostly 
due to reduced costs for visits, concomitant laboratory tests and other diagnostics. 
Moreover, the combination of nurse-led telephone follow-up plus EGP was conducive 
to cost reductions. It may be speculated that a combination of frequent contacts with 
a BCN, together with comprehensive education about signs and symptoms of possible 
treatment side effects, may have led to fewer contacts with (more specialized) health care 
professionals. 
Conceptually the cost differences between follow-up strategies were small. Mean 
cost differences from the societal perspective between telephone follow-up plus EGP 
and current clinical practice (hospital follow-up), were €448 for one year. However, by 
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extrapolating these fi gures to the breast cancer population in the Netherlands (Kiemeney 
et al., 2008) this may represent an important overall cost difference overall. With 12.416 
new breast cancer patients per year (Comprehensive Cancer Center, 2006), up to 5 million 
Euros could be saved annually, assuming successful implementation of this new strategy. 
Comparison with other studies
To our knowledge, there are no earlier such publications on cost-effectiveness of follow-
up for the fi rst year after treatment. Although similar studies have been conducted, these 
either compared traditional follow-up to different alternative strategies (Grunfeld et al., 
1999b; Koinberg et al., 2009), or involved a different follow-up time period (Beaver et 
al., 2009a). Grunfeld and colleagues showed that follow-up performed by the general 
practitioner did not increase use of other health care services, and reduced costs 
substantially (Grunfeld et al., 1999b). Koinberg and colleagues compared specialist 
nurse and medical specialist follow-ups and found that specialist nurse follow-up was 
approximately 20% less expensive (Koinberg et al., 2009). 
Beaver and colleagues conducted a cost-minimization study, comparing traditional hospital 
follow-up with nurse-led telephone follow-up, and concluded that telephone follow-up may 
reduce the burden on busy hospital clinics but would not necessarily lead to cost savings. 
While women randomized to telephone follow-up reported less hospital consultations, the 
longer duration of telephone consultations, use of junior medical staff, and training costs 
of nurses resulted in higher routine costs for telephone follow-up (Beaver et al., 2009a). 
In contrast, our study used a fi xed price for hospital follow-up visits, since it was often 
unclear which health care provider would perform the follow-up. Furthermore, training 
costs of nurses were not included in the cost price of telephone follow-up, as these costs 
diffuse among many patients outside the study domain. Importantly, changing cost prices 
for hospital and telephone consultations did not alter our conclusions. Hence, our studies 
show similar results in terms of resource use, however, the unit cost of a hospital visit 
resulted in contrasting conclusions (Beaver et al., 2009a).
Concerns regarding the economic analysis
Some unexpected cost differences were found between the study arms that were not 
obviously related to the interventions. In arm 1 (hospital follow-up) costs for in-hospital 
days were visibly higher compared to the other three strategies. In arm 1 three patients 
were admitted to the hospital for more than seven days due to breast cancer related 
complications, and were responsible for these high costs. It seems unlikely these 
admissions were related to the follow-up strategy, but it would have been inappropriate 
to exclude these costs in the base case analysis. A secondary analysis excluding these 
patients showed this did not alter conclusions. 
From the societal perspective, indirect costs due to absence from paid work or not able 
to perform domestic tasks accounted for a major part of the total costs of all study arms 
(almost 40%); however, these estimates showed large 95% confi dence intervals. 
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The present large differences in indirect costs between groups were unexpected and 
might be explained by relatively small sample sizes. Excluding the productivity costs 
in the base case analysis would have violated the pre-defi ned protocol and the Dutch 
guidelines for economic evaluation (Oostenbrink et al., 2004). Moreover, the mean age of 
the sample was 56 years old and one in three women was in paid employment at the time 
of her breast cancer diagnosis. To address the uncertainty induced by these high costs, a 
secondary analysis excluding these specifi c costs was also reported. This analysis showed 
that the ICER for hospital follow-up plus EGP versus telephone follow-up plus EGP dropped 
to 71.500/QALY. Since this ICER is still above the Dutch QALY threshold telephone follow-
up plus EGP remained the preferred strategy.
One might argue that, since no signifi cant differences were found in the clinical analysis 
and QALY differences were small, a cost-minimization analysis would have been more 
appropriate. However, the clinical effectiveness study used a 2x2 factorial design and 
therefore did not compare the four strategies separately as was done in this economic 
evaluation. Hence, the study was not designed to show equivalence in effectiveness of the 
four strategies. Therefore, a cost-minimization analysis would have been inappropriate 
(Briggs & O’Brien, 2001). Finally, one might be concerned that the use of the EQ-5D and 
the resulting estimates of QALYs are not sensitive enough in these patients to identify 
differences in their HRQoL. However, the EQ-5D was found to be a responsive measure 
in this breast cancer population, able to detect improvements and deteriorations in 
health (Kimman et al., 2009). The EQ-5D is also the recommended outcome measure 
for economic evaluations (Earnshaw & Lewis, 2008) and commonly used in cancer 
populations (Deconinck et al., 2010; Freedman et al., 2010; TOMBOLA, 2009). The use of 
the EQ-5D in this study therefore allows comparison to other studies.
Strengths
It is generally recognized that most breast cancer follow-up related costs are incurred in 
the fi rst two years after treatment (Lidgren et al., 2007). Also, most improvement in psycho-
social status is reported for the fi rst year after treatment (Ganz et al., 1996). Hence, the 
present study focused on a key time period after treatment for medical decision making. 
This economic evaluation was performed according to published international guidelines 
for trial-based economic evaluations (Earnshaw & Lewis, 2008), within the framework of 
a multicenter randomized controlled trial. The randomized setting minimized selection 
bias and due to the pragmatic nature of the trial it closely refl ects the effectiveness and 
resource use that would be observed in ordinary daily practice. We compared four alter-
native strategies, which is relatively uncommon, in order to address the often proposed 
disadvantage of trial-based economic evaluations that they represent only a limited form 
of analysis by comparing few alternatives (Sculpher et al., 2006). Furthermore, by using 
micro costing to value resources and presenting tables with resource use and cost prices, 
we have provided detailed information on follow-up costs and have been as transparent 
as possible. Case-by-case calculations for the purpose of generalizability are possible.
Economic evaluation of four follow-up strategies after breast cancer
       71
CONCLUSIONS
Results of this study may bridge an important evidence gap on cost-effectiveness of alter-
native follow-up strategies after breast cancer treatment. Our results and those of others 
(Beaver et al., 2009a; Grunfeld et al., 1999b; Koinberg et al., 2009) increasingly under-
score the importance of critically assessing current guidelines for breast cancer follow-up. 
This economic analysis showed that nurse-led telephone follow-up plus an EGP instead of 
traditional hospital clinic visits may lead to substantial cost reductions in the Netherlands.
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Patient satisfaction with 
nurse-led telephone follow-up 
after curative treatment for breast cancer
KIMMAN ML, BLOEBAUM MMF, DIRKSEN CD, HOUBEN RMA, LAMBIN Ph, BOERSMA LJ.
BMC CANCER 10(1): 174
ABSTRACT
[Background] Current frequent follow-up after treatment for breast cancer 
does not meet its intended aims, but does depend on expensive and scarce 
specialized knowledge for routine history taking and physical examinations. 
The study described in this paper compared patient satisfaction with a 
reduced follow-up strategy, i.e. nurse-led telephone follow-up, to satisfaction 
with traditional hospital follow-up. [Methods] Patient satisfaction was 
assessed among patients (n=299) who were participants of a randomized 
controlled trial investigating the cost-effectiveness of several follow-up 
strategies in the fi rst year after treatment for breast cancer. Data on patient 
satisfaction were collected at baseline, 3,6 and 12 months after treatment, 
using the Dutch version of Ware’s Patient Satisfaction Questionnaire 
III (PSQ III). In addition to general satisfaction, the PSQ III reports on 
satisfaction scores for technical competence, interpersonal aspects, and 
access of care. Regression analysis was used to predict satisfaction scores 
from whether or not nurse-led telephone follow-up was received. [Results] 
Nurse-led telephone follow-up had no statistically signifi cant infl uence 
on general patient satisfaction (p=0.379), satisfaction with technical 
competence (p=0.249), and satisfaction with interpersonal aspects 
(p=0.662). Regarding access of care, patient satisfaction scores were 
signifi cantly higher for patients receiving telephone follow-up (p=0.015). 
However, a mean difference at 12 months of 3.1 points was judged to be 
not clinically relevant. [Conclusions] No meaningful differences were found 
in satisfaction scores between nurse-led telephone and hospital follow-up 
in the fi rst year after breast cancer treatment. With high satisfaction scores 
and the potential to substantially reduce clinic visits, nurse-led telephone 
follow-up may be an acceptable alternative to traditional hospital follow-up. 
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INTRODUCTION
In most countries, follow-up after curative treatment for breast cancer consists of frequently 
scheduled follow-up visits (2-4 times a year) and an annual routine mammography 
(Pestalozzi & Castiglione, 2008). The main objectives of these visits are the early detection 
of a locoregional recurrence or a second primary breast cancer, detection and registration 
of side effects of treatment, and provision of information and psychological support 
(Pestalozzi & Castiglione, 2008; Struikmans et al., 2008). However, there is much debate 
whether these objectives are met in current clinical practice (Brada, 1995; Dewar, 1995). 
First of all, routine follow-up with clinical examination has been shown not to contribute to 
improved survival (GIVIO, 1994; Montgomery et al., 2009; Rosselli Del Turco et al., 1994; 
te Boekhorst et al., 2001; Wheeler et al., 1999). Additionally, outpatient clinic visits have 
been identifi ed as a transition time of high stress, generating increased anxiety because 
of the risk of detecting a recurrence (Allen, 2002). Also, some studies have suggested 
that outpatient clinic visits are insuffi cient to provide psychological support after breast 
cancer treatment, since these visits are often brief and do not include assessment of 
psychosocial problems (Pennery & Mallet, 2000). Hence, current frequent follow-up visits 
seem to miss their most important goals, but do depend heavily on expensive and scarce 
specialized knowledge for routine history taking and physical examinations. As a result, 
the improvement in quality and effi ciency of breast cancer follow-up care has been a 
government priority setting in many countries (Houlihan, 2009; Gezondheidsraad, 2007). 
Alternative strategies for follow-up such as nurse-led and telephone follow-up have been 
proposed (Beaver et al., 2009b; Koinberg et al., 2004; Montgomery et al., 2008a). To 
improve healthcare, feedback from patients on these alternative models of follow-up is 
essential. Feedback evaluates the quality of the care provided, and can isolate problem 
areas and help generating ideas for further improvement (Crow et al., 2002; Sitzia & 
Wood, 1997). Moreover, patients may respond better to treatment and comply better with 
instructions when they are satisfi ed with their care and treatment setting, improving their 
health outcomes (Jackson et al., 2001; Kizer, 2002; Worthington, 2004). 
Patient satisfaction with nurse-led follow-up and telephone services was found to be high 
(Cox & Wilson, 2003; Lewis et al., 2009), and good outcomes have been reported in terms 
of detecting medical problems and providing support to cancer patients (James et al., 
1994; Marcus et al., 2009). Recent studies in breast cancer patients have also shown 
that telephone follow-up by specialist breast care nurses (BCNs) was well-received by 
patients. A randomized clinical trial (RCT) by Beaver et al. (2009b), comparing nurse-led 
telephone follow-up with hospital follow-up showed that telephone follow-up signifi cantly 
improved satisfaction, and it produced no excess anxiety compared with hospital follow-
up. A prospective cohort study by Montgomery et al. (2008a) showed that an automated 
telephone system was easy to use and liked by most (71%) patients. 
These studies provided positive results regarding patient satisfaction for follow-up after 
breast cancer for women on average one to two years after diagnosis. However, there is 
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evidence that most physical and psychological recovery is achieved within the fi rst year 
following treatment (Ganz et al., 1996). Therefore, the introduction of nurse-led telephone 
follow-up in the fi rst year after treatment may affect patient satisfaction and quality of 
care differently than when applied in a later stage. It is expected that telephone follow-up 
by a BCN, who is familiar with the patient, can be appropriate to address psychological 
consequences after treatment (Beaver et al., 2009b). Moreover, especially in the fi rst 
year, telephone follow-up has the potential to reduce hospital visits. 
This paper focused on patient satisfaction with nurse-led telephone follow-up compared 
to hospital follow-up in the fi rst year after breast cancer treatment. Patient satisfaction 
was measured using a shortened (Dutch) version of the validated Patient Satisfaction 
Questionnaire (PSQ III) constructed by Ware et al. (Hagedoorn et al., 2003). The PSQ 
III measures the multidimensional concept of patient satisfaction, capturing the 
most important characteristics of services and providers that might infl uence patient 
satisfaction with care. It is believed to refl ect quality of care and patients’ preferences 
(Ware et al., 1983). 
METHODS
Recruitment, design and sample
Patient satisfaction was assessed using data from patients who were participants of a 
randomized controlled trial (RCT) investigating, among other things, the cost-effectiveness 
of nurse-led telephone follow-up after breast cancer (ISRCTN 74071417). A predefi ned 
(secondary) aim of the trial was to compare patient satisfaction between nurse-led 
telephone and hospital follow-up. Details of the trial design and protocol execution have 
been reported previously (Kimman et al., 2007b). The study was a multicenter randomized 
trial, with a 2x2 factorial design. Between 2005 and 2008, 320 women were recruited 
through seven hospitals and two radiotherapy clinics in the South of the Netherlands. 
Participants were eligible for inclusion if they had completed breast cancer treatment 
with curative intent less than six weeks prior to randomization with a WHO performance 
score between 0-2, and were fl uent in speaking and reading Dutch. Exclusion criteria 
were distant metastases, and/or participation in another clinical trial or medical illness 
requiring more frequent follow-up. All eligible patients received detailed study information, 
including an information sheet on follow-up after breast cancer treatment. This information 
sheet described the purpose and effectiveness of breast cancer follow-up and signs and 
symptoms of possible recurrences. 
After written informed consent was obtained, participants were randomly assigned to one 
of four follow-up strategies (study arms) during the fi rst 12 months after treatment; i.e. 1) 
hospital follow-up every three months, including mammography at 12 months; 2) nurse-
led telephone follow-up every three months, plus hospital visit and mammography at 12 
months; 3) arm 1 plus educational group program (EGP); 4) arm 2 plus EGP. 
Randomization by minimization (Taves, 1974) was performed by the Comprehensive 
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Cancer Center Limburg using a computerized randomization program (ALEA). Patients 
were pre-stratifi ed by hospital and treatment modality (surgery, surgery + radiotherapy, 
surgery + chemotherapy, and surgery + radiotherapy + chemotherapy). The study protocol 
was approved by the Medical Ethical Review Board of MAASTRO Clinic (NL). All participating 
centers signed a local feasibility declaration, according to Dutch law and regulations, prior 
to inclusion of the fi rst patient.
For the purpose of this analysis, hospital follow-up (arms 1 and 3) was compared to 
telephone follow-up (arms 2 and 4). In total, 162 patients were randomized to nurse-led 
telephone follow-up and 158 patients to traditional hospital follow-up. 
Procedures and intervention
In the Netherlands, follow-up after breast cancer in the fi rst year after treatment consists 
of routine follow-up visits to the hospital (i.e. at 3, 6, 9 and 12 months after treatment) 
(Struikmans et al., 2008). A mammography is made at 12 months after the start of 
treatment, which is combined with a hospital follow-up visit. The provider of follow-up 
alternates between the surgeon, BCN, medical oncologist and radiation oncologist.
In patients randomized for hospital follow-up, follow-up was performed according to the 
above described Dutch guidelines. The follow-up visits consisted of physical examination 
and medical history and had a scheduled duration of approximately 10 minutes. In 
patients randomized for telephone follow-up, follow-up at 3, 6 and 9 months was 
performed by telephone, by a BCN or nurse practitioner (NP) working at this hospital, 
preferably the same nurse at each follow-up moment. At 12 months, a mammography 
was made and combined with a hospital follow-up. The telephone follow-up included a 
semi-structured interview in which physical -especially loco-regional- and psychosocial 
symptoms, treatment side effects and compliance with hormonal therapy were discussed. 
Furthermore, the BCN informed about general well-being of the patient, her family life, 
relationships, and work reintegration. Time scheduled for the telephone interview was 
approximately 15-20 minutes. If the patient had specifi c complaints or did not feel 
reassured, an additional appointment was made for her to come to the hospital. In order 
to adequately perform the telephone interview, all participating nurses attained four half-
day training sessions, specifi cally developed for this study. In this training BCNs were 
informed on the most recent developments in breast cancer treatment and follow-up, 
and practiced their telephone communication skills with a simulation patient. Twenty-one 
BCNs from seven hospitals were trained. 
 
Outcome measures of effect
Patient satisfaction
To assess patient satisfaction the Dutch version of the validated Ware’s Patient’s 
Satisfaction Questionnaire III (PSQ III) was used. The PSQ III captures the most important 
characteristics of services and providers that might infl uence patient satisfaction with 
care. The Dutch version has left out fi nancial aspects of the original questionnaire (i.e. 
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questions 4, 10, 14, 19, 24, 27, 32 and 44), since in the Dutch health care system the 
personal fi nancial situation is not directly related to the provision and quality of medical 
care. The structure and reliability of the PSQ III has been tested in a large sample of 
cancer patients in the Netherlands who were on average 8.6 months after treatment. 
Of this sample 31.1% were breast cancer patients. The PSQ III appeared an appropriate 
measure of cancer patient’s satisfaction (Hagedoorn et al., 2003). 
The PSQ III is a three factor model: besides general satisfaction (PSQ total), it consists of 
satisfaction with interpersonal aspects (IA) of the health care professional (i.e. providing 
explanations, listening skills, hasty behavior, empathy and respect), technical competence 
(TC) (i.e. knowledge of latest treatment techniques, competences of specialist/nurse) 
and satisfaction with access of care (AC) (i.e. easy and quick access to care, quality of 
care, waiting time). The questionnaire contains 43 favorably and unfavorably worded 
statements. Respondents are asked to indicate their agreement with the statements 
with respect to the care they received. The statements in the questionnaire all assume 
that medical care is provided by a doctor. To adjust to the study environment, the ‘nurse’ 
was added to the questionnaire. For example, ‘the doctor/nurse who treats me has a 
genuine interest in me as a person’ (question 17). Items are included in the questionnaire 
in random order and the answer alternatives range from 1 (strongly agree) to 5 (strongly 
disagree) (Hagedoorn et al., 2003). Answers to favorably worded statements are reverse-
coded, so that a higher number indicates more satisfaction. Sum scores were calculated 
for the PSQ total scale and for the three dimensions and subsequently transformed into 
a 100-point scale. 
Possible response bias was investigated by using the matched-pairs method (Ware, 
1978). This methods checks whether a respondent tends to agree (or disagree) with 
two statements known to defi ne opposite ends of the same satisfaction continuum, e.g. 
‘Doctors/nurses carefully listen to what I have to say’ and ‘Doctors/nurses sometimes 
ignore what I tell them’. The PSQ III includes fi ve matched pairs. Each of these pairs 
is assigned a score 0 if no response bias is present, and 1 if response bias is present. 
Consequently, the theoretical range of response bias is 0 to 5; a score of 0 indicates no 
response bias, whereas a score of 2 or higher represents substantial bias.
The PSQ III was fi lled out before randomization at baseline, and 3, 6 and 12 months after 
treatment. Patients received the questionnaire at home approximately one week after the 
follow-up visit or telephone interview and were asked to return it by mail in an enclosed 
envelope.
 
Protocol compliance
Data on the actual follow-up received, thus number of hospital visits and telephone 
contacts with a BCN, were collected from patient fi les.
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Statistical analysis
The sample size for this study was determined by the sample size of the RCT, which was 
based on its primary outcome measure, i.e. health-related quality of life (HRQoL) at 12 
months after end of treatment (Kimman et al., 2007b). This paper deals with patient 
satisfaction at 12 months after treatment. We hypothesized that satisfaction with nurse-
led telephone follow-up, regarding general satisfaction, interpersonal aspects, technical 
competences, and access of care, could be different from satisfaction with hospital follow-
up. A difference in satisfaction scores of at least 0.5 standard deviation (SD), a medium 
effect, was considered to be clinically relevant. Assuming an SD of 17.9 for both groups 
(Hagedoorn et al., 2003), post hoc calculations showed that a sample of 299 patients 
from the RCT allowed to demonstrate a clinically relevant difference between nurse-led 
telephone and hospital follow-up (i.e. 8.95 points difference) with 90% statistical power 
and an α of 0.05.
Data were entered in a database by a professional center for data and information 
management and analyzed using SPSS version 17.0. Missing values within the survey’s 
subscales were replaced using the regression function in SPSS if no more than half 
of the items were missing. If more than half of the items were missing the subscale 
was considered missing. If three or four PSQ III questionnaires were not returned, the 
patient was judged to be lost to follow-up. Missing data (i.e. subscales) from one or 
two questionnaires or missing covariates were imputed by means of Rubin’s multiple 
imputation procedure (Schafer, 1999). 
Differences in patient characteristics between telephone and hospital follow-up were 
compared using the X2 test and independent sample t-test. Regression analyses were 
used to predict outcome differences by including or excluding the intervention. Linear 
mixed models were fi tted with telephone follow-up (yes/no) as a fi xed factor, and patient as 
random factor. In addition, time since end of treatment, age, hospital, treatment modality, 
education level, and the outcome variable at baseline were brought into the model. In the 
primary analysis data were analyzed according to the intention to treat principle. However, 
since protocol violation may bias the results (in either direction), per protocol analyses 
including only patients who properly followed the study protocol were also performed and 
reported (Jones et al., 1996; Piaggio et al., 2006).
RESULTS
Patients
Data from 299 patients were available for the purpose of this analysis. In the RCT, 21 
of 320 randomized patients had dropped out of the trial due to various reasons (e.g. 
development of metastases, recurrence, or three or more missing questionnaires). Data 
of 149 patients randomized to hospital follow-up and data of 150 patients randomized to 
telephone follow-up were available for the evaluation of patient satisfaction. Mean sample 
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age was 56 years. Sociodemographic and treatment characteristics as well as baseline 
satisfaction scores were similar in the two groups (table 1). 
Table 1. Sociodemographic and treatment characteristics of participants (n=299) according to hospital or 
telephone follow-up. Values are numbers (percentages) unless stated otherwise. 
Total group
(n=299)
Hospital 
follow-up 
(n=149)
Telephone 
follow-up 
(n=150)
p-value
Age at randomization (years)
Mean (SD) 56 (9.9) 56 (10.7) 55 (9.0) 0.50 
Range 23-78 23-78 34-75 0.06
<45 36 (12) 18 (12) 18 (12)
45-64 203 (68) 93 (62) 110 (73)
≥65 60 (20) 38 (26) 22 (15)
Level of education 0.36
Low 102 (34) 45 (30) 57 (39) 
Middle 118 (40) 62 (42) 56 (37)
High 79 (26) 42 (28) 37 (24)
Marital status 0.15
Married 212 (71) 109 (73) 103 (69)
Unmarried 33 (11) 16 (11) 17 (11)
Cohabiting 29 (10) 9 (6) 20 (13)
Widowed 25 (8) 15 (10) 10 (7)
Treatment modality 0.99
Surgery 29 (10) 15 (10) 14 (9)
Surgery + radiotherapy (RT) 178 (60) 89 (60) 89 (60)
Surgery + chemotherapy (CH) 15 (5) 7 (5) 8 (5)
Surgery + RT + CH 77 (25) 38 (25) 39 (26)
Hormonal therapy 0.60
Yes 94 (31) 50 (34) 44 (29) 
No 205 (69) 99 (66) 106 (71)
Baseline satisfaction scores
(mean (SD))
General satisfaction 77.2 (19.5) 77.7 (14.2) 76.7 (18.9) 0.65 
Interpersonal aspects 81.8 (17.5) 81.4 (17.6) 82.2 (17.5) 0.70 
Access of care 76.9 (14.0) 77.4 (14.2) 76.4 (13.8) 0.54 
Technical competence 77.0 (16.3) 76.7 (17.2) 77.4 (15.4) 0.69 
Compliance to the protocol
Ten patients randomized for telephone follow-up preferred to receive hospital follow-
up instead, and case record forms indicated that 20 patients with telephone follow-up 
received only one telephone follow-up contact, which was considered as protocol violation. 
Hence, 120 of the 150 patients in the telephone follow-up group, received telephone 
follow-up according to the protocol. Since hospital follow-up represented usual care, no 
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protocol violations were apparent in this group. 
The 30 patients who violated the protocol in the telephone group did not differ from other 
patients in this group regarding age, education, treatment modality and satisfaction 
scores at baseline (all p-values > 0.05). 
Table 2 shows the mean number of total hospital visits and telephone contacts with the 
breast care nurse per group for the study period of one year. In the hospital group patients 
had on average 5.9 visits to the hospital, of which four visits were conform protocol and 
1.9 were additional visits. In the telephone group patients had on average 2.4 telephone 
contacts with the BCN and 3.4 visits to the hospital, of which one hospital visit was 
conform protocol and 2.4 were additional visits.
Table 2. Number of contacts with medical specialist (MS) and breast care nurse (BCN) according to follow-
up group (hospital and telephone) in one year. Numbers are means and standard deviations.
Hospital follow-up Telephone follow-up
Conform 
protocol
Additional 
contacts
Total 
contacts
Conform 
protocol
Additional 
contacts
Total 
contacts
Intention to treat analysis
Visits hospital (MS or BCN) 4 1.9 5.9 (2.2) 1 2.4 3.4 (2.4)
Telephone contact BCN 0 0.1 0.1 (0.4) 3 -0.6 a 2.4 (1.1)
Per protocol analysis
Visits hospital (MS or BCN) 4 1.9 5.9 (2.2) 1 2.0 3.0 (2.3)
Telephone contact BCN 0 0.1 0.1 (0.4) 3 -0.2 a 2.8 (0.7)
a Negative numbers imply fewer contacts than set by the protocol
Patient satisfaction
Since patients who violated the protocol for telephone follow-up did not differ from patients 
who adhered to telephone follow-up, results from the intention to treat analyses are 
discussed as the primary outcomes in this section. Nevertheless, table 3 shows results of 
both intention to treat and per protocol analyses.
In the fi rst year after treatment patient satisfaction scores were high in both groups in 
all subscales of the PSQ III, at all time points (see fi gure 1). Table 3 (page 84) shows 
satisfaction scores at 12 months after treatment. General patient satisfaction at 12 
months was 75.3 (SD=19.6) in the hospital follow-up group and 76.4 (SD=19.7) in the 
telephone follow-up group. Patient satisfaction regarding technical competence was 73.7 
(SD=17.9) for the hospital follow-up group and 75.8 (SD=16.8) for the telephone follow-
up group. Satisfaction with interpersonal aspects was 78.7 (SD=18.5) for the hospital 
follow-up group and 78.9 (SD=17.6) for the telephone group. Regarding access of care 
satisfaction for the hospital follow-up group was 73.3 (SD=15.7) and for the telephone 
follow-up group 76.4 (SD=15.6). Regression analysis showed that nurse-led telephone 
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follow-up had no statistically signifi cant infl uence on general patient satisfaction (p=0.379), 
satisfaction with technical competence (p=0.249), and satisfaction with interpersonal 
aspects (p=0.662). Regarding access of care, patient satisfaction was signifi cantly higher 
for patients receiving telephone follow-up (p=0.015). However, a mean difference at 12 
months of 3.1 points may be statistically signifi cant, but was not considered clinically 
relevant (i.e. < medium effect). 
In the per protocol analyses, ten patients who had refused telephone follow-up after 
randomization were analyzed in the hospital follow-up group, while the 20 patients who 
had not properly received telephone follow-up were excluded from the analyses. Per 
protocol analyses showed almost identical results to intention to treat analyses. However, 
in contrast to the intention to treat analysis, higher patient satisfaction scores in the 
telephone group regarding access of care were not signifi cant (p=0.060).
Figure 1. Average satisfaction scores with general satisfaction, access of care, technical competences, 
and interpersonal aspects, at baseline, 3,6 and 12 months after treatment, for hospital follow-up (black 
line) compared to nurse-led telephone follow-up (grey line). Error bars represent 95% confi dence intervals.
Response bias
Response bias in the questionnaire was tested on the 12 months data. We found 
neglectable response bias scores for the tendency to disagree regardless of content 
(0.7% of respondents), but 14% of respondents showed substantial response bias, i.e. 
agreed with two or more (out of fi ve) opposite statements regardless of their content. 
Nevertheless, an analysis with a calibrated sample of respondents without response bias 
(n=257) showed identical results to the main analysis regarding all factors of satisfaction 
(data not shown). 
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DISCUSSION
To improve follow-up care after breast cancer, feedback from patients on satisfaction 
is important since it provides information on the quality of care received. Furthermore, 
patients may comply better with a specifi c follow-up strategy when they are satisfi ed 
with their care and follow-up setting. Insight into patient satisfaction when evaluating 
telephone follow-up was therefore an important aspect of our RCT. 
The results of this study show that nurse-led telephone follow-up after breast cancer 
may well be an appropriate alternative to hospital follow-up. Patient satisfaction scores 
at 12 months after treatment were high in all subscales of the PSQ III for both nurse-
led telephone and hospital follow-up. No meaningful differences were found between the 
two types of follow-up in scores for general satisfaction, satisfaction with interpersonal 
aspects, satisfaction with technical competences of staff, and access of care. Since 
equivalence was seen as a positive outcome in this study, it was important to carefully 
analyze protocol violators and perform both intention to treat and per protocol analyses 
(Jones et al., 1996). Both types of analyses showed almost identical results. This was 
expected since the 30 patients who violated the protocol in the telephone group did not 
Table 3. Outcome fi ndings at 12 months after treatment, by study group adjusted for treatment, hospital, 
outcome variable at baseline, age, educational level, support from partner and time since treatment.
Mean (SD) 
telephone 
f-up (12 
months)
Mean (SD) 
hospital 
f-up (12 
months)
Parameter 
estimate
95% 
Confi dence 
Interval for 
differenceª
p-value
Intention to treat analysis (n=150) (n=149)
General satisfaction
  Telephone vs hospital f-up 76.4 (19.7) 75.3 (19.6) 1.86 -2.30 to 6.03 0.379
Interpersonal aspects
  Telephone vs hospital f-up 80.5 (17.6) 78.7 (18.5) 0.91 -3.18 to 5.00 0.662
Access of care
  Telephone vs hospital f-up 76.4 (15.6) 73.3 (15.7) 3.71 .71 to 6.70 0.015
Technical competence
  Telephone vs hospital f-up 75.8 (16.8) 73.7 (17.9) 2.13 -1.51 to 5.77 0.249
Per protocol analysis (n=120) (n=159)
General satisfaction
  Telephone vs hospital f-up 76.2 (19.7) 75.7 (19.9) 1.13 -3.14 to 5.39 0.604
Interpersonal aspects
  Telephone vs hospital f-up 81.3 (17.5) 79.2 (18.2) 0.55 -3.63 to 4.73 0.796
Access of care
  Telephone vs hospital f-up 75.8 (16.1) 74.7 (15.3) 3.10 -.13 to 6.32 0.060
Technical competence
  Telephone vs hospital f-up 75.1 (16.7) 74.1 (18.0) 1.76 -1.91 to 5.42 0.347
ª Positive differences imply a higher level of satisfaction in the telephone group.
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signifi cantly differ from other participants of this group regarding age, level of education, 
treatment received and baseline satisfaction scores. 
To our knowledge, this was the fi rst study to evaluate the multidimensional concept of 
patient satisfaction with nurse-led telephone follow-up specifi cally aimed at the fi rst year 
after breast cancer treatment. It is also one of the few studies that used a validated 
questionnaire to measure patient satisfaction (Sitzia, 1999). Although the PSQ III was not 
specifi cally developed to measure satisfaction with follow-up care and response bias is a 
documented problem of the questionnaire, the Dutch version was validated among breast 
cancer patients after treatment and satisfaction and response bias scores found in our 
study were similar to the norm scores found by Hagedoorn et al. (2003). Furthermore, the 
pragmatic nature of the RCT led to the inclusion of a broad range of patients regarding 
age, treatment and location of treatment, including a sample representative of breast 
cancer patients in the Netherlands (Kiemeney et al., 2008). 
In general, the positive fi ndings in this study were similar to fi ndings reported in other 
studies investigating nurse-led telephone follow-up (Beaver et al., 2009b; Brown et al., 
2002; Hagedoorn et al., 2003; Montgomery et al., 2008a). Even though the results are 
diffi cult to compare, there is a strong trend towards acceptability, feasibility, and good 
patient satisfaction scores for telephone follow-up. The recent study by Beaver et al. 
(2009b) is most comparable to our study. In their randomized clinical trial (n=374), a 
structured telephone intervention was developed and nurses received four half day 
training sessions, similar to our study. Patient satisfaction was evaluated at the beginning, 
middle, and end of the trial, by asking participants if they were satisfi ed with information 
received and whether the appointment had been helpful in dealing with their concerns. 
It was found that patient satisfaction was signifi cantly higher for telephone follow-up 
compared to hospital follow-up at the middle and at the end of the trial. Women were 
recruited between 0.5 and 106 months after the end of treatment and remained in the 
trial for a mean of 24 months. In our study women entered immediately after treatment 
and remained in the trial for 12 months. Thus, the studies can be seen as complementary; 
both provide evidence that telephone follow-up can be appropriate for patients in different 
phases after breast cancer treatment (Beaver et al., 2009b). 
Several explanations can be hypothesized for the high satisfaction scores with nurse-
led telephone follow-up. First of all, telephone follow-up was performed by a specialized 
breast care nurse, most often a nurse familiar to the patient from the time of diagnosis 
and treatment. It was expected that patients felt comfortable expressing emotions and 
concerns to this nurse (Pennery & Mallet, 2000). The breast care nurses were also 
specifi cally trained to meet information and psychological needs. The follow-up may take 
up to 20 minutes and was done by open discussion, offering the patient the opportunity to 
discuss issues they were most concerned with. Furthermore, nurse-led telephone follow-
up provided continuity to the patient. In general, the same nurse provided the telephone 
follow-up for a patient, which is different from hospital follow-up where patients were seen 
by the medical oncologist, radiation oncologist, surgeon or breast care nurse. 
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Despite positive results, the conclusion that nurse-led telephone follow-up provides 
equal satisfaction compared to hospital follow-up must be made carefully, taking into 
account several possible limitations of this study. First, of eligible patients 64% declined 
participation in the randomized trial. This might be due to a lack of knowledge about 
the purpose and effectiveness of follow-up (de Bock et al., 2004b; Montgomery et al., 
2008b). Moreover, the fact that patients were informed about the usual care (hospital 
follow-up) before participation may have also negatively infl uenced the participation rate, 
since patients generally have a preference for what they know best, the so-called ‘status 
quo bias’ (Salkeld et al., 2000). Hence, patient education on follow-up will need special 
attention in future trials or when implementing telephone follow-up. Nevertheless, the 
relatively low participation rate of the RCT may have an impact on the generalizabilty of our 
results. It specifi cally infl uenced this patient satisfaction study, since patients who chose 
to participate in the RCT may have had either no strong preference for a follow-up strategy, 
or positive expectations of the interventions. Thus, patients may have been somewhat 
uncritical of the care provided, or prior expectations about follow-up may have infl uenced 
expressed satisfaction (Linder-Pelz, 1982; Williams, 1994). In other words, patients may 
have expressed satisfaction no matter what care was provided. It is unclear whether and 
if so, to what extent, the sample selection has infl uenced our results. Additionally, patients 
who had developed a recurrence or metastatic disease in the study period were lost to 
follow-up. Hence, the analysis included a sample of patients who remained disease-free 
in the fi rst year after treatment. It may be speculated that these patients will generally 
show high satisfaction scores.
 
Second, one in fi ve patients randomized to telephone follow-up did not receive telephone 
follow-up according to protocol, which may in itself be seen as evidence that the two 
follow-up strategies were not entirely equal in terms of preference and feasibility. Indeed, 
ten patients requested to receive hospital follow-up directly after having been randomized 
for telephone follow-up. However, most other protocol violations were related to logistic 
diffi culties or health-related problems (e.g. the patient needed to visit the hospital for a 
complaint, but was unintentionally not re-entered in the telephone follow-up). Moreover, 
even though hospital follow-up was better adhered to in the trial and generally preferred 
beforehand, per protocol analyses showed high satisfaction scores for telephone follow-
up, equal to patients who followed hospital follow-up.
Third, it must be recognized that all patients received some follow-up in the hospital, also 
the patients randomized to telephone follow-up, which may have contributed to the fact 
that no differences between the two forms of follow-up were found. 
Finally, other outcomes besides patient satisfaction are relevant when exploring 
alternative follow-up strategies for breast cancer, such as the effectiveness in terms of 
health-related quality of life, emotional functioning, feelings of anxiety and costs. These 
outcome measures will be assessed before implementation of telephone follow-up. 
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CONCLUSION
This study showed that regular telephone contact with a breast care nurse and a one-
year mammography combined with a hospital visit was equal to traditional hospital 
follow-up visits, in terms of general satisfaction, and satisfaction with regard to technical 
competences of staff, access of care and interpersonal aspects. It is concluded that 
nurse-led telephone follow-up in the fi rst year after breast cancer treatment may be an 
appropriate and acceptable alternative to hospital follow-up.
8“Due to heterogeneous    preferences, it seems promising       to introduce an individualized                  follow-up”
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One strategy fits all? 
An investigation of patient preferences 
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ABSTRACT
[Introduction] Clinical guidelines for the follow-up after breast cancer recommend 
frequent outpatient clinic visits to be examined for a possible recurrence or a second 
primary breast tumor, and to receive information and psychosocial support. However, 
needs and preferences for follow-up may differ between patients, raising the question 
whether the current ‘one size fi ts all’ approach is appropriate. This study explored 
patients’ preferences for follow-up. [Patients and methods] A discrete choice 
experiment survey with 16 choice tasks was fi lled out by 331 breast cancer patients. 
Each choice task consisted of two hypothetical follow-up scenarios for the fi rst year 
after treatment, described by levels of the following characteristics; attendance at an 
educational group program, frequency of visits, waiting time, contact mode, and type 
of health care provider. [Results] The health care provider and contact mode were 
the most important characteristics of follow-up to patients. The medical specialist 
was the most preferred to perform the follow-up, but a combination of the medical 
specialist and breast care nurse alternating was also acceptable to patients. Face-to-
face contact was strongly preferred to telephone contact. Follow-up visits every three 
months were preferred over visits every four, six, or twelve months. Heterogeneity in 
preference between patients was strong, especially for the health care provider and 
attendance at an educational group program. Age, education, and previous experience 
with follow-up characteristics infl uenced preferences, but treatment modality did not. 
[Conclusions] The results of this study show that overall patient satisfaction would 
not differ signifi cantly if patients have follow-up by medical specialist and breast care 
nurse alternating compared to follow-up by a medical specialist only. Furthermore, we 
found heterogeneity in preferences for most attributes, indicating that one strategy 
does not fi t all. Individualized follow-up seems to offer the potential for signifi cant 
increases in patient satisfaction.
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INTRODUCTION
Clinical guidelines for follow-up after curative treatment for breast cancer recommend 
that women attend frequent follow-up clinic visits, to be examined for possible local or 
regional recurrence or a second primary breast tumor, and to receive information and 
psychosocial support (Pestalozzi et al., 2005). However, clinical outcomes are not affected 
by frequency, intensity, and type of follow-up (GIVIO, 1994; Grunfeld et al., 2006; Koinberg 
et al., 2004; Rosselli Del Turco et al., 1994), and there is doubt whether short outpatient 
clinic visits are appropriate to provide psychosocial support (Allen, 2002; Pennery & 
Mallet, 2000). Hence, a more individualized follow-up, in which patient preferences are 
taken into account, is being proposed (Grunfeld, 2009a). Particularly in the fi rst year after 
treatment, when scheduled follow-up visits are most frequent, a shared decision making 
process and more fl exible follow-up may increase patient satisfaction, adherence to the 
strategy, and ultimately quality of life (Joosten et al., 2008).
Several studies have investigated patient preferences regarding breast cancer follow-
up using cross-sectional surveys. De Bock et al. (2004b) analyzed the needs of women 
who participated in a routine follow-up program (n=116). More than half of the patients 
preferred lifetime follow-up, twice a year, performed by the medical specialist. Furthermore, 
younger age was related to a greater need for information during follow-up. Montgomery 
et al. (2008b) found that women (n=79) expected some form of follow-up, but there was 
no consistency regarding the frequency. Renton et al. (2002) concluded that, although 
women were generally satisfi ed with current hospital follow-up, they would accept changes. 
Results of the study suggest that if services were reorganized, women would prefer 
involvement of specialist nurses in follow-up to that of their general practitioner. Hence, 
women do expect to receive some form of follow-up after breast cancer, but preferences 
for patient education, length, frequency, and provider of follow-up can vary considerably. 
Additionally, results from several clinical trials show that patients who have experienced 
alternative follow-up strategies, e.g. by a breast care nurse (Koinberg et al., 2004), by a 
general practitioner (Grunfeld et al., 2006), less frequent follow-up (Brown et al., 2002), 
or follow-up by telephone (Beaver et al., 2009b) were equally satisfi ed as patients who 
received traditional hospital follow-up.
This paper deals with women’s preferences for the follow-up after breast cancer treatment, 
including most alternative strategies that have been proposed in the literature, using a 
discrete choice experiment (DCE). A DCE is a survey methodology capable of establishing 
preferences, which is grounded in economic theory (Lancaster, 1966; McFadden, 1974), 
and has an advantage over traditional satisfaction questionnaires, in that it enables the 
researcher to measure strength of preferences for different characteristics of follow-up 
and the trade-offs made between them. DCEs are found to be a valid and reliable approach 
to elicit preferences in a health care context (Bryan et al., 2000) and are recognized as 
a useful tool for medical decision making (Lancsar & Louviere, 2008; Ryan & Gerard, 
2003). 
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In a DCE respondents are asked to choose the preferred alternative from a set of two 
or more hypothetical scenarios. The scenarios are described by key characteristics 
(‘attributes’) of follow-up, such as the health care provider. The respondents’ evaluation of 
a scenario depends on the levels of the attributes (for example, a nurse, medical specialist, 
or general practitioner). The relative importance of attributes and levels to respondents 
and the trade-offs made between them, can be assessed by asking respondents to make 
choices in multiple scenarios with different levels of attributes. A detailed explanation 
of the methodology applied in health care has been described by Lanscar and Louviere 
(2008), and Ryan and Gerard (2003). 
To our knowledge, this is the fi rst study that aims to measure the strength of preferences 
for several characteristics of breast cancer follow-up using a discrete choice experiment. 
We also explore the variety in patient preferences (i.e. ‘preference heterogeneity’) which 
ultimately allows us to explore optimal ways of providing individual-level follow-up to 
patients.
PATIENTS AND METHODS
Patients
This study was performed among Dutch breast cancer patients who fi nished curative 
treatment between June 2006 and December 2007. Data collection took place between 
May and July 2008. Of 557 eligible patients from fi ve participating hospitals, 359 agreed 
to participate and subsequently received a survey with the discrete choice experiment. 
Completed surveys from 331 patients were used for the analysis (response rate of 59%). 
Respondents’ characteristics can be found in table 1 (page 92). The average age was 
58 years (range 34 to 83) and the mean time since fi nalizing breast cancer treatment 
was 14 months (range 4 to 24 months). The study was approved by the Medical Ethical 
Committee of the Maastricht University Medical Center.
 
Methods
A discrete choice experiment survey was used. The survey comprised two sections: the 
DCE (16 hypothetical choice tasks) and a section with questions regarding background 
information of the respondent.
A crucial stage of DCE design is the identifi cation of the key characteristics (attributes) 
that describe the scenarios in the choice tasks, and their levels (Lancsar & Louviere, 
2008; Ryan, 1999). The choice of these attributes and levels was based on a review of 
the literature (Kimman et al., 2007a), local policy initiatives (Kimman et al., 2007b), and 
expert opinion. Attributes were included if they represented common current practice in 
follow-up or relevant potential initiatives. Table 2 (page 94) provides the attributes and 
levels used in the choice tasks.
The combination of attributes and levels in this study resulted in (4³x2²=) 256 possible 
scenarios (a ‘full factorial design’). Since presenting all 256 scenarios to respondents 
CHAPTER 8
92
would be too burdensome, only a subset of the scenarios, a fractional factorial design, was 
used. With a 32-profi le fractional factorial design we were able to estimate main effects 
and two-way interactions between contact mode and all other attributes. Subsequently, to 
construct choice tasks, a fold-over of the design was created. A fold-over takes the original 
design, shifts the attribute levels (e.g. medical specialist becomes breast care nurse, every 
three months becomes every four months, etc), and adds this fold-over design as extra 
scenarios to the original design, creating choice tasks. The design ensured orthogonality 
(the absence of multicollinearity between attributes) and was balanced in terms of the 
number of times each level of an attribute was seen (Street et al., 2005). A maximum of 
16 choice tasks per respondents was considered feasible, hence two surveys each with 
16 choice tasks were created by blocking the design. This means that each respondent 
faces only a subset of choice situations from the fractional factorial design. Blocks were 
determined based on an additional orthogonal column to the design with two levels. 
Respondents were randomly assigned to one of the two blocks. An example of a choice 
task is shown in fi gure 1. 
Category No. respondents (%)
Age
< 60 year 145 (43.8)
≥ 60 year 186 (56.2)
Living with a partner
Living alone or single parent 79 (23.9)
Living with partner (and children) 247 (74.6)
Other 5 (1.5)
Education
No education, primary school, lower education 111 (33.5)
Secondary education 134 (40.5)
Higher education 86 (25.0)
Treatment modality
Surgery 48 (14.5)
Surgery and radiotherapy 128 (38.7)
Surgery and chemotherapy 58 (17.5)
Surgery and radiotherapy and chemotherapy 96 (29.0)
Unknown 1 (0.3)
Hormonal therapy
Yes 126 (38.1)
No 204 (61.6)
Unknown 1 (0.3)
Experience with follow-up
Follow-up by a breast care nurse 37 (11.2)
Follow-up by a medical specialist 220 (66.5)
Combination of breast care nurse and medical specialist 74 (22.3)
Participation in educational group program 27 (8.2)
Experience with telephone follow-up 24 (7.3)
Table 1. Characteristics of the 331 respondents of the discrete choice experiment
 
Important! Before choosing between scenario A and B, please be aware of the following: 
 
Regardless of the scenario you will have an annual mammography combined with a visit (with 
physical examination) to the medical specialist. Also, you can always make additional appointments 
whenever you feel the need. Disease-free and overall survival are identical for both scenarios. 
Scenario A 
 
Your scheduled appointments are every 4 
months 
 
The appointment is with a medical specialist 
 
The appointment is face-to-face in hospital 
 
You have to wait for 60 minutes in hospital 
 
You do not attend an Educational Group 
Program 
Choice 
For the first year after treatment, would you prefer scenario A or B? 
Scenario B 
 
Your scheduled appointments are every 6 
months 
 
The appointment is with a breast care nurse 
 
The nurse will contact you at home, by telephone 
 
You have to wait for 90 minutes, at home 
 
You can attend an Educational Group Program 
 
Attribute levels 
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The survey started with a short introduction on why the study was performed and an 
outline of the purpose and effectiveness of follow-up after breast cancer. A comprehensive 
description of each attribute and its level to clarify their meaning and implications 
to respondents followed. Importantly, every choice task started with information on 
the effectiveness of follow-up, the annual mammography, and the possibility to make 
additional appointments (see fi gure 1). To be able to investigate whether patients preferred 
what they themselves had experienced (Salkeld et al., 2000), respondents were asked 
to describe the follow-up strategy they had received in their fi rst year after treatment. 
Additionally, background information on education level, living with a partner or alone, 
and received treatment modality was retrieved. The survey was pilot tested (n=10) to 
check for any problems in interpretation and face validity, which led to minor changes to 
the text and layout.
Figure 1. Structure of a discrete choice task. Scenarios varied systematically over 32 choice tasks.
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Establishing preferences
All eligible patients were contacted by telephone by independent employees of the 
Center for Data and Information Management of the Maastricht University to ask for 
participation. When informed consent was obtained, respondents received the postal 
survey. Respondents were asked to fi ll out the survey at home. Contact details of the 
researcher were given for any questions or clarifi cation. At a later time, answers to the 
completed survey were collected by telephone and entered into a database. NLOGIT 3.0 
software package (Econometric Software Inc.) was used to analyze the data.
Random parameter logit (RPL) modeling was used to estimate a choice model and specify 
a utility function (Kjaer & Gyrd-Hansen, 2008; Train, 2003). All probabilistic choice models 
are characterized by the following equation: 
 Uin = Vin + εin
where Vin = gn(Xi) is the systematic utility component that depends on the attributes of the 
alternative (Xi) and the indivual’s specifi c tastes, and εin is an error component. Assuming 
that a respondent can choose between two alternatives, i and j, then the probability that 
alternative i is chosen is given by:
 Pin = Prob(Uin > Ujn) = Prob(Vin + εin > Vjn + εjn) = Prob(Vin - Vjn > εjn - εin) if i   
 is not equal to j.
This generates the well known standard logit specifi cation if the error terms are assumed 
to follow independent and identical Gumbel distributions:
 Pin = exp(Vin)/(exp(Vin) + exp(Vjn))
In the random parameters logit model the systematic utility component is expressed as 
a function of the alternative’s attributes and an individual specifi c vector of preference 
parameters as follows:
 Vin = n’Xi with n = (+n),
where  constitutes the vector of average preferences of the population for each attribute 
and n the individual’s specifi c preference components which take on a normal distribution.
Our utility function was of the following form:
Uijt = 0 + 0i + (1+ 1i )*Educational group programj + (2+ 2i)*Frequencyj + (2+ 
3i)*(Frequencyj)² + (4+ 4i)*Waiting timej + (5+ 5i)*Telephone contactj + (6+ 6i)*Breast 
care nursej + (7+ 7i)*General practitionerj + (8+ 8i)*Medical specialist / Breast care 
nursej + εijt
For a detailed explanation see Appendix 1. In short, we investigated changes in utility (i.e. 
preference or satisfaction) when a level of an attribute changed. The parameter estimates 
(1–8) of the utility function describe the magnitude of these utility changes, and indicated 
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the relative importance of an attribute. A statistically signifi cant parameter estimate 
indicates that the attribute is indeed important to respondents. However, statistical non-
signifi cance of a parameter of an attribute should not be seen as necessarily meaning 
‘not relevant’ for each respondent since, due to heterogeneity in preferences, for some 
respondents the attribute may still infl uence their decisions. A positive or negative sign 
indicates that an attribute-level is either preferred or not preferred compared to the base 
level of the attribute. Preference heterogeneity was explored by examining the signifi cance 
of standard deviations of error components around the mean parameter estimates. 
Respondents’ characteristics were incorporated into the model as interaction terms with 
the attributes of the DCE to explore possible sources of preference heterogeneity.
Internal validity, i.e. the extent to which results are consistent with a priori expectations, 
was tested by examining the signs and signifi cances of parameter estimates. We expected 
all attributes to have a signifi cant infl uence on preferences for follow-up. Furthermore, it 
was expected that, in general, frequency would have a positive sign in the utility function 
and waiting time to have a negative sign. Since face-to-face follow-up by the medical 
specialist is common in current clinical practice, we expected a general preference for 
the medical specialist over the other health care professionals, and a general preference 
for face-to-face contact over telephone contact (hence a negative sign for the parameter 
estimate of telephone contact). No specifi c assumptions were made about preferences 
for the educational group program. Regarding two-way interactions, we were specifi cally 
interested in the interaction between waiting time and contact mode. It was a likely 
possibility that there were differences in preferences for waiting time between waiting 
time at the hospital (face-to-face contact) and waiting time at home (telephone contact).
Additionally, a consistency check (two identical choice tasks) was incorporated in the 
survey, and respondents were asked to report whether they experienced diffi culties 
understanding the choice tasks and choosing between the alternatives.
RESULTS
Validity of responses
Most respondents (74%) found the choice tasks clear or very clear, 16% were indifferent, 
and 10% found them unclear. Of the 331 respondents, 310 (94%) passed the consistency 
check. The Kappa statistic (K) for the identical choice tasks was 0.72, representing a good 
agreement. Following recent recommendations (Lancsar & Louviere, 2008), data from 
all respondents (n=331) were used for the main analysis. However, a secondary analysis 
was performed with a calibrated sample of respondents who found the choice tasks (very) 
clear (n=244). This analysis showed similar parameter estimates and model fi t (data 
not shown). Furthermore, most parameter estimates were signifi cant (p<0.05), and the 
parameter estimates of the attributes were in the expected direction, providing evidence 
of internal validity. In addition, the constant term was not signifi cant, indicating there was 
no general preference for alternative ‘A’ over alternative ‘B’, when all attributes and levels 
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were the same. Contrary to expectations, the two-way interaction between contact mode 
and waiting time was not signifi cant (p=0.687). Finally, an adjusted R-square of 0.369 in 
this study represented a good fi t of the model, indicating that respondents made choices 
in a systematic way, based on changes in the scenarios (Hensher et al., 2005). 
Preferences, relative importance of attributes and trade-offs
Table 3 shows the results of the discrete choice experiment. The two-way interactions 
between contact mode and other attributes did not improve the model fi t nor did they 
alter conclusions, therefore only results of the main effects model are reported. The 
main effects model showed that in general, for type of health care professional, follow-
up by the medical specialist was preferred to follow-up only by a breast care nurse or 
general practitioner, as indicated by their negative parameter estimates. The parameter 
estimates for medical specialist and breast care nurse alternating and the educational 
group program (EGP) were not signifi cant. This may indicate that, in general, a switch 
from the medical specialist performing the follow-up to alternating between the medical 
specialist and a breast care nurse, and whether or not an EGP is part of the follow-up, 
would not negatively (or positively) affect utility. Alternatively, it could mean that there is 
heterogeneity in preferences for these attributes.
As expected, more frequent visits per year and reducing waiting time also had a positive 
impact on utility. However, the signifi cant negative frequency² variable indicates that there 
is a linear and quadratic effect for frequency. Hence, marginal utility of more frequent 
follow-up visits decreased considerably when frequency increased. There was a large 
decrease in utility for a change from face-to-face contact to telephone contact. 
The relative importance of the attributes and their levels were determined by calculating 
part-worth utilities (Ryan, 1999); their ranking is shown in table 3. Overall, contact 
mode (face-to-face contact) and health care provider (medical specialist versus general 
practitioner) were the most important attributes of follow-up for respondents, while waiting 
time, the educational group program, and whether the health care provider was a breast 
care nurse or a medical specialist were least important.
Inputting parameter estimates and levels of attributes in the utility function provides 
information on how respondents were willing to trade between levels of attributes. For 
example, a change from the medical specialist to the breast care nurse performing the 
follow-up would result in a utility loss of 0.46, when all other attribute levels remain equal. 
However, this can be compensated by an increase in the frequency of visits. Utility for 
follow-up visits every six months (i.e. twice a year) is (*frequency + *(frequency)² = 
1.497*2 - 0.212*2² =) 2.146 and for follow-up visits every four months (i.e. 3 times a 
year) (1.497*3 - 0.212*3² =) 2.583. Hence, increasing the frequency results in a utility 
gain of 0.44, which could compensate for the loss of utility due to a change in health care 
provider.
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Table 3. Results for the random parameter logit model (n=331) with main effects only, results for the model with 
interactions with experience, and relative importance of attributes. Results presented are mean parameter 
estimates, standard deviations and p-values. EGP=educational group program, BCN=breast care nurse.
Main effects model ª Experience 
interaction model b
Relative 
impor-
tance c
Parameter 
estimate
p-value Parameter 
estimate
p-value
Random parameters in utility function d
EGP ¹ Mean -0.138 0.088 -0.212 0.011
Standard dev 1.171 < 0.001 1.117 < 0.001
Frequency of visits Mean 1.497 < 0.001 1.541 < 0.001 0.13 (3)
Standard dev 0.429 < 0.001 0.463 < 0.001
Telephone contact ² Mean -2.027 < 0.001 -2.279 < 0.001 0.36 (2)
Standard dev 1.533 < 0.001 1.505 < 0.001
Breast care nurse (BCN) ³ Mean -0.463 < 0.001 -0.617 < 0.001 0.08 (4)
Standard dev 1.057 < 0.001 1.126 < 0.001
General practitioner ³ Mean -2.124 < 0.001 -2.195 < 0.001 0.38 (1)
Standard dev 1.749 < 0.001 1.899 < 0.001
Waiting time Mean -0.007 < 0.001 -0.008 < 0.001 0.05 (5)
Standard dev 0.007 0.007 0.008 < 0.001
Non-random parameters in utility function e
Constant Mean -0.075 0.109 -0.076 0.114
Frequency² Mean -0.212 <0.001 -0.215 < 0.001
Medical specialist/ BCN ³ Mean 0.137 0.110 0.124 0.159
Experience * EGP Mean -0.138 0.088 0.698 0.011
Experience * tel f-up Mean 1.171 < 0.001 2.004 < 0.001
Experience * BCN Mean 1.497 < 0.001 1.101 < 0.001
LL(model) -2303.323 -2259.043 
Adjusted pseudo R2 0.369 0.377
N 5296 5296
a The main effects model assumed no interactions were present.
b The experience interaction model incorporated respondents’ previous experience with follow-up.
c The relative importance of attributes and their levels was determined by calculating the coeffi cient range, 
which is the difference between the smallest (negative) part-worth utility and the largest part-worth utility 
within the attribute levels, and dividing it by the sum of the coeffi cient ranges for all attributes and levels. 
d Attributes and levels were assigned to be normally distributed random parameters.
e When random parameters were found to have an insignifi cant standard deviation for their distribution, 
they were included as a nonrandom parameter in the model estimations.
¹ Refers to the attribute ‘attendance at educational group program’. Relative to ‘no attendance at 
educational group program’.
² Refers to the attribute ‘contact mode’. Relative to ‘face-to-face contact’.
³ Refers to the attribute ‘health care provider’. Relative to ‘medical specialist’.
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Exploring preference heterogeneity
Our estimation results demonstrated that there was a strong heterogeneity in patient 
preferences for follow-up characteristics (table 3). To gain insight into the strength of 
preference heterogeneity, individual parameter estimates were calculated of the 331 
respondents. By counting the number of patients with a positive parameter estimate for 
a specifi c attribute-level, the percentage of the sample that preferred that attribute-level 
compared to the base level was calculated. Especially, preferences for follow-up by a 
breast care nurse and participation in the EGP differed greatly among respondents (table 
4). For the total study population, a change from the medical specialist to a breast care 
nurse resulted in lower utility, but 28% of patients would nevertheless prefer this kind 
of follow-up. Also, the possibility to attend the EGP did not seem to infl uence utility, but 
indeed 47% of the study population preferred participation to no participation. 
To identify which patients might share specifi c preferences, the following interaction terms 
were incorporated into the model: chemotherapy, radiotherapy, hormonal therapy, living 
with a partner, older than 60 years, and high level of education. Only age and education 
level infl uenced preferences. Follow-up by a medical specialist was valued more positively 
by older than younger respondents (<60 years). Furthermore, older respondents and 
those with a low level of education were less likely to choose a scenario that included 
attending the EGP. Respondents with a higher education level positively valued an EGP 
in the follow-up. Though interactions between age, education and some attributes were 
signifi cant, collectively they only minimally improved the fi t of the model. Hence, much of 
the heterogeneity remained unexplained.
Positive parameter 
estimate (% of sample)
Negative parameter 
estimate (% of sample)
Educational group program 
(vs no educational group program) 156 (47) 175 (53)
Increase in frequency of visits 328 (99) 3 (1)
Telephone contact 
(vs face-to-face contact) 17 (5) 314 (95)
Follow-up by a breast care nurse 
(vs medical specialist) 93 (28) 238 (72)
Follow-up by a general practitioner 
(vs medical specialist) 10 (3) 321 (97)
Increase in waiting time 0 (0) 100 (100)
Table 4. Preference heterogeneity explored by individual parameter estimates (n=331): results presented 
are the number of respondents with a positive parameter estimate and negative parameter estimate for 
attributes of the discrete choice experiment (% of sample).
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Infl uence of previous experience on preferences
Our study population included some respondents who had experienced telephone follow-
up, nurse-led follow-up, and the EGP. Hence, we were able to create interactions between 
having experienced an attribute and the choice data for this attribute. The results are 
presented in table 3, and showed that respondents who had attended the EGP had a 
signifi cantly higher, and positive, parameter estimate for this attribute than those who 
had not. The same was true for respondents who had experienced follow-up by a breast 
care nurse. The parameter estimate for telephone contact was considerably higher for 
respondents who had experienced telephone follow-up, but telephone follow-up was still 
not preferred to face-to-face contact. These results indicated that there was indeed a 
tendency to prefer what one had personally experienced; however, the subgroups were 
small, and preference heterogeneity was still signifi cant when previous experience was 
accounted for.
DISCUSSION 
Patient preferences
To our knowledge this is the fi rst study to investigate patients’ preferences for breast 
cancer follow-up using discrete choice experimentation. Most patients preferred the 
medical specialist to perform the follow-up, but an alternating combination of the medical 
specialist and a breast care nurse was also acceptable to patients, and one in four patients 
preferred the follow-up to be performed solely by a breast care nurse. Face-to-face contact 
was much preferred to telephone contact. Furthermore, utility increased with an increase 
in the frequency of visits and when waiting time was reduced. Contact mode and type of 
health care provider were the most important characteristics of follow-up to patients. 
The fi nding that alternating between the medical specialist and breast care nurse 
is acceptable to patients is not surprising. There is evidence that emotional concerns 
are more easily expressed to a nurse (Pennery & Mallet, 2000), while seeing a medical 
specialist provides a feeling of security (de Bock et al., 2004b). Hence, alternating 
between both health care providers seems a good alternative (Renton et al., 2002). In line 
with our fi ndings, other studies have also found that the general practitioner was generally 
not preferred (Mao et al., 2009; Renton et al., 2002). A study conducted among American 
breast cancer patients revealed that patients had concerns about the communication 
between oncologists and general practitioners (Mao et al., 2009). Similar feelings among 
Dutch breast cancer patients may have caused the strong disutility for follow-up with a 
general practitioner, since in the Netherlands general practitioners only have a marginal 
role in breast cancer treatment and follow-up. A dislike for telephone follow-up is not 
surprising as it is unknown to patients, and may seem unsafe when patients still believe 
that frequent clinical examination to detect a relapse is an essential part of the follow-
up (de Bock et al., 2004b; Montgomery et al., 2008b). Even though we tried to provide 
information on the purpose and effectiveness of follow-up, we did not provide detailed 
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information on the value of clinical examinations. 
Finally, the need for information has also been studied before, and in general information 
needs varied greatly (Montgomery et al., 2008b). This is in line with our fi nding that 
preferences for participation in the EGP were very heterogeneous. Furthermore, in our 
study younger patients (< 60 years) and patients with a higher level of education had 
a stronger preferences for the EGP than older patients (and less educated), which is 
similar to other fi ndings (de Bock et al., 2004b; Montgomery et al., 2008b). De Bock et al. 
(2004b) did fi nd that higher information needs were associated with receiving adjuvant 
hormonal therapy or chemotherapy, but we could not fi nd evidence for the infl uence of 
treatment modality on preferences for the educational group program.
Importantly, when interpreting these results, we have to realize that people tend to prefer 
what they know best or have experienced (Salkeld et al., 2000), which was confi rmed in 
our study. Hence, preferences for participation in an unknown educational group program 
(EGP) and telephone contact or follow-up by a general practitioner might have been 
underestimated, while the importance of follow-up by the medical specialist and face-to-
face contact might have been overestimated. Moreover, this tendency to prefer what one 
has experienced might be part of the explanation why results of randomized clinical trials 
are in contrast with our fi ndings. A very recent study by Beaver et al. (2009b) found that 
telephone follow-up was acceptable to most patients, it signifi cantly improved satisfaction, 
and it produced no excess anxiety compared with hospital follow-up. A large randomized 
clinical trial by Grunfeld et al. (2006) investigating follow-up with the general practitioner 
also found high satisfaction rates for this type of follow-up. However, in both studies 40-
45% of the approached patients refused participation. Although reasons for refusal can 
vary, it may indicate that these alternative follow-up strategies were not acceptable to all 
patients, which is more in line with our fi ndings.
Implications for clinical practice
The results of this study raise several possibilities regarding the introduction of innovations 
in breast cancer follow-up. One possibility is to introduce a follow-up strategy in which 
the medical specialist and breast care nurse (alternating) provide the follow-up. With an 
increasing population of breast cancer survivors, a less specialized strategy could already 
create possibilities for scarce specialized knowledge to be used elsewhere. It can also 
be speculatively argued that, due to the tendency to favor the follow-up strategy that 
one has personally experienced, simply implementing the follow-up strategy that is the 
least costly might be effi cient. However, our results show that even when respondents 
had experience with the breast care nurse or telephone follow-up, some still preferred 
alternative strategies. Rather, due to the heterogeneous preferences, it seems promising 
to introduce an individualized follow-up to maximize utility. 
Identifying patient characteristics that predict preferences for follow-up would be of 
use in implementing fl exible follow-up. Interestingly, our study could not identify any 
objective patient characteristics that were strongly associated with preferences for follow-
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up attributes. Age and education interacted with preferences to some extent, but other 
individual-level factors such as personality type, lifestyle, risk aversion, anxiety, and 
perceived quality of life after treatment may further explain respondents’ preference 
differences. Better still, as preferences were hard to predict based on socio-economic or 
treatment characteristics, a self-selection procedure after treatment may well be the most 
effective option to classify patients for different follow-up strategies. Future research could 
evaluate such individualized follow-up in terms of satisfaction and its economic impact. 
It is expected that individualized follow-up could decrease health care costs, because of 
preferences for less specialized follow-up (e.g. a follow-up visit to a nurse is likely to cost 
less than a visit to the medical specialist), telephone contact, and less frequent follow-
up. However, individualized follow-up could also have a potential negative effect on costs 
because of loss of economies of scale and possibly increased use of health care services 
outside the hospital.
Limitations
Some limitations of DCEs in their application to this study must be mentioned. First, an 
important consideration in designing a DCE is the selection of attributes and levels. These 
were based on a literature review, local policy initiatives and expert opinions. Focus groups 
and other qualitative research methods could be part of future research to investigate 
whether important attributes were missing. 
Second, though a response rate of 59% is generally high, the validity of the fi ndings may 
have been affected by respondent selection bias, and it is unclear how this would affect 
preference estimates for follow-up strategies. However, sample characteristics were 
promising in the sense that respondents with different treatment modalities, treating 
hospitals, age, and educational level were well represented in the sample and matched 
those of the study population (Ernst et al., 2004). 
Third, a key element in the use of random parameter logit modeling is the assumption 
regarding the distribution of each of the random parameters. In our main analysis all 
attributes and the constant term were assigned as normally distributed random parameters 
to allow for a high fl exibility in possible heterogeneity. To ensure that our results were robust 
for distributions, we performed a secondary analysis, in which the attribute levels general 
practitioner, telephone contact, and frequency, were assigned a lognormal distribution 
(based on the observed relatively limited heterogeneity in preferences in these attributes, 
see table 3). This led to highly similar effects and a marginal improvement in model fi t 
(adjusted R-square of 0.372), but restricted respondents’ preferences to be either all 
positive or all negative for a given attribute level. Since an important aim of our study was 
to explore preference heterogeneity, allowing respondents to have either a negative or 
positive preference for an attribute level, the analysis results with normal distributions for 
the random parameters were used for the purpose of this paper. 
Fourth, respondents had to make a so-called forced choice, and were not offered an ‘opt-
out’ or ‘status-quo’ alternative in the experiment. It is argued that the exclusion of an opt-
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out or status-quo option is a violation of the underlying welfare measures of the economic 
experiment, since it makes it impossible to estimate the value of doing nothing, which 
may be real market behavior (Bateman et al., 2002). However, we felt that the inclusion 
of such an option had more disadvantages than advantages. A potential problem of 
an opt-out alternative is that if the respondent feels that the choice task is cognitively 
demanding, it will be tempting to simplify it by choosing the opt-out or status-quo option, 
even though this would not provide the highest utility. Moreover, even though in clinical 
practice women could choose not to have follow-up, there is no evidence in the literature 
that this is common in clinical practice. Adding a status-quo alternative would have been 
a possibility, but also raised two concerns. First of all we were cautious for the ‘status-quo 
bias’, the tendency to choose what respondents know best (Salkeld et al., 2000), since 
respondents were already experienced with breast cancer follow-up. Second, the status-
quo alternative differed among respondents, causing econometric and interpretation 
diffi culties. 
Finally, levels of anxiety or psychological distress of participants were not measured in 
this study, while it could be speculated that anxiety and psychological distress infl uence 
patient preferences and adherence to a follow-up strategy. Future research should 
incorporate such individual-level factors, and when appropriate, they might be taken 
into account in the decision-making process for a follow-up strategy. This is in line with 
recommendations from governmental and professional organizations that cancer patients 
be screened routinely for the presence of heightened psychological distress (NCCN, 1999; 
NICE, 2004). 
CONCLUSION
On balance, DCEs have great potential for medical decision making by offering a valid and 
reliable approach to provide estimates of the most valuable characteristics of follow-up 
to patients. We have investigated how changes in breast cancer follow-up affect patients’ 
preferences or utility. The results of this study contribute to the literature fi ndings that 
overall patient satisfaction would not differ signifi cantly if patients have follow-up by 
medical specialist and breast care nurse alternating compared to follow-up by a medical 
specialist only. Furthermore, we found heterogeneity in preferences for most attributes, 
indicating that one strategy does not fi t all. Since preferences are diffi cult to predict, the 
introduction of individualized follow-up based on self-selection seems to be a promising 
method to maximize benefi ts in terms of patient satisfaction. Subsequently, it would be 
interesting to investigate the economic impact of such an individualized follow-up and 
whether patients who choose their own follow-up are indeed more satisfi ed than patients 
assigned to a standard follow-up strategy. 
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Appendix 1. 
An RPL model takes account of preference heterogeneity by placing a distribution around 
some, or all, parameters. Furthermore, it allows one to capture the fact that multiple 
observations are obtained from a single respondent, which is most often the case in a 
DCE survey where each respondent typically evaluates multiple choice sets. In the RPL 
model, the dependent variable was whether or not a scenario (A or B) was selected by 
the patient in a given choice set, while the independent variables were the attributes. The 
attribute “frequency” was coded in terms of a linear and quadratic effect (i.e., frequency²) 
to investigate whether the incremental utility of a greater number of contacts decreased 
when frequency increased. All attributes and the constant term were initially assigned 
as normally distributed random parameters. A parameter with an insignifi cant standard 
deviation for its distribution, was re-specifi ed as a nonrandom parameter, and the model 
was re-estimated (Hensher et al., 2005). The RPL model was estimated for the total 
sample, using 500 Halton draws.
The function to be estimated was of the following form:
Uijt = 0 + 0i + (1+ 1i )*Educational group programj + (2+ 2i)*Frequencyj + (2+ 
3i)*(Frequencyj)² + (4+ 4i)*Waiting timej + (5+ 5i)*Telephone contactj + (6+ 6i)*Breast 
care nursej + (7+ 7i)*General practitionerj + (8+ 8i)*MS/BCNj + εijt
where;
Uijt is individual i’s utility (i.e., satisfaction) associated with a specifi c follow-up scenario j 
in choice observation t.
0 represents the constant term and shows the general preference for scenario A over B 
when all attributes and levels are the same. 
1–8 are the parameter estimates of the model that indicate the importance of each 
attribute as it occurs in scenario j. The sign of a parameter estimate refl ects whether the 
attribute has a positive or negative effect on utility. “EGP” is a dummy variable for EGP 
being available or not, “telephone contact” is a dummy variable for telephone vs. face-to-
face contact, and “BCN” (breast care nurse), “GP”, and “MS/BCN” (alternating between 
medical specialist and breast care nurse) are dummy variables refl ecting the different 
types of follow-up contact persons, with “MS” (medical specialist) as a base level. The 
base levels refl ect current practice levels in the Netherlands.
The different is correspond to the individual specifi c error terms for every parameter 
which are constant across all observations for the individual and are assumed to be 
independently normal distributed, and ijt is an error term which captures any remaining 
unobserved error and is assumed to be IID gumbel distributed among observations 
(Hensher et al., 2005). 
To test moderating effects of age, education, treatment modality and hormonal therapy 
we extended the model with the product variables of the corresponding individual 
characteristics and the variables manipulated in the DCE.
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General discussion
“New guidelines 
for breast 
cancer follow-
up are strongly 
encouraged”
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INTRODUCTION
The value of follow-up of breast cancer patients remains controversial despite almost two 
decades of research. Studies have shown that different models of follow-up can be equally 
effective, measured by a variety of outcomes. Ultimately, however, these studies have not 
been found to be suffi ciently convincing and researchers continue the search for the best 
model. This thesis was based on fi ve years of research concerning breast cancer follow-
up and focused on the fi rst year after completion of primary treatment. Two interventions 
were developed and tested in a randomized controlled setting. The fi rst intervention, 
nurse-led telephone follow-up, aimed to replace hospital follow-up visits without a loss 
of health-quality of life (HRQoL) or increase in anxiety. The second intervention, a short 
educational group program (EGP), aimed to provide information and improve HRQoL. An 
extensive economic evaluation was performed alongside the randomized controlled trial 
(RCT) to provide detailed insight into costs and consequences of four follow-up strategies 
and determine the most cost-effective strategy. Furthermore, patients’ satisfaction with 
nurse-led telephone follow-up was examined, and the strength of preferences for several 
characteristics of follow-up was explored using discrete choice experimentation. 
In this fi nal chapter, the main research fi ndings are briefl y summarized. Subsequently, 
both strengths and methodological concerns regarding the research are discussed, 
followed by recommendations and suggestions for future research.
SUMMARY OF MAIN FINDINGS
The research performed showed that most hospital clinic visits in the fi rst year after 
treatment may well be replaced by nurse-led telephone follow-up without loss of HRQoL 
or increase in feelings of anxiety. Additionally, replacing hospital follow-up with nurse-
led telephone follow-up did not affect role and emotional functioning, and feelings of 
control. Furthermore, patients were equally satisfi ed when follow-up was performed by 
telephone or in hospital. Hence, nurse-led telephone follow-up seems an appropriate way 
to reduce clinic visits and represents an accepted alternative strategy. An educational 
group program in addition to follow-up may be appropriate to address information needs, 
but it did not unequivocally affect positive HRQoL outcomes. Importantly, results of the 
economic evaluation showed that nurse-led telephone follow-up plus EGP was cost-
effective compared to three alternative follow-up strategies. Nevertheless, it was found 
that preferences for follow-up were very heterogeneous, suggesting that individualized 
follow-up may increase satisfaction.
STRENGTHS OF THE RESEARCH
The MaCare trial was an RCT designed as a pragmatic trial. Pragmatic trials measure the 
benefi cial effects of an intervention in a setting closely refl ecting real practice, as opposed 
to an ideal research situation (Roland & Torgerson, 1998). These trials are specifi cally 
General discussion
       109
interesting to provide evidence for health care providers and policy makers for policy 
decisions. Interventions are compared to usual care and selection criteria are kept to 
a minimum to refl ect variations between patients that occur in real practice. Hence, the 
MaCare trial included a broad range of patients, from seven hospitals in the Netherlands, 
with all stages of non-metastatic breast cancer (stage I, II or III), and treated with either 
surgery alone, or in combination with chemotherapy and/or radiotherapy. The fi rst study 
arm, hospital follow-up, represented care as usual in the participating hospitals.
The 2x2 factorial design of the MaCare trial allowed for effi cient testing of two interventions, 
reducing the impact of the trial on resources, doctors, and patients. Furthermore, a 
high quality economic evaluation was performed alongside the RCT. The economic 
evaluation was performed according to published international guidelines for trial-based 
economic evaluations (Earnshaw & Lewis, 2008), and closely refl ected the resource use 
that would be observed in practice. Four alternative strategies were compared, which 
is relatively uncommon and overcomes the often proposed disadvantage of trial-based 
economic evaluations that they represent only a limited form of analysis by comparing 
few alternatives (Sculpher et al., 2006). Importantly, by using micro costing to value 
resources and presenting tables with resource use and cost prices, detailed information 
was provided on follow-up costs, enabling case-by-case calculations for the purpose of 
generalizability (Sculpher et al., 2004). 
At the individual clinical decision level, women’s preferences for different characteristics of 
follow-up, including most alternative strategies that have been proposed in the literature, 
were explored using a discrete choice experiment (DCE). This survey methodology 
is grounded in economic theory (Lancaster, 1966; McFadden, 1974) and enables the 
researcher to measure heterogeneity in preferences, as well as the strength of preferences 
for different characteristics of follow-up and the trade-offs made between them. DCEs are 
found to be a valid and reliable approach to elicit preferences in a health care context 
(Bryan et al., 2000) and are recognized as a useful tool for medical decision making 
(Lancsar & Louviere, 2008; Ryan & Gerard, 2003). 
METHODOLOGICAL CONSIDERATIONS
Some methodological considerations regarding the studies performed in this thesis must 
be addressed.
First, in the CEA performed alongside the RCT, the generally recommended EQ-5D was 
used for the measurement and calculation of health state values (utilities) (Earnshaw & 
Lewis, 2008). However, concern has been raised whether the generic EQ-5D is sensitive 
enough to pick up (clinical) changes in certain patient groups (Eurich et al., 2006; Krahn 
et al., 2007; van de Willige et al., 2005). Results of the study into the responsiveness of 
the EQ-5D (chapter 5) showed that the EQ-5D was able to capture both improvements and 
deteriorations in HRQoL of breast cancer patients after treatment. However, according 
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to Cohen’s benchmarks for effect sizes (Cohen, 1988), the EQ-5D was only responsive 
to moderate and large changes in health, but not to small changes. Nevertheless, cut-
off points for effect sizes or discriminative ability are less relevant in the context of 
economic evaluations. A small difference in the EQ-5D might still be meaningful when 
additional costs for such a change in HRQoL are very low. Therefore, it was concluded that 
the EQ-5D was an appropriate measure for the economic evaluation. A limitation of this 
responsiveness study was that responsiveness was investigated using a single anchor, 
while ideally multiple anchors should be used to investigate the responsiveness of an 
instrument (Guyatt et al., 2002). For example, clinical expert opinion on a patient’s health 
status or a second measure of quality of life such as the SF-6D (Brazier et al., 2002) or 
SF-36 (Ware & Sherbourne, 1992) could have been collected in order to better assess 
responsiveness.
Second, of eligible patients, 64% declined participation in the RCT. Reasons for refusal 
varied; some patients preferred face-to-face contact to telephone contact (26.9%), others 
did not like the idea of participation in the educational group program (16.5%), 24.6% were 
too tired, disliked trials in general or felt uncomfortable completing questionnaires, and 
for 32% the reason for refusal was unknown. The fact that patients were informed about 
the usual care (hospital follow-up) before participation may have negatively infl uenced the 
participation rate, since patients generally have a preference for what they know best, the 
so-called ‘status quo bias’ (Salkeld et al., 2000). The relatively low participation rate of 
the RCT may have an impact on the generalizabilty of our results. It specifi cally infl uenced 
our patient satisfaction study, since patients who chose to participate in the RCT may 
have had either no strong preference for a follow-up strategy, or positive expectations of 
the interventions. Thus, patients may have been somewhat uncritical of the care provided, 
or prior expectations about follow-up may have infl uenced expressed satisfaction (Linder-
Pelz, 1982; Williams, 1994). In other words, patients may have expressed satisfaction no 
matter what care was provided. 
It is unclear whether and if so, to what extent, the sample selection has infl uenced our 
study results. Nevertheless, women who participated in the trial did not differ from non-
participants with respect to education, marital status, HRQoL or other psychological 
outcome measures. Furthermore, the pragmatic nature of the trial led to the inclusion 
of a broad range of patients regarding age, treatment and location of treatment, and as 
a result our study population was indeed representative of breast cancer patients in the 
Netherlands (Kiemeney et al., 2008). 
Finally, to gain insight into patient preferences for non-health aspects of follow-up, a 
patient preference study was performed in the form of a discrete choice experiment (DCE) 
(Hensher et al., 2005). When interpreting results of a DCE, it is important to realize that 
people tend to prefer what they know best or have experienced (Salkeld et al., 2000). 
As a consequence, the choice of the study population can therefore have a signifi cant 
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impact on the results. The DCE was performed among women who had been treated for 
breast cancer and who were between six months and two years in follow-up. An advantage 
of these respondents was that they provided relatively informed preferences for most 
attributes. However, the majority of the sample did not have experience with the EGP, 
telephone contact and follow-up by the general practitioner (GP). Hence, preferences for 
these characteristics of follow-up relied on the information provided during the experiment. 
While all attributes and their levels were extensively described in the survey, it is unclear 
whether this information was carefully read and understood. Due to the inexperience with 
the EGP, telephone contact and follow-up by the GP, preferences for these attribute levels 
may have been underestimated. Additionally, the importance of follow-up by the medical 
specialist and face-to-face contact might have been overestimated, since this form of 
follow-up was experienced by most patients. An analysis on a small subsample of patients 
with experience with nurse-led telephone follow-up and EGP indeed showed that they 
were more satisfi ed with these forms of follow-up compared to inexperienced patients. 
RECOMMENDATIONS FOR CLINICAL PRACTICE AND POLICY
Just recently, in 2009, the new NICE (National Institute for Clinical Excellence) guidance 
for early and locally advanced breast cancer was developed and was a long awaited 
replacement of the 2002 guidance. Importantly, a key recommendation of the new 
guidelines is that patients should have a choice in their method of follow-up (Harnett 
et al., 2009). Furthermore, in 2007, the Health Council of the Netherlands published 
a report on cancer follow-up, with its main recommendation being the implementation 
of an individualized ‘aftercare plan’ for each patient within fi ve years after publication 
(Gezondheidsraad, 2007). This aftercare plan must contain written information about the 
physical and psychological impact of the disease and its treatment, about the desirability 
and form of follow-up, and about other ongoing points for attention. 
However, incorporating individual preferences in treatment decisions may create confl ict. 
The treatment recommended to an individual patient to meet preferences may differ 
substantially from the most cost-effective treatment (Brazier et al., 2009). This confl ict is 
likely to arise in the case of breast cancer follow-up. While the CEA showed that nurse-led 
telephone follow-up plus EGP would be the most cost-effective strategy, the DCE showed 
that hospital follow-up was preferred to telephone follow-up and that preferences for 
health care provider and the EGP were very heterogeneous. Moreover, new guidelines for 
follow-up should be as much evidence based as possible, and the effectiveness and cost-
effectiveness of individualized follow-up remain to be investigated. Individualized follow-
up may, somewhat unexpectedly, not be cost-effective compared to usual care if it has a 
negative effect on costs because of loss of economies of scale or increased use of health 
care services outside the hospital. It also needs to be explored whether the implementation 
of a different strategy for each patient is feasible in clinical practice. Therefore, instead of 
implementing individualized follow-up it is suggested to fi rst investigate the feasibility and 
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cost-effectiveness of individualized follow-up.
At this time, based on the results reported in this thesis, it is recommended to reduce the 
frequent follow-up visits in the fi rst 12 months after treatment to one follow-up visit to the 
medical specialist, including physical examination and a mammography. Additionally, the 
three-monthly hospital visits can be replaced by nurse-led telephone follow-up and an 
EGP. Furthermore, it is recommended that the breast care nurse takes a central role in the 
follow-up. A well-designed nurse-led follow-up can increase continuity and devote more 
time to patient education. Moreover, it allows for the reallocation of medical specialist 
time from follow-up to diagnosis and treatment and utilizes the skills of specially trained 
nurses in an optimal way. For patients who are very anxious after completion of treatment 
it is recommended to provide hospital follow-up and the EGP, instead of telephone follow-
up, since a reduced follow-up strategy for these patients had contrary effects on their 
resource use.
New guidelines for breast cancer follow-up are strongly encouraged, since they can 
promote effi cient and discourage ineffi cient follow-up. However, guidelines do not 
automatically translate into clinical practice, especially when the new guideline requires 
better collaboration among disciplines, changes in patients’ behavior or changes in the 
organization of care (Grol & Grimshaw, 2003; Grol et al., 2007). Since patient preferences 
seem to be in favor of hospital follow-up, it is extremely important to readily invest in 
the implementation and dissemination of the new guideline. Insight into barriers and 
facilitators can help to design the most effective implementation strategy (Grol, 1997). 
In our opinion, successful implementation of this new guideline requires primarily a 
paradigm shift among doctors and patients. As long as there is a false idea among medical 
specialists that patients need constant reassurance and a long-standing belief that 
considering costs is unseemly and unethical, the implementation of a new guideline will 
likely be unsuccessful. At the same time, preferences for hospital follow-up may be a result 
of false expectations about the purpose and effectiveness of follow-up among patients (de 
Bock et al., 2004b). Hence, information about risks of recurrence, early detection, survival 
estimates and aims of follow-up, are crucial for the success of a new (reduced) follow-up 
strategy. Our EGP may be appropriate to address patients’ information needs and educate 
the patient about the purpose and effectiveness of follow-up. Also, an individual aftercare 
plan, as proposed by the Health Council, describing (among other things) the purpose of 
follow-up and when and where the follow-up and EGP take place, can enhance successful 
implementation and adherence to the new strategy. Furthermore, educational materials 
for health care professionals involved in follow-up as well as outreach visits may be used 
for the implementation of the new guideline (Grol & Grimshaw, 2003).
As a fi nal remark it must be noted that new developments regarding diagnostics and 
therapeutics may lead to changes in the follow-up. The follow-up should be as much 
evidence based as possible. Therefore, every fi ve years, the follow-up model should be 
reconsidered, taking into account new scientifi c insights, and adjust guidelines accordingly.
General discussion
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AREAS FOR FUTURE RESEARCH
Since our pragmatic trial has shown cost-effectiveness of nurse-led telephone follow-up 
with EGP, this is likely to be cost-effective in real-life, since the circumstances approximate 
real-life settings. However, guidelines are not always adhered to by both doctors and 
patients, and the cost-effectiveness of actual implementation of nurse-led telephone 
follow-up plus EGP may be less than estimated with the pragmatic trial if implementation 
is very costly and adherence poor (Mason et al., 2001). Ideally, future research should 
examine possible barriers and facilitators for implementation before the development of 
strategies to implement the new strategy (Grol, 1997). Subsequently, several scenarios 
with varying costs of implementation and doctor and patient adherence could be explored 
with regard to the cost-effectiveness of implementation (Mason et al., 2001).
Results of our preference study suggested that individualized follow-up could enhance 
patient satisfaction. Future research could investigate whether individualized follow-up is 
indeed feasible in clinical practice. In order to respond to individual preferences, the medical 
specialist will need to move from a generally paternalistic approach towards a shared 
model for the choice of follow-up (Coulter, 1999). A decision-support tool enhances this 
shared-decision making process, and can possibly improve satisfaction and compliance 
to the chosen follow-up strategy. This decision-support tool should incorporate a range of 
characteristics of the patient, including tumor characteristics, treatments received, and 
preferences for follow-up. We are currently exploring whether such a decision-support 
tool can be developed for breast cancer follow-up and implemented in clinical practice. 
Subsequently, it is important to study whether patients who were actively involved in the 
choice of follow-up strategy, indeed show improved outcomes in terms of satisfaction and 
quality of life, and how individualized follow-up impacts on cost-effectiveness. 
Finally, since this research has shown that nurse-led telephone follow-up is good value for 
money, it seems promising to study whether this follow-up strategy would be transferable 
to other cancer patient groups.
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Summary
There is much debate regarding the value 
of routine follow-up of women with breast 
cancer. Current follow-up patterns depend 
heavily on expensive and scarce specialized 
knowledge for routine history taking and for 
physical examinations, but do not always 
provide optimal care for patients. Hence, 
there is a need to evaluate costs in relation to 
benefi ts of current and alternative follow-up 
strategies. This thesis is based on fi ve years of 
research concerning breast cancer follow-up, 
focused on the fi rst year after completion of 
treatment. 
CHAPTER 1 provides background information on the follow-up of women with breast 
cancer, economic evaluations in health care and discrete choice experimentation. The 
chapter concludes with the specifi c objectives and outline of the thesis.
 
CHAPTER 2 provides an overview on current literature on breast cancer follow-up; 
guidelines for follow-up, effectiveness of follow-up, the needs of patients and proposed 
alternative strategies. The optimum frequency or duration of follow-up visits has not yet 
been properly established and there remains wide discrepancy in guideline statements 
of the frequency of visits. Several studies show that neither the frequency nor intensity of 
follow-up improves the chances of cure. Furthermore, instead of providing psychosocial 
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support, outpatient clinic visits may induce anxiety because of the potential of detecting 
tumor relapse. Hence, not only do the current frequent follow-up strategies seem to miss 
their most important goals, they also depend heavily on expensive and scarce specialized 
knowledge for routine history taking and physical examinations. As a result, alternative 
follow-up strategies have been proposed, such as follow-up by the general practitioner, 
and nurse-led follow-up or telephone follow-up. Although studies demonstrate that these 
alternative follow-up strategies can be equally effective as traditional hospital follow-
up, as measured by a variety of outcomes, these strategies are not yet widely applied in 
clinical practice. Results may not have been suffi ciently convincing, or perhaps medical 
specialists believe that patients need frequent reassurance. Moreover, patients may have 
false expectations that frequent follow-up will result in better overall survival. Since brief 
interventions based on self-education and information are able to improve quality of life, 
we hypothesize that these interventions may also lead to a better acceptance of reduced 
follow-up by both patients and professionals. For this reason, a randomized controlled trial 
(RCT) was developed to investigate the effectiveness and cost-effectiveness of a reduced 
follow-up strategy (i.e. nurse-led telephone follow-up), and of a short educational group 
program (EGP) in addition to the follow-up. 
CHAPTER 3 provides a detailed description of the design and execution of the RCT, the so-
called MaCare trial. Participants (n=320) were randomly assigned to one of four follow-up 
strategies (study arms) during the fi rst 18 months after treatment; i.e. 1) hospital follow-
up every three months, including mammography at 12 months; 2) nurse-led telephone 
follow-up every three months, plus hospital visit and mammography at 12 months; 3) arm 
1 plus educational group program (EGP); 4) arm 2 plus EGP. 
For patients randomized to hospital follow-up (arms 1 and 3), follow-up visits consisted 
of physical examination and medical history taking by a medical specialist or breast care 
nurse (BCN). Nurse-led telephone follow-up (arms 2 and 4) was done by open discussion 
and a semi-structured questionnaire including screening for physical -especially loco 
regional- and psychosocial symptoms, treatment side effects, compliance with hormonal 
therapy plus an open discussion of these issues. In study arms 3 and 4, patients and their 
partners were invited to participate in the EGP. The EGP consisted of two group-sessions, 
led by a breast care nurse and health psychologist, in which physical and psychosocial 
sequelae of diagnosis and treatment were discussed. The primary endpoint of the trial 
was health-related quality of life (HRQoL) at 12 months after treatment, measured by 
the EORTC QLQ-C30. Secondary outcomes were perceived feelings of control, anxiety, 
patient satisfaction and costs. An economic evaluation was performed from a societal 
perspective, comparing costs and quality-adjusted life years (QALYs) of the four strategies. 
All data was collected at baseline and 3, 6, 12 and 18 months after treatment.
In CHAPTER 4 the results of the RCT are reported regarding the effectiveness of both 
nurse-led telephone follow-up and the EGP in addition to follow-up. Results showed that 
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most hospital clinic visits in the fi rst year after treatment could be replaced by nurse-led 
telephone follow-up without loss of HRQoL or increase in feelings of anxiety. Additionally, 
patients with nurse-led telephone follow-up showed the same levels of role and emotional 
functioning, and feelings of control as patients with hospital follow-up by 12 months. 
Adding the EGP to follow-up may be appropriate to address information needs, but it did not 
lead to a signifi cant improvement in HRQoL, emotional functioning or feelings of control as 
compared to follow-up without an EGP. It was concluded that nurse-led telephone follow-
up may be appropriate way to reduce clinic visits and represents an accepted alternative 
strategy, while an EGP does not unequivocally affect positive HRQoL outcomes.
The EQ-5D is a generic HRQoL measure that is recommended for the use in economic 
evaluations of health interventions. Concerns have been raised about its ability to pick up 
meaningful changes in health in cancer populations. In CHAPTER 5 the results of a study 
investigating the responsiveness of the EQ-5D in breast cancer patients in their fi rst year 
after treatment are reported. The validated HRQoL measure EORTC QLQ-C30 was used as 
a reference instrument to determine meaningful changes in health and identify subgroups 
of patients. Responsiveness was evaluated by calculating standardized response means 
(SRMs) and performing analysis of variance procedures. The two HRQoL measures were 
completed two weeks and one year after fi nalizing curative treatment for breast cancer 
(n=192). SRMs of the EQ-5D utility score were close to zero in the subgroup reporting no 
change and increased and decreased adequately in the subgroups reporting small and 
moderate changes. Additional analysis of variance procedures showed that the EQ-5D was 
able to differentiate between subgroups of patients with no change and moderate-large 
deterioration or improvement in health. Importantly, the EQ-5D appeared an appropriate 
measure for the purpose of economic evaluations of health intervention in breast cancer 
patients after treatment.
 
CHAPTER 6 reports on the economic evaluation, performed alongside the RCT, to 
determine the most cost-effective follow-up strategy. The economic evaluation (n=299) 
compared one-year costs and effects of the four follow-up strategies as described in 
chapter 3. Costs were measured using patient level data from cost diaries and hospital 
registrations. Quality-adjusted life years (QALYs) were measured using the EQ-5D. 
Outcomes were expressed in incremental cost-effectiveness ratios and cost-effectiveness 
acceptability curves. Results showed that hospital follow-up plus EGP yielded most QALYs 
(0.776), but also incurred the highest mean annual costs (€4914). The incremental cost-
effectiveness ratio (ICER) of hospital follow-up plus EGP versus the next best alternative 
telephone follow-up plus EGP (0.772 QALYs and €3971) amounted to €235.750/QALY. 
As hospital and telephone follow-up without EGP both had higher costs and less QALYs 
than telephone follow-up plus EGP, the former were judged inferior. Assuming a threshold 
value of €40.000 per QALY, telephone follow-up plus EGP was the preferred strategy. The 
probability of this strategy being most cost-effective ranged from 49% to 62% for different 
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QALY threshold values. Secondary and sensitivity analyses showed that these results 
were robust. Thus, nurse-led telephone follow-up plus EGP instead of traditional, routine 
hospital clinic visits, during the fi rst year after breast cancer treatment, may lead to a 
substantial cost reduction. 
Although the economic evaluation showed that telephone follow-up plus EGP offers good 
value for money, a policy maker may wish to incorporate other factors such as patient 
satisfaction and preferences. CHAPTER 7 concerns patients’ satisfaction with nurse-led 
telephone follow-up compared to traditional hospital follow-up for the fi rst 12 months after 
treatment. Data on patient satisfaction were collected at baseline, and 3, 6 and 12 months 
after treatment, using the Dutch version of Ware’s Patient Satisfaction Questionnaire III 
(PSQ III). In addition to general satisfaction, the PSQ III reports on satisfaction scores 
for technical competence, interpersonal aspects and access of care. It was found that 
there were no meaningful differences in satisfaction scores between patients who were 
randomized to nurse-led telephone follow-up and those randomized to hospital follow-up. 
In CHAPTER 8 patient preferences for characteristics of breast cancer follow-up are 
explored. A discrete choice experiment survey with 16 choice tasks was fi lled out by 
331 breast cancer patients who were on average 14 months after end of treatment. 
Each choice task consisted of two hypothetical follow-up scenarios for the fi rst year 
after treatment, described by levels of the following characteristics; attendance at an 
educational group program (EGP), frequency of visits, waiting time, contact mode and 
type of health care provider. Results showed that the health care provider and contact 
mode were the most important characteristics of follow-up to respondents. The medical 
specialist was the most preferred to perform the follow-up, but a combination of the 
medical specialist and breast care nurse alternating was also acceptable. Face-to-face 
contact was strongly preferred to telephone contact. Heterogeneity in preference between 
respondents was strong, especially for the health care provider (28% would positively 
value a change from medical specialist to nurse-led follow-up) and attendance at the EGP 
(47% of respondents preferred participation to no participation). Follow-up by a medical 
specialist was valued more positively by older (>60 years) than younger respondents. 
Furthermore, older respondents and those with a low level of education were less likely to 
choose a scenario that included attending the EGP. Importantly, respondents with previous 
experience with the EGP and nurse-led follow-up had a signifi cantly stronger preference 
for these characteristics. Treatment modality did not infl uence preferences. Heterogeneity 
in preferences for most attributes suggested that one follow-up strategy may not fi t all. 
CHAPTER 9 discusses the main research fi ndings of this thesis, the strength of the studies 
performed, as well as some methodological considerations regarding the research. The 
RCT was performed as a pragmatic trial and the economic evaluation closely refl ected 
effectiveness and resource use that would be observed in real practice. Since QALYs fail to 
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incorporate non-health related issues in the decision making process, such as satisfaction 
with and preferences for process outcomes of follow-up (e.g. accessibility, provision 
of information and continuity), these aspects were measured separately. However, 
preferences and satisfaction were diffi cult concepts to measure and concerns regarding 
the validity of the fi ndings and the infl uence of chosen study samples were discussed. 
Moreover, merging evidence from our economic evaluation and patients’ perspectives 
created some confl ict, since follow-up based on individual preferences was likely to differ 
from the follow-up recommended in terms of cost-effectiveness. It was recommended to 
change current breast cancer guidelines from hospital follow-up to nurse-led telephone 
follow-up plus EGP. Future research may investigate the feasibility and cost-effectiveness 
of more individualized follow-up.
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Er bestaat twijfel of het frequent controleren 
van patiënten na de behandeling van 
borstkanker effi ciënt is. Het huidige follow-
up beleid leidt tot een grote belasting van de 
medisch specialisten en daarmee tot hoge 
kosten, en bovendien is de aangeboden zorg 
niet optimaal. Er bestaat een behoefte om 
de kosten en de effectiviteit van de huidige 
follow-up, evenals van alternatieve modellen 
van follow-up, te onderzoeken. Dit proefschrift 
is gebaseerd op vijf jaar onderzoek naar de 
follow-up na borstkanker met de focus op het 
eerste jaar na de behandeling.
HOOFDSTUK 1 geeft achtergrond informatie over de huidige follow-up na borstkanker, 
economische evaluaties in de zorg en keuze-experimenten. Het hoofdstuk wordt afgesloten 
met de specifi eke doelstellingen en inhoud van het proefschrift. 
 
In HOOFDSTUK 2 wordt een overzicht van de huidige literatuur over borstkanker follow-
up gegeven; richtlijnen, effectiviteit, het patiëntenperspectief en alternatieve follow-up 
modellen. De optimale frequentie van follow-up controles, evenals hoe lang de follow-
up zou moeten duren, staat niet vast en internationale richtlijnen komen niet overeen. 
Verschillende studies hebben laten zien dat jaarlijkse follow-up met mammografi e even 
effectief is wat betreft de overleving als meer intensieve follow-up. Daarnaast is gebleken 
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dat het bieden van psychosociale ondersteuning nog onvoldoende is in de huidige follow-up, 
en ook dat frequente controles angstgevoelens opwekken rondom het kunnen terugkeren 
van de kanker. Het huidige follow-up beleid voldoet enerzijds niet aan de voorafgestelde 
doelen, en anderzijds leidt het tot een grote belasting van de medisch specialisten en 
daarmee tot hoge kosten. Als gevolg hiervan zijn alternatieve modellen van follow-up 
in diverse studies onderzocht, zoals follow-up door de huisarts, de verpleegkundige en 
telefonische follow-up. Hoewel deze alternatieve vormen minstens zo effectief en veilig 
waren als traditionele follow-up in het ziekenhuis, worden deze follow-up strategieën nog 
niet standaard toegepast in de klinische praktijk. Dit zou kunnen komen door fi nanciële 
overwegingen, maar een wellicht logischer verklaring is dat veel medisch specialisten, 
mogelijk onterecht, denken dat patiënten continue bevestiging en geruststelling nodig 
hebben. Daarnaast heeft een groot deel van de patiënten irreële verwachtingen van 
follow-up, namelijk dat intensieve en frequente follow-up tot een betere overleving zouden 
leiden. Ook economische evaluaties om de kosteneffectiviteit van alternatieve follow-up 
strategieën te bepalen, worden nog te weinig meegenomen in nieuwe studies. Op grond 
van de literatuur is het de verwachting dat verbetering in de psychosociale ondersteuning 
en educatie van patiënten kan leiden tot een betere acceptatie door zowel patiënten als 
medisch specialisten van minder frequente follow-up. Daarom werd een gerandomiseerde 
studie gestart, gericht op de kosten en de effectiviteit (kwaliteit van leven) van een 
gereduceerde follow-up strategie (namelijk telefonische follow-up door de mammacare 
verpleegkundige) en een educatief groepsprogramma (EGP), voor curatief behandelde 
borstkankerpatiënten.
HOOFDSTUK 3 geeft een gedetailleerde beschrijving van de opzet en uitvoering van de 
gerandomiseerde studie. Deelnemers (n=320) werden door loting toegewezen aan een van 
vier follow-up strategieën (studie-armen) voor de eerste 18 maanden na de behandeling; 
1) standaard follow-up (bezoek ziekenhuis op 3, 6, 9, 12 en 18 maanden en een jaarlijkse 
mammografi e; 2) follow-up 1 x per jaar inclusief mammografi e, gecombineerd met 
telefonische follow-up door een mammacare verpleegkundige op dezelfde momenten als 
de standaard follow-up; 3) arm 1 met daarbij een groepsinterventie gericht op voorlichting 
(educatief groepsprogramma (EGP)); 4) arm 2 met EGP.
Voor patiënten in de ziekenhuis follow-up (arm 1 en 3) bestond de follow-up uit anamnese 
en lichamelijk onderzoek door een medisch specialist of mammacare verpleegkundige. De 
telefonische follow-up (arm 2 en 4) vond plaats in de vorm van een open gesprek waarin 
gescreend werd voor een aantal belangrijke symptomen van een recidief. Daarnaast 
informeerde de verpleegkundige naar het algemeen welbevinden van de patiënt, haar 
gezinsleven en werkhervatting. 
In arm 3 en 4 werden patiënten (en partners) uitgenodigd deel te nemen aan het 
EGP. Het EGP bestond uit twee sessies van ongeveer 2,5 uur en werd geleid door een 
gezondheidszorg psycholoog en mammacare verpleegkundige. Er werd informatie gegeven 
over mogelijke late bijwerkingen van de verschillende behandelingen en hormonale 
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therapie, symptomen van een eventueel recidief, evenals de mogelijke psychologische 
gevolgen van de diagnose en behandeling van borstkanker en hoe daar mee om te gaan. 
Het primaire eindpunt van de studie was gezondheidsgerelateerde kwaliteit van leven op 
12 maanden na behandeling, gemeten met de EORTC QLQ-C30 vragenlijst. Secundaire 
uitkomstmaten waren gevoelens van controle, angst, tevredenheid en kosten. Daarnaast 
werd een economische evaluatie vanuit een maatschappelijk perspectief uitgevoerd, 
waarin kosten en QALYs (voor kwaliteit gecorrigeerde levensjaren) van de vier follow-
up strategieën werden vergeleken. Alle gegevens werden verzameld op 3, 6, 12 en 18 
maanden na randomisatie.
In HOOFDSTUK 4 worden de resultaten van de gerandomiseerde studie beschreven 
wat betreft de effectiviteit van zowel de telefonische follow-up door de mammacare 
verpleegkundige als het EGP. De meeste ziekenhuis follow-up bezoeken in het eerste jaar 
na de behandeling konden vervangen worden door telefonische follow-up zonder een 
afname van kwaliteit van leven of een toename in angstgevoelens. Telefonische follow-
up had ook geen negatieve invloed op emotioneel functioneren of controle gevoelens. 
Het toevoegen van een EGP aan de follow-up leidde niet tot signifi cante verbetering in 
kwaliteit van leven of andere psychologische uitkomstmaten. Er werd geconcludeerd dat 
telefonische follow-up een effectieve en geaccepteerde follow-up strategie is, maar dat 
het EGP niet tot een betere kwaliteit van leven leidt.
De EQ-5D is een generieke gezondheidsgerelateerde kwaliteit van leven vragenlijst 
die gebruikt wordt in economische evaluaties van gezondheidsinterventies. Er is 
echter twijfel of de EQ-5D belangrijke verschillen in gezondheid kan identifi ceren. In 
HOOFDSTUK 5 worden de resultaten beschreven van een studie die de responsiviteit 
van de EQ-5D onderzocht in borstkankerpatiënten in het eerste jaar na behandeling. 
De subschaal ‘algemene gezondheid’ van de EORTC QLQ-C30 werd gebruikt als een 
referentiemaat om veranderingen in gezondheidstoestand te bepalen en subgroepen 
te identifi ceren. Responsiviteit werd vervolgens geëvalueerd door het berekenen van de 
zgn. standardized response means (SRMs) en variantie analyse. De EQ-5D en EORTC 
QLQ-C30 waren ingevuld op 2 weken en 1 jaar na einde van de behandeling (n=192). 
SRMs van de EQ-5D utiliteits scores waren nagenoeg gelijk aan 0 in de subgroep die 
geen gezondheidsverandering liet zien volgens de referentiemaat, en de SRMs namen 
gelijkmatig toe en af in de subgroepen die respectievelijk een verbetering of verslechtering 
in gezondheidstoestand lieten zien. Variantie analyse liet zien dat de EQ-5D in staat was 
om te differentiëren tussen subgroepen zonder gezondheidsverandering en subgroepen 
met een gemiddelde tot grote gezondheidsverandering. De EQ-5D lijkt een bruikbaar 
instrument voor economische evaluaties van gezondheidsinterventies voor patiënten na 
de behandeling van borstkanker.
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HOOFDSTUK 6 beschrijft de economische evaluatie die uitgevoerd was binnen de 
gerandomiseerde studie om de meest kosteneffectieve follow-up strategie te bepalen. 
De economische evaluatie (n=299) vergeleek de kosten en effecten van de vier follow-
up strategieën voor het eerste jaar na de behandeling, zoals beschreven in hoofdstuk 
3. Zorggebruik was gemeten met behulp van kostendagboeken ingevuld door patiënten 
en de registratiesystemen van de ziekenhuizen. QALYs waren gemeten met de EQ-5D. 
Uitkomsten werden uitgedrukt in incrementele kosten-effectiviteitsratio’s (ICER) en kosten-
effectiviteit-acceptatie grafi eken. Resultaten lieten zien dat ziekenhuis follow-up met het 
EGP resulteerde in de meeste QALYs (0.776), maar ook de hoogste kosten met zich mee 
bracht (€4914). De ICER van ziekenhuis follow-up met EGP versus het volgend beste 
alternatief (telefonische follow-up met EGP) (0.772 QALYs en €3971) was €235.750/
QALY. Ziekenhuis en telefonische follow-up zonder het EGP hadden beide hogere 
kosten en minder QALYs dan telefonische follow-up met EGP en werden als inferieure 
strategieën beschouwd. Uitgaande van een grenswaarde van €40.000 voor een QALY, 
werd ziekenhuis follow-up met EGP niet kosteneffectief beschouwd en was telefonische 
follow-up met EGP de geprefereerde strategie. De kans dat deze strategie het meest 
kosteneffectief was varieerde tussen de 49% en 62% voor verschillende grenswaarden 
van een QALY. Secundaire en gevoeligheidsanalyses lieten zien dat de resultaten robuust 
waren. Telefonische follow-up met EGP, in plaats van de traditionele ziekenhuis follow-up, 
kan tot signifi cante kostenbesparingen in Nederland leiden. 
Ondanks dat de economische evaluatie liet zien dat telefonische follow-up met EGP 
kosteneffectief was, kan het zijn dat beleidsmakers en/of verzekeringsmaatschappijen 
ook andere factoren zoals patiënten tevredenheid en voorkeuren, mee willen laten wegen 
in hun beleidsbeslissing. HOOFDSTUK 7 beschrijft de tevredenheid van patiënten met 
telefonische follow-up vergeleken met de tevredenheid van patiënten met ziekenhuis 
follow-up, zoals gemeten in de RCT beschreven in hoofdstuk 3. Tevredenheidsscores 
werden verzameld op 3, 6, 9 en 12 maanden na de behandeling met de Nederlandse 
versie van Ware’s Patient Tevredenheidsvragenlijst, de PSQ III. Naast algemene 
tevredenheid meet de PSQ III ook tevredenheid wat betreft technische competentie 
van zorgverleners, interpersoonlijke aspecten en toegang tot de zorg. Er werden geen 
betekenisvolle verschillen in patiënten tevredenheid gevonden tussen telefonische follow-
up en follow-up in het ziekenhuis.
In HOOFDSTUK 8 wordt een keuze-experiment naar voorkeuren van patiënten voor 
de follow-up beschreven. Het keuze-experiment bestond uit een vragenlijst met 16 
keuzesets en was ingevuld door 331 borstkanker patiënten. Elke keuzeset bestond uit 
twee hypothetische follow-up scenario’s voor het eerste jaar na de behandeling, waarin 
de volgende kenmerken van de follow-up beschreven stonden: deelname aan het EGP, 
frequentie van follow-up bezoeken, wachttijd, wijze van contact en het type zorgverlener. 
De resultaten lieten zien dat voor patiënten het type zorgverlener en wijze van contact 
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de belangrijkste kenmerken van follow-up waren. De medisch specialist was de meest 
geprefereerde zorgverlener voor de follow-up, maar een combinatie van (afwisselend) 
de medisch specialist en mammacare verpleegkundige was ook acceptabel. Er was een 
sterke voorkeur voor persoonlijk contact boven telefonisch contact. Preferenties waren 
duidelijk heterogeen, met name voor de zorgverlener (28% van participanten zou een 
verandering van medische specialist naar mammacare verpleegkundige als positief 
ervaren) en deelname aan het EGP (47% van participanten had een voorkeur voor 
deelname t.o.v. geen deelname). Een hogere leeftijd was geassocieerd met een voorkeur 
voor de medisch specialist. Daarnaast bleken participanten met een hogere leeftijd 
en een lager opleidingsniveau een minder sterke voorkeur te hebben voor deelname 
aan het EGP. Ervaring met bepaalde aspecten van follow-up (zoals de mammacare 
verpleegkundige en het EGP) resulteerde in signifi cant sterkere voorkeuren voor deze 
aspecten. Behandelingsmodaliteit had geen invloed op de preferenties van patiënten. 
De sterke heterogeniteit in preferenties suggereert dat eenzelfde follow-up strategie voor 
iedereen niet de voorkeur heeft.
In HOOFDSTUK 9 worden de hoofdbevindingen van het proefschrift samengevat en enkele 
methodologische vraagstukken gerelateerd aan het verrichte onderzoek bediscussieerd. 
De gerandomiseerde studie was pragmatisch van aard en vertegenwoordigde daarmee 
nauw de effectiviteit en kosteneffectiviteit in de praktijk. Aangezien de QALY enkele niet-
gezondheidsgerelateerde aspecten die van belang zijn in medische besliskunde negeert, 
zoals patiënten tevredenheid en voorkeuren voor logistieke aspecten van follow-up, 
werden deze aspecten apart onderzocht in dit proefschrift. Echter, patiënten tevredenheid 
en voorkeuren zijn moeilijk te meten en de validiteit van de gevonden resultaten werd in 
dit laatste hoofdstuk onder de loep genomen. Daarnaast werd ingegaan op de invloed van 
de resultaten van de economische evaluatie en het preferentie onderzoek op de klinische 
praktijk en beleid. Er werd aanbevolen de huidige richtlijn voor follow-up te veranderen 
van traditioneel ziekenhuis follow-up naar telefonische follow-up in combinatie met 
het EGP. Toekomstig onderzoek zou de haalbaarheid en kosteneffectiviteit van meer 
geïndividualiseerde follow-up moeten onderzoeken.
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